0001437749-23-006178 10-K 76 20221231 20230310 20230310 SAFEGUARD SCIENTIFICS INC 0000086115 6799 231609753 PA 1231 10-K 34 001-05620 23724006 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 610 293 0600 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 SAFEGUARD INDUSTRIES INC 19810525 SAFEGUARD CORP 19690521 10-K 1 sfe20221231_10k.htm FORM 10-K sfe20221231_10k.htm
0000086115 SAFEGUARD SCIENTIFICS INC false --12-31 FY 2022 0.10 0.10 0.10 0.10 1,000 1,000 0.10 0.10 83,333 83,333 21,573 21,573 2,157 2,157 5,478 5,068 0.5 0.6 2.5 0 0 0 2 0 0 4 8 0 0 0 0.0 21.0 21.0 21.0 0 0 0 1 Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests. 00000861152022-01-012022-12-31 iso4217:USD 00000861152022-06-30 xbrli:shares 00000861152023-03-06 thunderdome:item iso4217:USDxbrli:shares 00000861152022-12-31 00000861152021-12-31 00000861152021-01-012021-12-31 00000861152020-12-31 0000086115us-gaap:RetainedEarningsMember2020-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000086115us-gaap:CommonStockMember2020-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000086115us-gaap:TreasuryStockMember2020-12-31 0000086115us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0000086115us-gaap:CommonStockMember2021-01-012021-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0000086115us-gaap:TreasuryStockMember2021-01-012021-12-31 0000086115us-gaap:RetainedEarningsMember2021-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000086115us-gaap:CommonStockMember2021-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000086115us-gaap:TreasuryStockMember2021-12-31 0000086115us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0000086115us-gaap:CommonStockMember2022-01-012022-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000086115us-gaap:TreasuryStockMember2022-01-012022-12-31 0000086115us-gaap:RetainedEarningsMember2022-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0000086115us-gaap:CommonStockMember2022-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000086115us-gaap:TreasuryStockMember2022-12-31 0000086115sfe:BrightHealthMember2022-12-31 xbrli:pure 0000086115srt:PartnershipInterestMember2022-12-31 0000086115srt:PartnershipInterestMember2021-12-31 0000086115us-gaap:PrivateEquityFundsMember2022-12-31 0000086115us-gaap:PrivateEquityFundsMember2021-12-31 0000086115sfe:LumesisIncMember2022-09-012022-09-30 0000086115sfe:LumesisIncMember2022-09-30 0000086115sfe:ZipnosisMember2021-03-012021-03-31 0000086115sfe:PreferredEquityInAcquirorInConnectionWithSaleOfZipnosisIncMember2021-03-31 0000086115sfe:ZipnosisMember2021-03-31 0000086115sfe:BrightHealthMember2021-01-012021-12-31 0000086115sfe:BrightHealthMember2022-01-012022-12-31 0000086115sfe:FlashtalkingMember2021-01-012021-12-31 0000086115sfe:WebLincIncMember2021-01-012021-12-31 0000086115sfe:WebLincIncMember2022-01-012022-12-31 0000086115sfe:TrexGroupIncMember2021-03-012021-03-31 0000086115sfe:VelanoVascularMember2021-01-012021-12-31 0000086115sfe:AdvantedgeHealthcareSolutionsIncMember2021-12-012021-12-31 0000086115sfe:AktanaIncMember2022-12-31 0000086115sfe:AktanaIncMember2021-12-31 0000086115sfe:ClutchHoldingsMember2022-12-31 0000086115sfe:ClutchHoldingsMember2021-12-31 0000086115sfe:InfoBionicIncMember2022-12-31 0000086115sfe:InfoBionicIncMember2021-12-31 0000086115sfe:meQuilibriumMember2022-12-31 0000086115sfe:meQuilibriumMember2021-12-31 0000086115sfe:MoxeHealthCorporationMember2022-12-31 0000086115sfe:MoxeHealthCorporationMember2021-12-31 0000086115sfe:PrognosHealthIncMember2022-12-31 0000086115sfe:PrognosHealthIncMember2021-12-31 0000086115sfe:SyapseIncMember2022-12-31 0000086115sfe:SyapseIncMember2021-12-31 0000086115sfe:TriceMedicalIncMember2022-12-31 0000086115sfe:TriceMedicalIncMember2021-12-31 0000086115sfe:HighTractionStageMember2022-12-31 0000086115sfe:HighTractionStageMember2021-12-31 0000086115us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2022-01-012022-12-31 0000086115us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-01-012021-12-31 0000086115us-gaap:GoodwillMember2022-12-31 0000086115sfe:IntangibleAssetsMember2022-12-31 0000086115sfe:SyapseIncMember2022-01-012022-12-31 0000086115sfe:PrognosHealthIncMember2022-01-012022-12-31 0000086115sfe:ClutchHoldingsMember2022-01-012022-12-31 0000086115sfe:meQuilibriumMember2022-01-012022-12-31 0000086115sfe:TriceMedicalIncMember2022-01-012022-12-31 0000086115sfe:CreditFacilityMemberus-gaap:EquityMethodInvesteeMembersfe:TriceMedicalIncMember2022-12-31 0000086115sfe:CreditFacilityMemberus-gaap:EquityMethodInvesteeMembersfe:TriceMedicalIncMemberus-gaap:SubsequentEventMember2023-01-31 0000086115sfe:AktanaIncMember2021-07-012021-09-30 0000086115sfe:AktanaIncMember2021-09-30 0000086115sfe:SyapseIncMember2021-01-012021-03-31 0000086115sfe:SyapseIncMember2021-03-31 0000086115sfe:TriceMedicalIncMember2021-04-012021-06-30 0000086115sfe:TriceMedicalIncMember2021-09-30 0000086115sfe:TriceMedicalIncMember2021-01-012021-12-31 0000086115us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000086115us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000086115us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000086115us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0000086115us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-31 0000086115us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-31 0000086115us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-31 0000086115us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-31 0000086115us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member2015-07-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member2022-01-012022-12-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member2021-01-012021-12-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInMay2021Member2021-05-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInMay2021Member2021-01-012021-12-31 0000086115sfe:DutchAuctionSelftenderMember2021-10-012021-10-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInMarch2022Member2022-03-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInMarch2022Member2022-01-012022-12-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInMarch2022Memberus-gaap:SubsequentEventMember2023-01-012023-01-31 0000086115sfe:EquityCompensationPlanMember2022-12-31 0000086115us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-31 0000086115us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-31 0000086115us-gaap:PerformanceSharesMember2022-01-012022-12-31 0000086115us-gaap:PerformanceSharesMember2021-01-012021-12-31 0000086115us-gaap:RestrictedStockMembersrt:DirectorMember2022-01-012022-12-31 0000086115us-gaap:RestrictedStockMembersrt:DirectorMember2021-01-012021-12-31 0000086115us-gaap:RestrictedStockMember2022-01-012022-12-31 0000086115us-gaap:RestrictedStockMember2021-01-012021-12-31 0000086115us-gaap:RestrictedStockMembersfe:OtherManagementMember2022-01-012022-12-31 0000086115us-gaap:RestrictedStockMembersfe:OtherManagementMember2021-01-012021-12-31 0000086115us-gaap:RestrictedStockMembersfe:NonemployeeMember2022-01-012022-12-31 0000086115us-gaap:RestrictedStockMembersfe:NonemployeeMember2021-01-012021-12-31 0000086115srt:DirectorMember2022-12-31 0000086115srt:DirectorMember2021-12-31 0000086115sfe:PerformanceStockUnitMember2022-01-012022-12-31 0000086115sfe:PerformanceStockUnitMember2021-01-012021-12-31 0000086115sfe:PerformanceStockUnitMember2020-12-31 0000086115sfe:The2020AwardMember2022-01-012022-12-31 0000086115sfe:The2020AwardMember2021-01-012021-12-31 0000086115sfe:PerformanceBasedOptionsMember2022-01-012022-12-31 0000086115sfe:PerformanceBasedOptionsMember2021-01-012021-12-31 0000086115sfe:PerformanceBasedOptionsMember2022-12-31 utr:Y 0000086115sfe:ServiceBasedAwardMember2022-01-012022-12-31 0000086115sfe:ServiceBasedAwardMember2021-01-012021-12-31 0000086115us-gaap:EmployeeStockOptionMember2020-12-31 0000086115us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0000086115us-gaap:EmployeeStockOptionMember2021-12-31 0000086115us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000086115us-gaap:EmployeeStockOptionMember2022-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2020-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2021-01-012021-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2021-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2022-01-012022-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2022-12-31 0000086115us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000086115us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0000086115us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-12-31 0000086115us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-12-31 0000086115us-gaap:EmployeeStockOptionMembersrt:MinimumMember2021-01-012021-12-31 0000086115us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-01-012021-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2022-01-012022-12-31 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2021-01-012021-12-31 0000086115srt:MinimumMember2022-01-012022-12-31 0000086115srt:MinimumMember2021-01-012021-12-31 0000086115srt:MaximumMember2022-01-012022-12-31 0000086115sfe:AmendedAndRestatedSafeguardScientificsTransactionBonusPlanMember2022-01-012022-12-31 0000086115sfe:AmendedAndRestatedSafeguardScientificsTransactionBonusPlanMember2021-01-012021-12-31 00000861152022-01-012022-03-31 00000861152022-04-012022-06-30 00000861152022-07-012022-09-30 00000861152022-10-012022-12-31 00000861152021-01-012021-03-31 00000861152021-04-012021-06-30 00000861152021-07-012021-09-30 00000861152021-10-012021-12-31
 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark One)

☑

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ___________

 

Commission File Number 1-5620

 Safeguard Scientifics, Inc.

(Exact name of registrant as specified in its charter)

Pennsylvania

 

23-1609753

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer Identification No.)

   

150 N. Radnor Chester Road

Suite F-200

Radnor, PA

 

19087

(Address of principal executive offices)

 

(Zip Code)

 

(610) 293-0600

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock ($.10 par value)

SFE

The NASDAQ Stock Market LLC 

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ☐

Accelerated filer  ☐

 

Smaller reporting company ☑

Non-accelerated filer   ☑

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒

 

As of June 30, 2022, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was $50,494,095 based on the closing sale price as reported on the New York Stock Exchange.

 

The number of shares outstanding of the registrant’s common stock as of March 6, 2023 was 16,268,270.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the definitive proxy statement (the “Definitive Proxy Statement”) to be filed with the Securities and Exchange Commission for the Company’s 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this report.

 

 
Table of Contents
 

 

 

SAFEGUARD SCIENTIFICS, INC.

FORM 10-K

December 31, 2022

 

 

Page

PART I

Item 1. Business

3

Item 1A. Risk Factors

8

Item 1B. Unresolved Staff Comments

13

Item 2. Properties

13

Item 3. Legal Proceedings

13

Item 4. Mine Safety Disclosures

13

PART II

Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

14

Item 6. Selected Consolidated Financial Data

15

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

20

Item 8. Financial Statements and Supplementary Data

21

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

42

Item 9A. Controls and Procedures

42

Item 9B. Other Information

42

PART III

Item 10. Directors, Executive Officers and Corporate Governance

43

Item 11. Executive Compensation

43

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

43

Item 13. Certain Relationships and Related Transactions, and Director Independence

44

Item 14. Principal Accountant Fees and Services

44

PART IV

Item 15. Exhibits and Financial Statement Schedules

45

 

2
Table of Contents

 

 

PART I

 

Cautionary Note Concerning Forward-Looking Statements

 

This Annual Report on Form 10-K contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard” or “we”), the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts.  These statements include, in particular, statements about our plans, strategies and prospects.  For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Our forward-looking statements are subject to risks and uncertainties.  Factors that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our ownership interests may vary from period to period, our substantial capital requirements and absence of liquidity from our ownership interests, fluctuations in the market prices of our publicly traded ownership interests, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, our ability to execute our strategy, market valuations in sectors in which our companies operate, our inability to control our ownership interests, the uncertainty of the outcomes of corporate strategic transactions, if any, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our ownership interests and their performance, including the fact that most of our ownership interests have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our ownership interests operate, compliance with government regulation and legal liabilities, all of which are discussed in Item 1A. “Risk Factors.” Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur.

 

Item 1. Business

 

Business Overview

 

Historically, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses. In many, but not all cases, we are actively involved influencing development through board representation and management support in addition to the influence we exert through our equity ownership. We also continue to hold relatively small equity interests in other enterprises where we do not exert significant influence and do not participate in management activities. In some cases, those ownership interests relate to residual interests from prior larger interests or from companies that acquired companies in which we had ownership interests.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  In December 2019, we declared and paid a $1.00 per share special dividend.  In 2021, we repurchased 4.5 million shares through a combination of open market purchases and a tender offer for an aggregate of $40.7 million resulting in an average price of $8.95 per share.  In 2022, we repurchased 711,481 shares for $2.9 million at an average price of $4.13 per share through subsequent open market repurchase plans.  We will continue to actively work with our ownership interests to seek monetization opportunities while we also evaluate additional strategic alternatives.  These strategic alternatives could include the sale of all of our ownership interests in a single transaction or a series of transactions, merger, business combinations or other strategic transactions.   

 

 

3
Table of Contents

 

We incorporated in the Commonwealth of Pennsylvania in 1953. Our corporate headquarters are located at 150 N. Radnor Chester Road, Suite F-200, Radnor, Pennsylvania 19087.

 

Our Strategy

 

Founded in 1953, Safeguard has a distinguished track record of building market leading companies through providing capital and operational support to entrepreneurs across an evolving and innovative spectrum of industries. Over the recent past, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Since January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests with the goal of pursuing monetization opportunities and maximizing the value returned to shareholders.

 

Helping Our Companies Build Value

 

We offer strategic, operational and management support to certain of our ownership interests.

 

Strategic Support. We play an active role in developing the strategic direction to certain of our ownership interests, which include:

 

•

defining short and long-term strategic goals;
 

•

identifying and planning for the critical success factors to reach these goals;
 

•

identifying and addressing the challenges and operational improvements required to achieve the critical success factors and, ultimately, the strategic goals;
 

•

identifying and implementing the business measurements that we and others will apply to measure a company’s success; and
 

•

identifying sources of and providing capital to drive growth.

 

Management and Operational Support. Our executives serve on the boards of directors of certain of our companies, working with them to develop and implement strategic and operating plans. We measure and monitor achievement of these plans through regular review of operational and financial performance measurements.

 

Realizing Value

 

The primary way we realize value from our ownership interests is when the underlying company enters into a sale or merger transaction and we receive cash consideration for our ownership stake. From time to time, we engage in discussions with other companies interested in acquiring our ownership interests, either in response to inquiries or as part of a process we initiate. To the extent we believe that a company’s further growth and development can best be supported by a different ownership structure or if we otherwise believe it is in our shareholders’ best interests, we will seek to sell some or all of our position in the company. These sales may take the form of privately negotiated sales of stock or assets, mergers and acquisitions, public offerings of the company’s securities and, in the case of publicly traded companies, sales of their securities in the open market. In the past, we have taken companies public through rights offerings and directed share subscription programs. We will continue to consider these (or similar) programs and the sale of certain company interests in secondary market transactions to maximize value for our shareholders.

 

Given our strategy, the value of Safeguard is primarily dependent upon the value of our existing ownership interests.  We have returned capital to our shareholders in the form of stock repurchases and a special dividends to shareholders.

 

Our Ownership Interests

 

An understanding of our ownership interests is important to understanding Safeguard. We categorize our ownership interests into stages based upon revenue generation.  This includes those positions which are accounted for under the equity method as well as certain companies where we do not have significant influence but whose value is a substantial portion of our portfolio.  The Company reflects revenue categories based on a one quarter lag, i.e. the categories below reflect the trailing year ended September 30, 2022.

 

4
Table of Contents

 

The ownership percentages indicated below are presented as of December 31, 2022 for certain companies in which we held ownership interests and reflect the percentage of the vote we were entitled to cast at that date based on issued and outstanding voting securities (on a common stock equivalent basis), excluding the effect of options, warrants and convertible debt (primary ownership).

 

Revenue of $5 million to $10 million

 

Moxe Health Corporation

 

(Safeguard Ownership: 19.3%)

 

Headquartered in Madison, Wisconsin, Moxe Health provides a clinical data clearinghouse that connects health systems with their network of health plans.  Moxe’s key products, Substrate and Convergence, allow for bi-directional data flow between payors and providers to complete various risk adjustment, quality, and prior authorization use cases. www.moxehealth.com

 

5
Table of Contents

 

 

Revenue of $10 million to $20 million

 

Clutch Holdings, Inc.

 

(Safeguard Ownership: 41.7%)

 

Headquartered in Ambler, Pennsylvania, Clutch has revolutionized how marketing teams for premier brands develop and foster relationships with their customers. Clutch’s advanced marketing platform serves as a customer hub, delivering deep intelligence derived from real-time behaviors and transactions across in-store, online, mobile and social channels. www.clutch.com

 

InfoBionic, Inc.

 

(Safeguard Ownership: 25.2%)

 

Headquartered in Waltham, Massachusetts, InfoBionic is an emerging digital health company focused on creating patient monitoring solutions for cardiac arrhythmias. InfoBionic’s MoMe® Kardia cloud-based, remote patient monitoring platform delivers on-demand, actionable monitoring data and analytics directly to the physicians themselves. www.infobionic.com

 

meQuilibrium

 

(Safeguard Ownership: 31.3%)

 

Headquartered in Boston, Massachusetts, meQuilibrium is an engagement and performance platform that leverages behavioral psychology and data science to improve workforce resilience, agility, and adaptive capacity.  The Company offers solutions for managers, teams, and individual employees. www.mequilibrium.com

 

Syapse, Inc.

 

(Safeguard Ownership: 11.0%)

 

Headquartered in Palo Alto, California, Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Syapse’s platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. www.syapse.com

 

Revenue of $20 million to $50 million

 

Aktana, Inc.

 

(Safeguard Ownership: 13.6%)

 

Headquartered in San Francisco, California, Aktana is a pioneer in decision support for global life science sales teams. Aktana helps its customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions and providing insight regarding which strategies work best for which customers under which conditions. www.aktana.com

  

Prognos Health Inc.

 

(Safeguard Ownership: 28.4%)

 

Headquartered in New York, New York, Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with life sciences brands, payers, and clinical diagnostics organizations. Prognos’ innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques. www.prognos.ai

 

Trice Medical, Inc.

 

(Safeguard Ownership: 11.6%)

 

Headquartered in Malvern, Pennsylvania, Trice Medical was founded to fundamentally improve orthopedic diagnostics for the patient, physician and payor by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physician's office. Trice's mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. www.tricemedical.com

 

 

 

6
Table of Contents

 

Other ownership interests

 

In addition to the above companies, we also have smaller ownership interests in a variety of other companies where we do not exert significant influence and do not participate in any management activities. In some cases, these ownership interests generally are the result of previous positions that have been diluted or residual interests resulting from the acquisition of companies where we had an ownership interest.

 

 Bright Health Group:  A technology-enabled, fully aligned system of care built for healthcare's consumer retail market.  Bright HealthCare offers commercial and Medicare health plan products to over 1 million consumers across the nation.  www.brighthealthgroup.com 

 

MedCrypt: Developer of a data security platform designed to protect medical devices. The company's platform enables functions such as authenticating users, encrypting data and cryptographically sign settings and patient prescriptions, as well as has the ability to monitor transactions between clinicians and devices for malicious behavior, enabling hospitals and health systems to prevent unauthorized access and misuse of their medical devices. www.medcrypt.com

 

WellTrackONE: Provider of wellness program services. The company's services include scheduling, screening and documentation that provide data for outcomes and clinical measurements, enabling healthcare professionals to offer wellness visits to their patients. www.welltrackone.com

 

We also have residual interests in a variety of private funds that are in the process of winding down and other companies.  

 

FINANCIAL INFORMATION ABOUT OPERATING SEGMENTS

 

We operate as one operating segment based upon the similar nature of our technology-driven companies, the functional alignment of the organizational structure and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

OTHER INFORMATION

 

The operations of Safeguard and the companies in which it has ownership interests are subject to environmental laws and regulations. Safeguard does not believe that expenditures relating to those laws and regulations will have a material adverse effect on the business, financial condition or results of operations of Safeguard.

 

AVAILABLE INFORMATION

 

Safeguard is subject to the informational requirements of the Securities Exchange Act of 1934, as amended. Therefore, we file our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements and other information with, and furnish other reports to, the Securities and Exchange Commission (“SEC”). You can read and copy such documents at the SEC’s public reference facilities in Washington, D.C., New York, New York and Chicago, Illinois. You may obtain information on the operation of the SEC’s public reference facilities by calling the SEC at 1-800-SEC-0330. Such material may also be accessed electronically by means of the SEC’s home page on the Internet at www.sec.gov or through Safeguard’s website at www.safeguard.com. Such documents are available as soon as reasonably practicable after electronic filing of the material with the SEC. Copies of these reports (excluding exhibits) also may be obtained free of charge, upon written request to: Investor Relations, Safeguard Scientifics, Inc., 150 N. Radnor Chester Road, Suite F-200, Radnor, Pennsylvania 19087.

 

The Internet website addresses for Safeguard and its ownership interests are included in this report for identification purposes. The information contained therein or connected thereto is not intended to be incorporated into this Annual Report on Form 10-K.

 

The following corporate governance documents are available free of charge on Safeguard’s website: the charters of our Audit, Compensation and Nominating & Corporate Governance Committees, our Corporate Governance Guidelines and our Code of Business Conduct and Ethics. We also will post on our website any amendments to or waivers of our Code of Business Conduct and Ethics that relate to our directors and executive officers.

 

7
Table of Contents

 

Item 1A. Risk Factors

 

You should carefully consider the information set forth below. The following risk factors describe situations in which our business, financial condition and/or results of operations could be materially harmed, and the value of our securities may be adversely affected. You should also refer to other information included or incorporated by reference in this report. 

 

 

Our ability to obtain value from our companies and the return of such value to our shareholders are subject to factors beyond our control.

 

In January 2018, we announced that we will not deploy any capital into new companies.  We will instead focus on supporting, and maximizing monetization opportunities for, our existing company interests to return value to shareholders.  In that context, we have considered and continue to consider monetization initiatives including, among others: the sale of our ownership interests, the sale of certain or all ownership interests in secondary market transactions, or a combination thereof, the sale of all of our ownership interests in a single transaction or a series of transactions, business combinations and other strategic transactions as well as other opportunities to maximize shareholder value.  However, this strategic plan may require providing additional capital and operational support to such existing companies and we may not be able to complete any such transaction during any specific time frame or otherwise on desirable terms, if at all, and there can be no assurance as to how long this process will take or the results that this process will yield.  In addition, there can be no assurance that any exploration of a strategic transaction will result in any strategic change or outcome and disclosure of any developments related to such exploration may not be disclosed until required. Further, if one or more strategic or other transactions are completed, we may be required to retain or reinvest additional amounts of our capital as part of such transaction.  There can also be no assurance as to whether we will realize the value of escrowed proceeds, holdbacks or other contingent consideration, if any, associated with any transaction. Additionally, there can be no assurance that we will be able to satisfy our liabilities during this process.  The method, timing and amount of any return of value resulting from such a transaction will also be at the discretion of our Board of Directors and may depend on market and business conditions and our overall liabilities, capital structure and liquidity position.

 

A disposition of one or more of our company interests may occur at a time that will yield less value than if we held such interests for a longer period of time.

 

Our companies are at various stages in their lifecycles. The value of our interests in our companies at any point in time is highly dependent on the progress and success such companies have made at such time with respect to the development and marketing of their products and services and that value may fluctuate significantly. The resulting effects of the COVID-19 pandemic and certain other macroeconomic factors continue to impact the mergers and acquisitions market for certain companies, which in some cases has resulted in lower valuation expectations and extended exit timelines for such companies. This, in turn, could negatively affect the amount and timing of the monetization opportunities for such companies and our ability to return value to shareholders.

 

The effects of the COVID-19 pandemic may adversely affect the businesses, financial conditions and operating results of the companies in which we have an ownership interest, as well as our ability to monetize such interests, and it may also cause us to increase the amount of additional capital we will need to provide to such companies.

 

To varying degrees, the economic and market conditions caused by the COVID-19 pandemic have negatively impacted, and continue to negatively impact, the companies in which we have ownership interests, including, without limitation, their operations, supply chains, sales infrastructures and the demand for their products and services.  This is negatively affecting their businesses, financial conditions and operating results.  As a result, we may be required to provide additional capital to certain companies, which may cause us to face liquidity issues that will constrain our ability to execute our business strategy and limit our ability to provide financial support to all of our existing companies in the amounts that we desire.  The COVID-19 pandemic is also impacting the mergers and acquisitions market for certain companies, which in some cases has resulted in lower valuation expectations and extended exit timelines for such companies. This, in turn, could negatively affect the amount and timing of the monetization opportunities for such companies and our ability to return value to shareholders.

 

 

Our principal business strategy depends upon our ability to make good decisions regarding the deployment of capital into, and subsequent disposition of, our existing company interests and, ultimately, the performance of such companies, which is uncertain.

 

If we make poor decisions regarding the deployment of capital into, and subsequent disposition of, our existing companies, our business strategy will not succeed. If such companies do not succeed, the value of our assets could be significantly reduced and require substantial impairments or write-offs and our results of operations and the price of our common stock would be adversely affected. The risks relating to our companies include:

 

 

•

most of our companies have a history of operating losses and/or limited operating history;

 

•

the intense competition affecting the products and services our companies offer could adversely affect their businesses, financial condition, results of operations and prospects for growth;

 

•

the inability to adapt to changing marketplaces;

 

•

the inability to manage growth;

 

•

the need for additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all;

 

•

the inability to protect their proprietary rights and/or infringing on the proprietary rights of others;

 

•

that our companies could face legal liabilities from claims made against them based upon their operations, products or work;

 

•

the impact of economic downturns on their operations, results and growth prospects;

 

•

the inability to attract and retain qualified personnel;

 

•

the existence of government regulations and legal uncertainties may place financial burdens on the businesses of our companies; and

 

•

the inability to plan for and manage catastrophic events.

 

8
Table of Contents

 

These and other risks are discussed in detail under the caption “Risks Related to Our Companies” below.

 

As we execute against our strategy, a significant amount of our deployed capital may be concentrated in fewer companies.  These remaining companies may also operate in the same or similar industries.  This will limit our diversification and make us more susceptible to a single negative event. 

 

As we execute against our strategy, our capital deployments will be deployed in a decreasing number of companies.  Further, our remaining companies could be concentrated in the same or similar industries. Fewer companies, as well as potential industry concentration, may cause us to be more susceptible to any single economic, regulatory or other occurrence affecting a single company or a particular industry than we would have otherwise been if we had a larger number of companies and our companies operated in more diversified industries.

 

Our business model does not rely upon, or plan for, the receipt of operating cash flows from our companies. Our companies do not provide us with cash flow from their operations. We rely on cash on hand, liquidity events and our ability to generate cash from capital raising activities to finance our operations.

 

We need capital to fund the capital needs of our existing companies. We also need cash to finance our corporate overhead and meet our existing funding commitments. As a result, we have substantial cash requirements. Our companies do not provide us with cash flow from their operations. To the extent our companies generate any cash from operations, they generally retain the funds to develop their own businesses. As a result, we must rely on cash on hand, company liquidity events and new capital raising activities to meet our cash needs. If we are unable to find ways of monetizing our holdings of company interests or raising additional capital on attractive terms, we may face liquidity issues that will require us to constrain our ability to execute our business strategy and limit our ability to provide financial support to our existing companies.

 

 

We may be unable to obtain maximum value for our holdings or to sell our holdings on a timely basis.

 

We hold significant positions in our companies. If we were to divest all or part of our holdings in a company, we may have to sell our interests at a relative discount to intrinsic value. For companies with publicly traded stock, we may be unable to sell our holdings at then-quoted market prices. The trading volume and public float in the common stock of a publicly traded company in which we have an interest may be small relative to our holdings. As a result, any significant open-market divestiture by us of our holdings in such a company, if possible at all, would likely have a material adverse effect on the market price of its common stock and on our proceeds from such a divestiture. Additionally, we may not be able to take our companies public as a means of monetizing our position or creating shareholder value. Registration and other requirements under applicable securities laws and contractual restrictions also may adversely affect our ability to dispose of our company holdings on a timely basis.

 

Our success is dependent on our senior management.

 

Our success is dependent on our senior management team’s ability to execute our strategy. In connection with our strategy announced in 2018, we made a series of management changes intended to streamline our organizational structure and reduce our operating costs and since then we have made, and may make, further management changes from time to time.  A loss of one or more of the remaining members of our senior management team without adequate replacement could have a material adverse effect on us.

 

Our business strategy may not be successful if valuations in the market sectors in which our companies participate decline.

 

Our strategy involves creating value for our shareholders by helping our companies build value and, if appropriate, access the public and private capital markets. Therefore, our success is dependent on the value of our companies as determined by the public and private capital markets. Many factors, including reduced market interest, may cause the market value of our companies to decline. If valuations in the market sectors in which our companies participate decline, their access to the public and private capital markets on terms acceptable to them may be limited.

 

Our companies could make business decisions that are not in our best interests or with which we do not agree, which could impair the value of our holdings.

 

Although we currently own a significant, influential interest in some of our companies, we do not maintain a controlling interest in any of our companies. Acquisitions of interests in companies in which we share or have no control, and the dilution of our interests in or a further reduction of our control of companies, will involve additional risks that could cause the performance of our interests and our operating results to suffer, including:

 

 

•

the management teams or other equity or debt holders of our companies having economic or business interests or objectives that are different from ours; and

 

•

the companies not taking our advice with respect to the financial or operating issues they may encounter.

 

Our inability to control our companies also could prevent us from assisting them, financially or otherwise, or could prevent us from liquidating our interests in them at a time or at a price that is favorable to us. Additionally, our companies may not act in ways that are consistent with our business strategy. These factors could hamper our ability to maximize returns on our interests and cause us to incur losses on our interests in these companies.

 

We may have to buy, sell or retain assets when we would otherwise not wish to do so in order to avoid registration under the Investment Company Act.

 

The Investment Company Act of 1940 regulates companies which are engaged primarily in the business of investing, reinvesting, owning, holding or trading in securities. Under the Investment Company Act, a company may be deemed to be an investment company if it owns investment securities with a value exceeding 40% of the value of its total assets (excluding government securities and cash items) on an unconsolidated basis, unless an exemption or safe harbor applies. We refer to this test as the “40% Test.” Securities issued by companies other than consolidated companies are generally considered “investment securities” for purposes of the Investment Company Act, unless other circumstances exist which actively involve the company holding such interests in the management of the underlying company. We are a company that partners with growth-stage companies to build value; we are not engaged primarily in the business of investing, reinvesting or trading in securities. We are in compliance with the 40% Test. Consequently, we do not believe that we are an investment company under the Investment Company Act.

 

 

We monitor our compliance with the 40% Test and seek to conduct our business activities to comply with this test. It is not feasible for us to be regulated as an investment company because the Investment Company Act rules are inconsistent with our strategy of actively helping our companies in their efforts to build value. In order to continue to comply with the 40% Test, we may need to take various actions which we would otherwise not pursue. For example, we may be limited in the manner or timing in which we sell our interests in a company. Our ownership levels also may be affected if our companies are acquired by third parties or if our companies issue stock which dilutes our ownership interest. The actions we may need to take to address these issues while maintaining compliance with the 40% Test could adversely affect our ability to create and realize value at our companies

 

 

9
Table of Contents

 

The COVID-19 pandemic may adversely affect parties with obligations to us, including the subtenant of our previous office space.

 

In March 2019, we entered into a sublease of our prior corporate headquarters office space beginning in June 2019. The term of the sublease is through April 2026, the same as our underlying lease. Fixed sublease payments to us are escalating over the term of the sublease.  We remain obligated under the original lease for such office space and, in the event the subtenant of such office space fails to satisfy its obligations under the sublease, we would be required to satisfy our obligations directly to the landlord under such original lease.

 

 

 

Risks Related to Our Companies

 

 

Most of our companies have a history of operating losses and/or limited operating history and may never be profitable.

 

Most of our companies have a history of operating losses and/or limited operating history, have significant historical losses and may never be profitable. Many have incurred substantial costs to develop and market their products, have incurred net losses and cannot fund their cash needs from operations. We expect that the operating expenses of certain of our companies will increase substantially in the foreseeable future as they continue to develop products and services, increase sales and marketing efforts, and expand operations.

 

Our companies face intense competition, which could adversely affect their business, financial condition, results of operations and prospects for growth.

 

There is intense competition in the technology marketplaces, and we expect competition to intensify in the future. Our business, financial condition, and results of operations will be materially adversely affected if our companies are not able to compete successfully. Many of the present and potential competitors may have greater financial, technical, marketing and other resources than those of our companies. This may place our companies at a disadvantage in responding to the offerings of their competitors, technological changes or changes in client requirements. Also, our companies may be at a competitive disadvantage because many of their competitors have greater name recognition, more extensive client bases and a broader range of product offerings. In addition, our companies may compete against one another.

 

The success or failure of many of our companies is dependent upon the ultimate effectiveness of newly-created technologies, medical devices, healthcare diagnostics, etc.

 

Our companies’ business strategies are often highly dependent upon the successful launch and commercialization of an innovative technology or device, including, without limitation, technologies or devices used in healthcare or digital media.  Despite all of our efforts to understand the research and development underlying the innovation or creation of such technologies and devices before we deploy capital into a company, sometimes the performance of the technology or device does not match our expectations or those of such company. In those situations, it is likely that we will incur a partial or total loss of the capital which we deployed in such company.

 

Our companies may fail if they do not adapt to changing marketplaces.

 

If our companies fail to adapt to changes in technology and customer and supplier demands, they may not become or remain profitable. There is no assurance that the products and services of our companies will achieve or maintain market penetration or commercial success, or that the businesses of our companies will be successful.

 

 

The technology marketplaces are characterized by:

 

•

rapidly changing technology;

 

•

evolving industry standards;

 

•

frequent introduction of new products and services;

 

•

shifting distribution channels;

 

•

evolving government regulation;

 

•

frequently changing intellectual property landscapes; and

 

•

changing customer demands.

 

Our future success will depend on our companies’ ability to adapt to these evolving marketplaces. They may not be able to adequately or economically adapt their products and services, develop new products and services or establish and maintain effective distribution channels for their products and services. If our companies are unable to offer competitive products and services or maintain effective distribution channels, they will sell fewer products and services and forego potential revenue, possibly causing them to lose money. In addition, we and our companies may not be able to respond to the marketplace changes in an economically efficient manner, and our companies may become or remain unprofitable.

 

 

10
Table of Contents

 

Our companies may grow rapidly, including through acquisitions of other businesses, and may be unable to manage their growth.

 

We expect some of our companies to grow rapidly, including through acquisitions of other businesses. Such growth often places considerable operational, managerial, integration and financial strain on a business. To successfully manage such growth, our companies must, among other things:

 

•

improve, upgrade and expand their business infrastructures;

 

•

successfully integrate and operate any newly acquired businesses;

 

•

scale up production operations;

 

•

develop appropriate financial reporting controls;

 

•

attract and retain qualified personnel; and

 

•

maintain appropriate levels of liquidity.

 

If our companies are unable to manage their growth successfully, their ability to respond effectively to competition and to achieve or maintain profitability will be adversely affected. Further, a material weakness in any of our companies’ internal controls over their financial reporting could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.

 

Based on our business model, some or all of our companies will need to raise additional capital to fund their operations at any given time. We may not be able to, or decline to, fund some or all of such amounts and such amounts may not be available from third parties on acceptable terms, if at all. Further, if our companies do raise additional capital from third parties, either debt or equity, such capital may rank senior to, or dilute, our interests in such companies.

 

We cannot be certain that our companies will be able to obtain additional financing on favorable terms when needed, if at all. We may not be able to, or decline to, provide our companies with sufficient capital resources to enable them to reach a cash-flow positive position or a sale of the company. General economic disruptions and downturns may also negatively affect the ability of some of our companies to fund their operations from other stockholders and capital sources. We also may fail to accurately project the capital needs of companies. If our companies need capital, but are not able to raise capital from us or other outside sources, or our companies are unable to service their debt obligations, they may need to, or be forced to, cease or scale back operations. In such event, our interest in any such company will become less valuable. If our companies raise additional capital from third parties, either debt or equity, such capital may be dilutive, making our interests less valuable or if such capital ranks senior to the capital we have deployed, such capital may entitle its holders to receive returns of capital before we are entitled to receive any return of our deployed capital. Also, in the event of any insolvency, liquidation, dissolution, reorganization or bankruptcy of one or more our companies, holders of such company’s instruments that rank senior to our deployed capital will typically be entitled to receive payment in full before we receive any return of our deployed capital. After returning such senior capital, such company may not have any remaining assets to use for returning capital to us, causing us to lose some or all of our deployed capital in such company.

 

 

Economic disruptions and downturns may negatively affect our companies’ plans and their results of operations.

 

Many of our companies are largely dependent upon outside sources of capital to fund their operations. Disruptions in the availability of capital from such sources will negatively affect the ability of such companies to pursue their business models and will force such companies to revise their growth and development plans accordingly. Any such changes will, in turn, negatively affect our ability to realize the value of our capital deployments in such companies.

 

In addition, downturns in the economy as well as possible governmental responses to such downturns and/or to specific situations in the economy could affect the business prospects of certain of our companies, including, but not limited to, in the following ways: reduced business and/or consumer spending; and/or systemic changes in the ways the healthcare system operates in the United States.

 

 

Some of our companies may be unable to protect their proprietary rights and may infringe on the proprietary rights of others.

 

Our companies assert various forms of intellectual property protection. Intellectual property may constitute an important part of our companies’ assets and competitive strengths. Federal law, most typically copyright, patent, trademark and trade secret laws, generally protects intellectual property rights. Although we expect that our companies will take reasonable efforts to protect the rights to their intellectual property, third parties may develop similar intellectual property independently. Moreover, the complexity of international trade secret, copyright, trademark and patent law, coupled with the limited resources of our companies and the demands of quick delivery of products and services to market, create a risk that our companies’ efforts to prevent misappropriation of their technology will prove inadequate.

 

Some of our companies also license intellectual property from third parties and it is possible that they could become subject to infringement actions based upon their use of the intellectual property licensed from those third parties. Our companies generally obtain representations as to the origin and ownership of such licensed intellectual property. However, this may not adequately protect them. Any claims against our companies’ proprietary rights, with or without merit, could subject the companies to costly litigation and divert their technical and management personnel from other business concerns. If our companies incur costly litigation and their personnel are not effectively deployed, the expenses and losses incurred by our companies will increase and their profits, if any, will decrease.

 

Third parties have and may assert infringement or other intellectual property claims against our companies based on their patents or other intellectual property claims. Even though we believe our companies’ products do not infringe any third party’s patents, they may have to pay substantial damages, possibly including treble damages, if it is ultimately determined that they do. They may have to obtain a license to sell their products if it is determined that their products infringe on another person’s intellectual property. Our companies might be prohibited from selling their products before they obtain a license, which, if available at all, may require them to pay substantial royalties. Even if infringement claims against our companies are without merit, defending these types of lawsuits takes significant time, is expensive and may divert management attention from other business concerns.

 

 

11
Table of Contents

 

Certain of our companies could face legal liabilities from claims made against their operations, products or work.

 

Because the manufacture and sale of certain company products entail an inherent risk of product liability, certain of our companies maintain product liability insurance. Although none of our current companies have experienced any material losses in this regard, there can be no assurance that they will be able to maintain or acquire adequate product liability insurance in the future and any product liability claim could have a material adverse effect on a company’s financial stability, revenues and results of operations. In addition, many of the engagements of our companies involve projects that are critical to the operation of their clients’ businesses. If our companies fail to meet their contractual obligations, they could be subject to legal liability, which could adversely affect their business, operating results and financial condition. Our companies’ contracts typically include provisions designed to limit their exposure to legal claims relating to their services and products. However, these provisions may not protect our companies or may not be enforceable. Also, some of our companies depend on their relationships with their clients and their reputation for high-quality services and integrity to retain and attract clients. As a result, claims made against our companies’ work may damage their reputation, which in turn could impact their ability to compete for new work and negatively impact their revenue and profitability.

 

Our companies’ success depends on their ability to attract and retain qualified personnel.

 

Our companies depend upon their ability to attract and retain senior management and key personnel, including trained technical and marketing personnel. Our companies also will need to continue to hire additional personnel as they expand. Although our current companies have not been the subject of a work stoppage, any future work stoppage could have a material adverse effect on their respective operations. A shortage in the availability of the requisite qualified personnel or work stoppage would limit the ability of our companies to grow, to increase sales of their existing products and services, and to launch new products and services.

 

Government regulations and legal uncertainties may place financial burdens on the businesses of our companies.

 

Manufacturers of medical diagnostic devices and operators of laboratory facilities are subject to strict federal and state regulation regarding validation and the quality of manufacturing and laboratory facilities. Failure to comply with these quality regulation systems requirements could result in civil or criminal penalties or enforcement proceedings, including the recall of a product or a “cease distribution” order. The enactment of any additional laws or regulations that affect healthcare insurance policy and reimbursement (including Medicare reimbursement) could negatively affect some of our companies. If Medicare or private payers change the rates at which our companies or their customers are reimbursed by insurance providers for their products, such changes could adversely impact our companies.

 

 

  Some of our companies may be subject to significant environmental, health, data security and safety regulation.

 

Some of our companies may be subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as to the safety and health of manufacturing and laboratory employees. In addition, some of our companies are subject to federal, state and local financial securities and data security regulations, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, as amended, the California Consumer Privacy Act and the European General Data Protection Regulation, which impose varying degrees of additional obligations, costs and risks upon such companies, including the imposition of significant penalties in the event of any non-compliance. Further, the federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety. Compliance with such regulations could increase operating costs at certain of our companies, and the failure to comply could negatively affect the operations and results of some of our companies.

 

Catastrophic events may disrupt our companies’ businesses.

 

Some of our companies are highly automated businesses and rely on their network infrastructure, various software applications and many internal technology systems and data networks for their customer support, development, sales and marketing and accounting and finance functions. Further, some of our companies provide services to their customers from data center facilities in multiple locations. Some of these data centers are operated by third parties, and the companies have limited control over those facilities. A disruption or failure of these systems or data centers in the event of a natural disaster, telecommunications failure, power outage, cyber-attack, war, terrorist attack or other catastrophic event could cause system interruptions, reputational harm, delays in product development, breaches of data security and loss of critical data. Such an event could also prevent the companies from fulfilling customer orders or maintaining certain service level requirements, particularly in respect of their SaaS offerings. While certain of our companies have developed certain disaster recovery plans and maintain backup systems to reduce the potentially adverse effect of such events, a catastrophic event that resulted in the destruction or disruption of any of their data centers or their critical business or information technology systems could severely affect their ability to conduct normal business operations and, as a result, their business, operating results and financial condition could be adversely affected.

 

We cannot provide assurance that our companies’ disaster recovery plans will address all of the issues they may encounter in the event of a disaster or other unanticipated issue, and their business interruption insurance may not adequately compensate them for losses that may occur from any of the foregoing. In the event that a natural disaster, terrorist attack or other catastrophic event were to destroy any part of their facilities or interrupt their operations for any extended period of time, or if harsh weather or health conditions prevent them from delivering products in a timely manner, their business, financial condition and operating results could be adversely affected.

 

Risks Related to an Investment in our Securities

 

Fluctuations in the price of the common stock of our publicly traded holdings may affect the price of our common stock.

 

From time to time, we may hold equity interests in companies that are publicly traded. Fluctuations in the market prices of the common stock of publicly traded holdings may affect the price of our common stock. Historically, the market prices of our publicly traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance.

 

 

 

12
Table of Contents

 

The continuing costs and burdens associated with being a public company will constitute a much larger percentage of our expenses and we may in the future delist our common stock with the NASDAQ exchange and seek to deregister our common stock with the SEC.

 

We will remain a public company and will continue to be subject to the listing standards of the NASDAQ exchange and SEC rules and regulations, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the Sarbanes-Oxley Act of 2002. The costs and burdens of being a public company will be a significant and continually increasing portion of our expenses if we are able to monetize our company interests. We may in the future delist our common stock from the NASDAQ exchange and seek to deregister our common stock with the SEC.  However, there can be no assurance as to the timing of such transactions, or whether such transactions will be undertaken at all, and we will continue to face the costs and burdens of being a public company until such time as our common stock is delisted with the NASDAQ exchange and deregistered with the SEC.

 

Economic disruptions and downturns may have negative repercussions for us.

 

Events in the United States and international capital markets, debt markets and economies may negatively impact our stock price and our ability to pursue certain tactical and strategic initiatives, such as accessing additional public or private equity or debt financing for us or for our companies and selling our interests in companies on terms acceptable to us and in time frames consistent with our expectations.

 

We cannot provide assurance that material weaknesses in our internal control over financial reporting will not be identified in the future.

 

We cannot assure you that material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in a material weakness, or could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.

 

 

Item 1B. Unresolved Staff Comments

 

None.

 

Item 2. Properties

 

Our current corporate headquarters and administrative offices in Radnor, Pennsylvania is approximately 100 square feet of office space in one building.  The lease term expires in November 2023.  

 

 Additionally, we have additional administrative offices located in Radnor, Pennsylvania comprising approximately 15,600 square feet, that have been sublet to an unaffiliated party through April, 2026, the remainder of the lease term.

 

Item 3. Legal Proceedings

 

We, as well as our companies in which we hold ownership interests, are from time to time involved in various claims and legal actions arising in the ordinary course of business. While in the current opinion of management, the ultimate disposition of any of these matters which are currently pending will not have a material adverse effect on our consolidated financial position or results of operations, no assurance can be given as to the outcome of these situations, and one or more adverse dispositions could have a material adverse effect on our consolidated financial position and results of operations, or that of our companies. See Note 11 to the Consolidated Financial Statements for a discussion of ongoing claims and legal actions.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

ANNEX TO PART I — EXECUTIVE OFFICERS OF THE REGISTRANT

 

Name

Age

 

Position

 

Executive Officer Since

Eric C. Salzman

55

 

Chief Executive Officer

 

2020

Mark A. Herndon

53

 

Senior Vice President and Chief Financial Officer

 

2018

 

Mr. Salzman joined Safeguard as Chief Restructuring Officer in April 2020.  Mr. Salzman began serving as the Chief Executive Officer in December 2020.  Mr. Salzman has a 25-year track record partnering with growth companies as an investor, board member and strategic advisor.  He has worked in M&A, restructuring, growth and special situations investing at a number of investment banks and private equity funds, including Credit Suisse and Lehman Brothers.  Mr. Salzman helped oversee the monetization of a $2 billion portfolio of illiquid assets in the Lehman Brothers Bankruptcy Estate and subsequently advised several investment funds on value-maximization strategies for their respective portfolios.  He currently serves as a director on a number of Safeguard portfolio companies as well as an independent director at publicly traded Leonardo DRS, Inc., Movella Holdings Inc. and 8x8, Inc.  Mr. Salzman earned a B.A. Honors from the University of Michigan and an MBA from Harvard University.

 

Mr. Herndon joined Safeguard as Senior Vice President and Chief Financial Officer in September 2018. Prior to joining Safeguard, Mr. Herndon served in a variety of client service and national office roles at PricewaterhouseCoopers from 1991 to 2018, including his position as Assurance Partner from 2006 until 2018. Mr. Herndon earned a B.B.A in Accounting from Georgia Southern University and an MBA from Emory University’s Goizueta Business School.

 

13
Table of Contents

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock is listed on the NASDAQ Exchange (Symbol: SFE). The high and low sale prices reported within each quarter of 2022 and 2021 were as follows: 

 

   

High

    

Low

  

Fiscal year 2022:

                

First quarter

   $ 7.53     $ 4.81  

Second quarter

     5.48       3.32  

Third quarter

     4.54       3.60  

Fourth quarter

     3.89       2.95  

Fiscal year 2021:

                

First quarter

   $ 8.59     $ 6.35  

Second quarter

     7.90       5.95  

Third quarter

     8.93       7.38  

Fourth quarter

     8.98       6.23  

 

The high and low sale prices reported in the first quarter of 2023 through March 6, 2023 were $3.25 and $2.85 respectively, and the last sale price reported on March 6, 2023, was $3.03.  As of March 6, 2023, there were approximately 7,774 beneficial holders of our common stock.

 

Special Dividend

 

On November 7, 2019, the Board of Directors declared a special cash dividend of $1.00 per share, payable on December 30, 2019 to shareholders of record as of the close of business on December 23, 2019.

 

Issuer Purchases of Equity Securities

 

The following table provides information about our purchases of equity securities during the quarter ended December 31, 2022 registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"):

 

Period

   Total Number of Shares Purchased (a)     Average Price Paid Per Share    

Total Number of Shares Purchased as Part of Publicly Announced Plan (b)

    

Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plan (b)

  

October 1, 2022 - October 31, 2022

     38,934     $ 3.61       36,392     $ 15,454,297  

November 1, 2022 - November 30, 2022

     177,526     $ 3.45       174,984     $ 14,854,705  

December 1, 2022 - December 31, 2022

     49,112     $ 3.09       46,570     $ 14,711,067  

Total

     265,572     $ 3.41       257,946          

 

(a) During the fourth quarter of 2022, we repurchased an aggregate of approximately 8 thousand shares of our common stock initially issued as restricted stock awards to employees and subsequently withheld from employees to satisfy the statutory withholding tax liability upon the vesting of such restricted stock awards.

 

(b) In 2015, the Company's Board of Directors authorized us, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended December 31, 2022 and 2021, we did not repurchase any shares under this authorization. In May 2021, the Company's Board of Directors authorized a $6.0 million share repurchase program (the "2021 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2021, the Company purchased 236,159 shares under the 2021 Plan at an aggregate cost of $1.6 million, or $6.94 per share.  During October 2021, the Company suspended the 2021 Plan and completed a modified Dutch auction self-tender that resulted in the repurchase of 4.3 million common shares for an aggregate price of $38.7 million, or $9.00 per share. In March 2022, the Company's Board of Directors replaced the 2021 Plan and authorized a separate $3.0 million share repurchase program (the "2022 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2022, the Company purchased 711,481 shares under the 2022 Plan at an aggregate cost of $2.9 million, or $4.13 per share.  The Company completed the 2022 Plan in January 2023 by purchasing an additional 25,096 shares, resulting in an average price of $4.09 for the 2022 Program.

 

14
Table of Contents

 

Item 6. Selected Consolidated Financial Data

 

Not applicable for a smaller reporting company.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Concerning Forward-Looking Statements

 

This Annual Report on Form 10-K contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard” or “we”), the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts.  These statements include, in particular, statements about our plans, strategies and prospects.  For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Our forward-looking statements are subject to risks and uncertainties.  Factors that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our ownership interests may vary from period to period, our substantial capital requirements and absence of liquidity from our holdings, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, our ability to execute our strategy, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests companies, the uncertainty of the outcomes of corporate strategic transactions, if any, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our ownership interests and their performance, including the fact that most of the companies in which we have an ownership interest have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which they operate, compliance with government regulation and legal liabilities, all of which are discussed in Item 1A. “Risk Factors.” Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur.

 

Overview

 

Historically, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Typically, we are actively involved in strategic and operational decisions through our board representation in addition to the influence we exert through our equity ownership. We also continue to hold relatively small equity interests in other enterprises where we do not exert significant influence and do not participate in management activities. In some cases, those ownership interests relate to residual interests from prior larger interests or from companies that acquired companies in which we had ownership interests.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders.  We have considered and taken action on various initiatives including the sale of our ownership interests, the sale of certain or all of our ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  In December 2019, we declared and paid a $1.00 per share special dividend. In 2021, we repurchased 4.5 million shares through a combination of open market purchases and a tender offer for an aggregate of $40.7 million resulting in an average price of $8.95 per share.  In 2022, we repurchased 711,481 shares for $2.9 million at an average price of $4.13 per share through subsequent open market repurchase plans. We will continue to actively work with our ownership interests to seek monetization opportunities while we also evaluate additional strategic alternatives. These strategic alternatives could include the sale of all of our ownership interests in a single transaction or a series of transactions, merger, business combinations or other strategic transactions. 

 

Principles of Accounting for Ownership Interests

 

We account for our ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of our influence over the entity, primarily determined by our voting interest in the entity.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost.  Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations.  The Company also adjusts the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

15
Table of Contents

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative.  Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interests of the same issuer.  Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets. 

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  Under this method, the changes in fair value are reflected in Other income (loss), net. As of December 31, 2022 those ownership interests consist of approximately 1.3 million shares of Bright Health Group ("Bright Health") common shares valued at $0.9 million.

 

Critical Accounting Policies and Estimates

 

Accounting policies, methods and estimates are an integral part of the Consolidated Financial Statements prepared by management and are based upon management’s current judgments. These judgments are normally based on knowledge and experience with regard to past and current events and assumptions about future events. Certain accounting policies, methods and estimates are particularly important because of their significance to the financial statements and because of the possibility that future events affecting them may differ from management’s current judgments. While there are a number of accounting policies, methods and estimates affecting our financial statements as described in Note 1 to our Consolidated Financial Statements, the most significant relate to impairment of ownership interests and advances.

 

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company, and other relevant factors. The business plan objectives and milestones we consider include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.  Management then determines whether there has been an other than temporary decline in the company.  Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. 

 

The reduced carrying value a previously impaired company accounted for using the Equity method is not increased even if circumstances suggest the value of the company has subsequently recovered.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies, or based on other valuation methods including discounted cash flows, valuations of comparable public companies and valuations of acquisitions of comparable companies. 

 

Our companies operate in industries which are rapidly evolving and extremely competitive. It is reasonably possible that our accounting estimates with respect to the ultimate recoverability of the carrying value of ownership interests and advances could change in the near term and that the effect of such changes on our Consolidated Financial Statements could be material. While we believe that the current recorded carrying values of our equity and other method companies are not impaired, there can be no assurance that our future results will confirm this assessment or that a significant write-down or write-off will not be required in the future.

 

Total impairment charges related to our Ownership interests and advances were as follows: 

 

   

Year Ended December 31,

  

Accounting Method

  

2022

    

2021

  
   

(In thousands)

  

Equity

   $ —     $ —  

Other

     —       2,521  

Total

   $ —     $ 2,521  

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to other ownership interests are included in Other income (loss), net in the Consolidated Statements of Operations.

 

16
Table of Contents

 

Results of Operations

 

We operate as one operating segment based upon the similar nature of our technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

There is intense competition in the markets in which our companies operate. Additionally, the markets in which these companies operate are characterized by rapidly changing technology, evolving industry standards, frequent introduction of new products and services, shifting distribution channels, evolving government regulation, frequently changing intellectual property landscapes and changing customer demands. Their future success depends on each company’s ability to execute its business plan and to adapt to its respective rapidly changing market.

 

The following is a listing of certain of our ownership interests as of December 31, 2022 and 2021. The ownership percentages indicated below are presented as of December 31, 2022 for certain companies in which we held ownership interests and reflect the percentage of the vote we were entitled to cast at that date based on issued and outstanding voting securities (on a common stock equivalent basis), excluding the effect of options, warrants and convertible debt (primary ownership).

 

    Safeguard Primary Ownership as of December 31,    

Company Name

  

2022

  

2021

  

Accounting Method

Aktana, Inc.

     13.6 %     13.4 %  

Equity

Clutch Holdings, Inc.

     41.7 %     41.7 %  

Equity

InfoBionic, Inc.

     25.2 %     25.2 %  

Equity

meQuilibrium

     31.3 %     31.9 %  

Equity

Moxe Health Corporation

     19.3 %     27.6 %  

Equity

Prognos Health Inc.

     28.4 %     28.5 %  

Equity

Syapse, Inc.

     11.0 %     11.1 %  

Equity

Trice Medical, Inc.

     11.6 %     12.6 %  

Equity

 

Year ended December 31, 2022 versus year ended December 31, 2021

 

   

Year Ended December 31,

  
   

2022

    

2021

    

Variance

  
   

(In thousands)

  

General and administrative expense

   $ (4,775 )   $ (7,153 )   $ 2,378  

Other income (loss), net

     (3,297 )     22,035       (25,332 )

Interest income

     794       276       518  

Equity income (loss), net

     (6,985 )     11,846       (18,831 )

Net income (loss)

   $ (14,263 )   $ 27,004     $ (41,267 )

 

General and Administrative Expense. Our general and administrative expenses consist primarily of employee compensation, stock based compensation, insurance, office costs and professional services. General and administrative expense decreased $2.4 million, or 33%, for the year ended December 31, 2022 compared to the prior year due to lower employee compensation of $1.1 million, lower severance costs of $0.8 million, lower stock based compensation costs of $0.3 million, lower insurance costs of $0.2 million and various other lower costs. General and administrative expenses also can include amounts estimated for the Transaction Bonus Plan (the "LTIP"), which is a component of employee compensation.  As described in Note 11 in the accompany consolidated financial statements, the LTIP provides a cash bonus pool to employees based upon meeting certain thresholds of sales of the Company's ownership interests.  Expense recognized pursuant to the LTIP was zero and $0.7 million during the years ended December 31, 2022 and 2021, respectively.  The Company paid $2.5 million pursuant to the LTIP plan during 2021.  No further amounts have been accrued with respect to the LTIP.  General and administrative expense also includes stock based compensation expense of $1.4 million and $1.8 million years ended December 31, 2022 and 2021, respectively.  Stock based compensation continues to include a significant proportion of management's overall compensation, including the settlement of amounts due pursuant to the annual management incentive plan, and Director compensation, which aggregated to $0.7 million for the year ended December 31, 2022.

 

17
Table of Contents

 

Other income (loss), net. Other income (loss), net decreased by $25.3 million for the year ended December 31, 2022, compared to the prior year.  During the year ended December 31, 2022, the primary component was unrealized losses resulting from the decline in the fair value of BHG common stock of $3.7 million.  During the year ended December 31, 2021, the Company recorded a gain from the sale of Flashtalking of $32.5 million, gains aggregating to $2.8 million from the sales of Velano Vascular and T-REX Group, unrealized losses net of $10.8 million from an observable price change and subsequent changes in the fair value of BHG common stock, and a $2.5 million impairment related to certain other ownership interests.  The impairments were determined based on declines in the fair value of our ownership interests resulting from reduced valuation expectations and extended exit timelines resulting from the more challenging mergers and acquisitions environment related to COVID-19 and the related uncertain economic impact.   

 

Interest Income. Interest income increased $0.5 million for the year ended December 31, 2022 compared to the prior year due primarily to higher market interest rates on marketable securities during 2022.

 

Equity Income (Loss), net. Equity income (loss), net fluctuates with the number of companies accounted for under the equity method, our voting ownership percentage in those companies and the net results of operations of those companies. We recognize our share of losses to the extent we have cost basis in the equity of the company or we have outstanding commitments or guarantees. Certain amounts recorded to reflect our share of the income or losses of our companies accounted for under the equity method are based on estimates and on unaudited results of operations of those companies and may require adjustments in the future when audits of these entities are made final. We report our share of the results of our equity method companies on a one quarter lag basis.

 

Equity income (loss), net decreased $18.8 million for the year ended December 31, 2022 compared to the prior year. The components of equity income (loss), net for the years ended December 31, 2022 and 2021 were as follows:

 

   

Year Ended December 31,

  
   

2022

    

2021

    

Variance

  
   

(In thousands)

  

Gains on sales of ownership interests

   $ 5,627     $ 19,146     $ (13,519 )

Unrealized dilution gains

     5,285       9,252       (3,967 )

Loss on impairments

     —       —       —  

Share of losses of our equity method companies, net

     (17,897 )     (16,552 )     (1,345 )
    $ (6,985 )   $ 11,846     $ (18,831 )

 

During the year ended December 31, 2022, the gains on sales of ownership interests are primarily related to Lumesis of $4.9 million.  During the year ended December 31, 2021, the gains on sales of ownership interests are comprised primarily of gains related to Zipnosis for $17.3 million and AHS for $2.0 million.   

 

The unrealized dilution gains for the year ended December 31, 2022 were related to Moxe and for the year ended December 31, 2021 were the result of Syapse and Trice, who each raised additional equity capital that diluted the Company's interest in those entities. 

 

18
Table of Contents

 

 

The increase in our share of losses of our equity method companies for the 2022 year compared to the prior year period was due to increased losses at principally three companies which did not experience their planned revenue growth.  These increases were offset the decrease in losses applicable to two ownership interests where our carrying value was reduced to zero.

 

Income Tax Benefit (Expense)

 

There was no income tax benefit (expense) for the years ended December 31, 2022 and 2021. We have recorded a valuation allowance to reduce our net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in each year was offset by changes in the valuation allowance.

 

Liquidity And Capital Resources

 

As of December 31, 2022, the Company had $13.3 million of cash and cash equivalents and $6.0 million of marketable securities.

 

In 2015, the Company's Board of Directors authorized us, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended December 31, 2022 and 2021, we did not repurchase any shares under this authorization.

 

In May 2021, the Company's Board of Directors authorized a $6.0 million share repurchase program (the "2021 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2021, the Company purchased 236,159 shares under the 2021 Plan at an aggregate cost of $1.6 million, or $6.94 per share.  During October 2021, the Company suspended the 2021 Plan and completed a modified Dutch auction self-tender that resulted in the repurchase of 4.3 million common shares for an aggregate price of $38.7 million, or $9.00 per share.

 

In March 2022, the Company's Board of Directors replaced the 2021 Plan and authorized a separate $3.0 million share repurchase program (the "2022 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2022, the Company purchased 711,481 shares under the 2022 Plan at an aggregate cost of $2.9 million, or $4.13 per share.  The Company completed the 2022 Plan in January 2023 by purchasing an additional 25,096 shares, resulting in an average price of $4.09 for the 2022 Program.

 

We may consider additional stock repurchases or dividends in the future based on prevailing market conditions and other factors when and if additional liquidity becomes available.

 

Our ability to generate liquidity from transactions involving our ownership interests has been adversely affected from time to time by adverse circumstances in the U.S. capital markets and other factors, including the impact of COVID-19.  We may be requested to provide additional capital to our companies, which may cause us to face liquidity issues that will constrain our ability to execute our business strategy and limit our ability to provide financial support to all of our existing companies in the amounts that we desire. The transactions we enter into in pursuit of our strategy could increase or decrease our liquidity at any point in time. As we seek to provide additional funding to existing companies where we have an ownership interest or commit capital to other initiatives, we may be required to expend our cash or incur debt, which will decrease our liquidity. Conversely, as we dispose of our interests in our ownership interests, we may receive proceeds from such sales, which could increase our liquidity. From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly. Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.  The Company believes that its cash and cash equivalents at December 31, 2022 will be sufficient to fund operations past one year from the issuance of these financial statements.

 

Analysis of Consolidated Cash Flows

 

Cash flow activity was as follows: 

 

   

Year Ended December 31,

  
   

2022

    

2021

    

Variance

  
   

(In thousands)

          

Net cash used in operating activities

   $ (3,258 )   $ (8,152 )   $ 4,894  

Net cash provided by (used in) investing activities

     (4,662 )     58,114       (62,776 )

Net cash used in financing activities

     (3,488 )     (40,799 )     37,311  
    $ (11,408 )   $ 9,163     $ (20,571 )

 

19
Table of Contents

 

Net Cash Used In Operating Activities

 

Year ended December 31, 2022 versus year ended December 31, 2021. Net cash used in operating activities decreased for the year ended December 31, 2022 compared to the prior year. The activity during the year ended December 31, 2022 was primarily the result of various non-cash adjustments to net loss, including $7.0 million of equity loss and a $3.7 million unrealized loss on the decrease in fair value of Bright Health common stock. The activity during the year ended December 31, 2021 was primarily the result of various non-cash adjustments to net income, including the $11.8 million of equity income, non-cash gains, net, of $8.5 million for observable prices changes and $35.3 million for gain on sales of ownership interests which were partially offset by $19.3 million change in the fair value of ownership interests and $2.5 million impairment losses at certain Other ownership interests. 

 

Net Cash (Used in) provided by Investing Activities

 

Year ended December 31, 2022 versus year ended December 31, 2021. Net cash (used in) provided by investing activities decreased by $62.8 million for the year ended December 31, 2022 compared to the prior year. During the year ended December 31, 2022, the Company funded an aggregate of $5.7 million to Syapse, Inc, Prognos Health, Clutch Holdings, meQuilibrium and Trice Medical, Inc. as compared to aggregate of $2.7 million funded to Trice Medical and Aktana during the year ended December 31, 2021.  During the year ended December 31, 2022, the Company received $5.5 million of cash proceeds from the Lumesis transaction and various other amounts resulting from the resolution or expiration of escrow contingencies, as compared to the Company receiving an aggregate of $60.8 million of cash proceeds from the Flashtalking, WebLinc, Zipnosis, T-REX and Velano Vascular transactions during the year ended December 31, 2021.    

 

Net Cash Used In Financing Activities

 

Year ended December 31, 2022 versus year ended December 31, 2021. Net cash used in financing activities decreased by $37.3 million for the year ended December 31, 2022 compared to the prior year. The decrease was primarily the result of  repurchases of common stock of $2.9 million for the year ended December 31, 2022 as compared to $40.7 million for the year ended December 31, 2021.  There were no other significant financing activities for the years ended December 31, 2022. 

 

Contractual Cash Obligations and Other Commercial Commitments

 

   

Payments Due by Period

  
   

Total

    

2023

    

2024 and 2025

    

2026 and 2027

    

After 2027

  
   

(In millions)

  

Contractual Cash Obligations:

                                        

Operating leases (a)

   $ 2.0     $ 0.6     $ 1.2     $ 0.2     $ —  

Total Contractual Cash Obligations (b)

   $ 2.0     $ 0.6     $ 1.2     $ 0.2     $ —  

 

(a)  In 2015, we entered into an agreement for the lease of our former principal executive offices which expires in April 2026.  Payments pursuant to this lease are approximately $2.0 million through expiration, however, in March 2019 we entered into a sublease for this office space which is expected to result in future aggregate sublease receipts of $1.9 million through April 2026. 

 

(b)  The  maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $1.1 million at December 31, 2022 and up to 250,000 common shares. We are involved from time to time in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of any of these matters which are currently pending will not have a material adverse effect on our consolidated financial position or results of operation.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable for a smaller reporting company.

 

20
Table of Contents

 

 

Item 8. Financial Statements and Supplementary Data

 

The following Consolidated Financial Statements, and the related Notes thereto, of Safeguard Scientifics, Inc. and the Reports of Independent Registered Public Accounting Firm are filed as a part of this Form 10-K.

 

 

 

Page

Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248) 

22

Consolidated Balance Sheets as of December 31, 2022 and 2021

23

Consolidated Statements of Operations for the years ended December 31, 2022 and 2021

24

Consolidated Statements of Changes in Shareholders' Equity for the years ended December 31, 2022 and 2021

25

Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021

26

Notes to Consolidated Financial Statements

27

 

21
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

Board of Directors and Shareholders
Safeguard Scientifics, Inc

 

Opinion on the financial statements

 

We have audited the accompanying consolidated balance sheets of Safeguard Scientifics, Inc. (a Pennsylvania corporation) and subsidiaries (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, changes in shareholders’ equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical audit matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Impairment of ownership interests and advances

 

The Company evaluates the carrying value of its ownership interests and advances for possible impairment. This evaluation requires management to apply significant judgment particularly related to the achievement of business plan objectives and milestones, the financial condition and prospects of the portfolio company, market conditions and other relevant factors. Based on the above, management then determines whether there has been an other than temporary decline in the value of its ownership interest in or advance to the portfolio company. The identification of other than temporary impairment of ownership interests and advances was determined to be a critical audit matter.

 

The principal consideration for our determination that the identification of other than temporary impairment of ownership interests and advances is a critical audit matter is due to it being an area of the financial statements requiring significant auditor judgment and subjectivity in assessing the results of management’s qualitative impairment analysis. Ownership interests and advances held by the Company are primarily comprised of early-stage companies in industries that are rapidly evolving, where evaluation of other than temporary declines in value requires significant judgment by management.

 

Our audit procedures related to identification of other than temporary impairment of ownership interests and advances included the following, among others:

 

 

●

We evaluated the design of certain internal controls related to the Company’s impairment assessment. This included controls over the identification of other than temporary declines in value and the impairment analysis, including financial condition, prospects and other factors present at the portfolio company.

 

 

●

We held discussions with those outside of accounting with intimate knowledge of the portfolio companies, including those with board positions and those employed by the portfolio companies, to gain an understanding of operational performance, milestones achieved, and potential indicators of other than temporary declines in value.

 

 

●

For a selection of portfolio companies, we reviewed the financial performance, relevant third-party information with indications of company values, board materials, press releases and other public information for potential indicators of other than temporary declines in value.

 

 

/s/ GRANT THORNTON LLP

 

We have served as the Company’s auditor since 2021.

 

Philadelphia, Pennsylvania

March 10, 2023

 

22
Table of Contents

  

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

 

  

As of December 31,

 
  

2022

  

2021

 

ASSETS

        

Current Assets:

        

Cash and cash equivalents

 $13,331  $24,739 

Restricted cash

  25   25 

Marketable securities

  5,956   — 

Ownership interests

  860   4,549 

Prepaid expenses and other current assets

  1,251   965 

Total current assets

  21,423   30,278 

Right-of-use asset, net

  1,290   1,561 

Ownership interests and advances

  14,545   21,972 

Other assets

  434   217 

Total Assets

 $37,692  $54,028 

LIABILITIES AND EQUITY

        

Current Liabilities:

        

Accounts payable

 $16  $41 

Accrued compensation and benefits

  507   794 

Accrued expenses and other current liabilities

  865   524 

Lease liability - current

  429   375 

Total current liabilities

  1,817   1,734 

Lease liability - non-current

  1,249   1,678 

Other long-term liabilities

  50   50 

Total Liabilities

  3,116   3,462 

Commitments and contingencies (Note 11)

          

Equity:

        

Preferred stock, $0.10 par value; 1,000 shares authorized

  —   — 

Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2022 and 2021, respectively

  2,157   2,157 

Additional paid-in capital

  804,752   806,638 

Treasury stock, at cost; 5,478 and 5,068 shares at December 31, 2022 and 2021, respectively

  (48,410)  (48,569)

Accumulated deficit

  (723,898)  (709,635)

Accumulated other comprehensive loss

  (25)  (25)

Total Equity

  34,576   50,566 

Total Liabilities and Equity

 $37,692  $54,028 

 

See Notes to Consolidated Financial Statements.

 

23
Table of Contents

 

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

 

   

Year Ended December 31,

  
   

2022

    

2021

  

General and administrative expense

   $ 4,775     $ 7,153  

Operating loss

     (4,775 )     (7,153 )

Other income (loss), net

     (3,297 )     22,035  

Interest income

     794       276  

Equity income (loss), net

     (6,985 )     11,846  

Net income (loss) before income taxes

     (14,263 )     27,004  

Income tax benefit (expense)

     —       —  

Net income (loss)

   $ (14,263 )   $ 27,004  

Net income (loss) per share:

                

Basic

   $ (0.87 )   $ 1.36  

Diluted

   $ (0.87 )   $ 1.36  

Weighted average shares used in computing net income (loss) per share:

                

Basic

     16,337       19,827  

Diluted

     16,337       19,827  

 

See Notes to Consolidated Financial Statements.

 

24
Table of Contents

 

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(In thousands)

 

           

Accumulated

    

Accumulated Other Comprehensive

    

Common Stock

    

Additional Paid-In

    

Treasury Stock

  
   

Total

    

Deficit

    

Loss

    

Shares

    

Amount

    

Capital

    

Shares

    

Amount

  

Balance — December 31, 2020

   $ 62,875     $ (736,639 )   $ (25 )     21,573     $ 2,157     $ 807,582       688     $ (10,200 )

Net income

     27,004       27,004       —       —       —       —       —       —  

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

     736       —       —       —       —       (1,550 )     (161 )     2,286  

Stock-based compensation

     606       —       —       —       —       606       —       —  

Repurchases of common stock

     (40,655 )     —       —       —       —       —       4,541       (40,655 )

Balance — December 31, 2021

   $ 50,566     $ (709,635 )   $ (25 )     21,573     $ 2,157     $ 806,638       5,068     $ (48,569 )

Net loss

     (14,263 )     (14,263 )     —       —       —       —       —       —  

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

     477       —       —       —       —       (2,622 )     (302 )     3,099  

Stock-based compensation

     736       —       —       —       —       736       —       —  

Repurchases of common stock

     (2,940 )     —       —       —       —       —       712       (2,940 )

Balance — December 31, 2022

   $ 34,576     $ (723,898 )   $ (25 )     21,573     $ 2,157     $ 804,752       5,478     $ (48,410 )

 

See Notes to Consolidated Financial Statements.

 

25
Table of Contents

 

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Cash Flows from Operating Activities:

                

Net income (loss)

   $ (14,263 )   $ 27,004  

Adjustments to reconcile to net cash used in operating activities:

                

Amortization of right of use asset

     271       229  

Equity (income) loss, net

     6,985       (11,846 )

Impairments of ownership interests and advances

     —       2,521  

Gain from observable price changes

     (553 )     (8,505 )

Gain from sales of ownership interests

     —       (35,284 )

Change in fair value of ownership interests

     3,689       19,255  

Other, net

     76       (22 )

Stock-based compensation, including liability classified awards

     1,445       1,779  

Changes in assets and liabilities:

                

Prepaid expenses and other current assets

     (534 )     (238 )

Accounts payable, accrued expenses, and other current liabilities

     (374 )     (3,045 )

Net cash used in operating activities

     (3,258 )     (8,152 )

Cash Flows from Investing Activities:

                

Proceeds from sales and distributions from ownership interests

     6,879       60,832  

Advances and loans to ownership interests

     (5,670 )     (2,718 )

Purchase of marketable securities

     (11,871 )     —  

Proceeds, from sales and maturities in marketable securities

     6,000       —  

Net cash (used in) provided by investing activities

     (4,662 )     58,114  

Cash Flows from Financing Activities:

                

Repurchases of common stock

     (2,939 )     (40,655 )

Tax withholdings related to equity-based awards

     (549 )     (144 )

Net cash used in financing activities

     (3,488 )     (40,799 )

Net change in cash, cash equivalents and restricted cash

     (11,408 )     9,163  

Cash, cash equivalents and restricted cash equivalents at beginning of period

     24,764       15,601  

Cash, cash equivalents and restricted cash at end of period

   $ 13,356     $ 24,764  

 

See Notes to Consolidated Financial Statements.

 

26
Table of Contents

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

1. General

 

Liquidity And Capital Resources

 

As of December 31, 2022, Safeguard Scientifics, Inc. ("the Company") had $13.3 million of cash and cash equivalents and $6.0 million of marketable securities.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders.   We have considered and taken action on various initiatives including the sale of our ownership interests, the sale of certain or all of our ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value. As we seek to provide additional funding to existing companies where we have an ownership interest, we may be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    

 

The Company believes that its cash and cash equivalents at December 31, 2022 will be sufficient to fund operations past one year from the issuance of these consolidated financial statements. 

 

Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

 

Principles of Accounting for Ownership Interests in Companies

 

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

 

In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost.  Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations.  The Company also adjust the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative.  Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interests of the same issuer.  Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  Under this method, the changes in fair value are reflected in Other income (loss), net. As of December 31, 2022 those ownership interests consist of approximately 1.3 million common shares of Bright Health Group ("Bright Health") valued at $0.9 million.  

 

Comprehensive Income (loss) 

 

During the years ended December 31, 2022 or 2021, there were no items of comprehensive income (loss).

 

27
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

Accounting Estimates

 

The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

 

Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may require adjustments in the future when audits of these entities’ financial statements are completed.

 

It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2022, the Company believes the carrying value of the Company’s ownership interests and advances is not impaired, although there can be no assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will not be required in the future or that a significant loss will not be recorded in the future upon the sale of a company.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits that are readily convertible into cash.  The Company has not experienced any significant losses on cash equivalents and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

 

Restricted Cash

 

Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows:

 

  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Cash and cash equivalents

 $13,331  $24,739 

Restricted cash

  25   25 

Total cash, cash equivalents and restricted cash

 $13,356  $24,764 

 

Financial Instruments

 

The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. 

 

Right-of-use asset

 

Right-of-use assets represent an operating lease for office facilities.  The right-of-use assets are reduced over the remaining term of the applicable lease (principally April 2026) in a manner that results in a straight-line lease expense, when combined with the interest factor on the lease liability.     

 

28
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

Lease liability

 

The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 associated with the Company's prior corporate headquarters operating office lease. The discount rate used to calculate the lease liability was based on the Company's incremental borrowing rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease, which was approximately 12%, at the transition to the guidance of ASU No. 2016-02, Leases. Subsequent values of the lease liability reflect the reduction in the lease liability for operating lease payments less an amount representing interest, which is included in the straight-line lease expense. There is no residual value guarantee associated with this operating lease arrangement. The Company has incurred operating lease expenses and operating cash outflows of $0.5 million for each of the years ended December 31, 2022 and 2021, respectively, and $0.6 million for each of the years ended December 31, 2022 and 2021.

 

 

In March 2019, the Company entered into a sublease of its prior corporate headquarters office space. The term of the sublease is through April 2026, the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.

 

A summary of the Company's operating lease cash flows at December 31, 2022 follows:

 

  Operating lease payments  

Expected sublease receipts

 
  

(In thousands)

 

2023

 $607  $556 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

  —   — 

2028

  —   — 

Thereafter

  —   — 

Total future minimum lease payments

  2,046   1,918 

Less imputed interest

  (368)    

Total operating lease liabilities

 $1,678     

 

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

 

29
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations.

 

The reduced cost basis of a previously impaired company accounted for using the Equity method are not written-up if circumstances suggest the value of the company has subsequently recovered.

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not considered more likely than not to be realized.

 

Net Income (Loss) Per Share

 

The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.

 

Segment Information

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

30
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 
 

2. Ownership Interests and Advances

 

The following summarizes the carrying value of the Company’s ownership interests and advances.

 

  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Equity Method:

        

Companies

 $8,749  $21,091 

Private equity funds

  97   117 
   8,846   21,208 

Other Method:

        

Companies, fair value

  860   4,549 

Companies, fair value measurement alternative

  1,067   514 

Private equity funds, fair value measurement alternative

  250   250 
   2,177   5,313 

Advances to companies

  4,382   — 
  $15,405  $26,521 

 

In September 2022, Lumesis, Inc. was acquired by another entity for cash.  The Company received $5.5 million in cash proceeds in connection with this transaction, excluding holdbacks and escrows.  This transaction resulted in a gain of $4.9 million, including $0.8 million other receivable related to an indemnification escrow during the year ended December 31, 2022.   

 

In March 2021, Zipnosis, Inc. was acquired by another entity, Bright Health.  The Company received $3.5 million in cash proceeds, including escrows, and $15.3 million in preferred equity in the acquiror in connection with this transaction.  This ownership interest represented a security that did not have a readily determinable fair value.  Due to the inherent uncertainty of determining the fair value of ownership interests that do not have a readily determinable fair value, this estimated value  may differ significantly from the value that would have been reported had a ready market for the security existed, and it is reasonably possible that the difference could be material.  The Company recognized a $17.3 million gain on the sale, which is included in Equity income (loss), net in the Consolidated Statements of Operations.  The fair value of the ownership interest received as a result of the acquisition was estimated based on evaluating several valuation methods available, including the value at which independent third parties have recently invested, the valuation of comparable public companies, and the present value of our expected outcomes.  Assumptions considered within these methods include determining which public companies are comparable, projecting forward revenues, selecting an appropriate valuation multiple, discounts to apply for the lack of marketability or lack of comparability, other factors and the relative weight to apply to each valuation method available.  Due to the unobservable nature of some of these inputs, we determined this initial estimate to be a Level 3 fair value measurement.  During the three months ended June 30, 2021, Bright Health completed an initial public offering that resulted in our ownership interest converting into approximately 1.3 million common shares.  Accordingly, the Bright Health common shares represent an ownership interest with a readily determinable fair value (Level 1), which will subsequently be measured at fair value with unrealized gains (losses) being reported as a component of Other income (loss), net.  As a result, the Company recognized a $10.8 million unrealized loss, net, on Bright Health subsequent to the initial public offering during the year ended December 31, 2021. The Company recognized a $3.7 million unrealized loss on Bright Health during the year ended December 31, 2022.

 

In August 2021, Flashtalking was acquired by another entity.  The Company has received $45.0 million in cash proceeds, including escrows, and included a $32.5 million gain in Other income (loss), net, during the year ended December 31, 2021.  The Company may receive additional amounts of up to approximately $0.5 million over the next 12 months from the resolution of escrow contingencies.  

 

In January 2021, WebLinc, Inc. was acquired by another entity.  The Company has received $3.6 million in cash proceeds to-date, which could be partially offset by indemnifiable claims.  The Company has recognized a $0.1 million loss on the sale during the year ended December 31, 2021, which is included in Equity income (loss), as certain contingencies were resolved.  During the year ended December 31, 2022, the Company recognized $0.5 million as gain on sale as the result of the collection of additional amounts and as contingencies were resolved, those amounts were recorded as gain on the sale and included within Equity income (loss). 

 

QuanticMind and Hoopla were acquired in separate transactions during the first quarter of 2021 by other entities, however there were no resultant proceeds to the Company.  There was no resulting gain or loss due to this equity method ownership interest being impaired during the prior year.

 

In March 2021, the Company's ownership interest in T-REX Group, Inc., which was accounted for using the fair value measurement alternative, was acquired for $3.0 million in cash.  The Company recognized a $0.9 million gain, which is included in Other income (loss), net.  

 

In April 2021, Velano Vascular was acquired by another entity.  The Company has received $4.0 million in cash proceeds, including escrows, and included a $1.9 million gain in Other income (loss), net, for the year ended December 31, 2021.  

 

In December 2021, the Company received $2 million of contingent proceeds resulting from resolution of certain valuation thresholds remaining from the 2018 sale of AdvantEdge Healthcare Solutions.

 

During the year ended December 31, 2021, the Company recorded an impairment of $2.5 million related to reduced expectations for certain Other ownership interests, which is included in Other income (loss), net. 

 

31
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

As of December 31, 2022, the Company held ownership interests accounted for using the equity method in 8 non-consolidated companies. 

 

Certain of the Company’s ownership interests as of December 31, 2022 and 2021 included the following:

 

  

Safeguard Primary Ownership as of December 31,

  

Company Name

 

2022

  

2021

 

Accounting Method

Aktana, Inc.

  13.6%  13.4%

Equity

Clutch Holdings, Inc.

  41.7%  41.7%

Equity

InfoBionic, Inc.

  25.2%  25.2%

Equity

meQuilibrium

  31.3%  31.9%

Equity

Moxe Health Corporation

  19.3%  27.6%

Equity

Prognos Health Inc.

  28.4%  28.5%

Equity

Syapse, Inc.

  11.0%  11.1%

Equity

Trice Medical, Inc.

  11.6%  12.6%

Equity

 

Summarized Financial Information

 

The following table provides summarized financial information for ownership interests accounted for under the equity method for the periods presented and has been compiled from respective company financial statements, reflect certain historical adjustments, and are reported on a one quarter lag. Results of operations are excluded for periods prior to their acquisition and subsequent to their disposition. Historical results are not adjusted when the Company exits or writes-off a company. 

 

  

As of December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Balance Sheets:

        

Current assets

 $126,042  $127,651 

Non-current assets

  55,073   53,220 

Total assets

 $181,115  $180,871 

Current liabilities

 $92,990  $62,538 

Non-current liabilities

  220,681   158,975 

Shareholders’ deficit

  (132,556)  (40,642)

Total liabilities and shareholders’ deficit

 $181,115  $180,871 
         

Number of equity method ownership interests

  8   9 

 

  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Results of Operations:

        

Revenue

 $144,771  $140,670 

Gross profit

 $88,666  $90,388 

Net loss

 $(152,936) $(106,363)

 

As of December 31, 2022, the Company’s carrying value in equity method companies, in the aggregate, exceeded the Company’s share of the net assets of such companies by approximately $2.7 million. Of this excess, $2.5 million was allocated to goodwill and $0.2 million was allocated to intangible assets.

 
 

3. Acquisitions of Ownership Interests

 

2022 Transactions

 

The Company funded $1.6 million of convertible loans to Syapse, Inc.  The Company had previously deployed an aggregate of $25.0 million.  Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models.

 

The Company funded $2.0 million of convertible loans to Prognos Health Inc.  The Company had previously deployed an aggregate of $12.6 million.  Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with life sciences brands, payers, and clinical diagnostics organizations.  Prognos' innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.

 

The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million.  Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. 

 

The Company funded $0.5 million of convertible loans to meQuilibrium.  The Company had previously deployed an aggregate of $14.0 million.  meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers, and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being.

 

The Company funded $0.1 million of convertible loans to Trice Medical.  The Company had previously deployed an aggregate of $11.8 million.  Trice Medical is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians.  The Company also committed to provide another $0.3 million under certain conditions pursuant to a subordinated line of credit.  The Company's obligation under this line of credit is included in accrued expenses. Subsequent to the year end, the Company funded $0.3 million in accordance with this line of credit.

 

2021 Transactions

 

The Company funded $1.7 million to Aktana, Inc. during the three months ended September 30, 2021. The Company had previously deployed an aggregate of $14.2 million. Aktana helps its customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions and providing insight regarding which strategies work best for which customers under which conditions.

 

Syapse raised $68 million of preferred equity during the three months ended March 31, 2021, which reduced the Company's ownership interest to approximately 11.1%.  The Company recorded a $7.3 million dilution gain as a result of this transaction, which is included in Equity income (loss), net in the Consolidated Statements of Operation.  

 

The Company funded $1 million of convertible loans to Trice Medical, Inc. during the three months ended June 30, 2021.  During the three months ended September 30, 2021, Trice Medical raised additional preferred equity which reduced the Company's ownership interest to 12.6%.  The Company's existing convertible loans and related interest in Trice Medical were also converted into this new class of preferred equity.  As a result of this transaction, the Company recorded a $2.0 million dilution gain for the year ended December 31, 2021.

 

 

32
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

 
 

4. Fair Value Measurements

 

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.

 

Cash, cash equivalents and restricted cash approximate fair value due to their short term nature.  The Company did not have any Level 2 or Level 3 financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022.

 

  

Carrying

  

Fair Value Measurement at December 31, 2022

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(in thousands)

 

Cash and cash equivalents

 $13,331  $13,331  $—  $— 
                 

Restricted cash

 $25  $25  $—  $— 
                 

Marketable securities—held-to-maturity:

                

U.S. Government securities

 $5,956  $5,956  $—  $— 
                 

Ownership interests

 $860  $860  $—  $— 

 

  

Carrying

  

Fair Value Measurement at December 31, 2021

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(In thousands)

 

Cash and cash equivalents

 $24,739  $24,739  $—  $— 
                 

Restricted cash equivalents

 $25  $25  $—  $— 
                 

Ownership interests

 $4,549  $4,549  $—  $— 
                 
                 

 

Ownership interests accounted for at fair value as of December 31, 2022 consist of approximately 1.3 million common shares of Bright Health. The securities are carried at fair value based on the closing stock price on the last trading day of the reporting period. The Company was restricted from trading these securities until December 2021 as a result of a lock-up agreement from the Bright Health Group initial public offering.

 
 

5. Equity

 

In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended December 31, 2022 and 2021, the Company did not repurchase any shares under the existing authorization. 

 

In May 2021, the Company's Board of Directors authorized a $6.0 million share repurchase program (the "2021 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2021, the Company purchased 236,159 shares under the 2021 Plan at an aggregate cost of $1.6 million, or $6.94 per share.  During October 2021, the Company suspended the 2021 Plan and completed a modified Dutch auction self-tender that resulted in the repurchase of 4.3 million common shares for an aggregate price of $38.7 million, or $9.00 per share.

 

In March 2022, the Company's Board of Directors replaced the 2021 Plan and authorized a separate $3.0 million share repurchase program (the "2022 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2022, the Company purchased 711,481 shares under the 2022 Plan at an aggregate cost of $2.9 million, or $4.13 per share.  The Company completed the 2022 Plan in January 2023 by purchasing an additional 25,096 shares, resulting in an average price of $4.09 for the 2022 Program.

 

33
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 
 

6. Stock-Based Compensation

 

Equity Compensation Plans

 

The 2014 Equity Compensation Plan has 4.1 million shares authorized for issuance. During 2022 and 2021, the Company issued no stock-based awards outside of existing plans. To the extent allowable, service-based options are incentive stock options. Options granted under the plans are at prices equal to or greater than the fair market value at the date of grant. Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares. At December 31, 2022, the Company had reserved 2.2 million shares of common stock for possible future issuance under its 2014 Equity Compensation Plan and other previously expired equity compensation plans.

 

Classification of Stock-Based Compensation Expense

 

Stock-based compensation consists of time based awards to employees, financial liability based awards to employees and non-employees to be settled in stock, performance based awards to employees, and financial liability based awards to Directors for quarterly and annual services. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: 

 

  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

General and administrative expense

 $1,445  $1,779 
  $1,445  $1,779 

 

Stock-based compensation expense of $1.2 million and $1.2 million was recognized during the years ended  December 31, 2022 and 2021, respectively, related to annual and quarterly Board fees, time based management awards and management bonuses earned during the year that were subsequently settled in stock.  For the years ended December 31, 2022 and 2021, respectively, the Company issued 165 thousand and 83 thousand of restricted shares to Directors for their annual and quarterly services.  The annual grants vest over a one year period, or are vested at issuance for directors 65 or older, while quarterly amounts are paid in arrears.  The Company vested 110 thousand and 95 thousand shares during the years ended December 31, 2022 and 2021.  The Company vested 22 thousand and 67 thousand shares during the years ended December 31, 2022 and 2021, respectively, for time based management compensation.  The Company settled in stock other management bonuses resulting in the issuance of 82 thousand and 60 thousand vested shares for the years ended December 31, 2022 and 2021, respectively.  The Company issued 15 thousand and 20 thousand vested shares to a non-employee for services during the years ended December 31, 2022 and 2021. The Company had liabilities of $0.4 million and $0.8 million as of December 31, 2022 and 2021, respectively, that were settled through the issuance of common stock in the subsequent period. 

 

The Company has previously granted certain performance-based stock units that vest based on the achievement of targeted capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified companies. The requisite service periods for these performance-based awards were based on the Company’s estimate of when the performance conditions will be met. Compensation expense was recognized for performance-based awards for which the performance condition is considered probable of achievement. During the years ended December 31, 2022 and 2021, respectively, 92 thousand and 6 thousand performance-based stock units pursuant to these targeted capital return pools were canceled or forfeited. The Company recorded a reduction of compensation expense related to these performance-based awards of zero and $0.1 million for the years ended December 31, 2022 and 2021, respectively. During October 2020 and in January 2022, the Company granted the CEO restricted stock units that may vest based on certain performance targets and criteria determined by the Board of Directors.  Such performance-based stock units represent the right to receive shares of the Company’s common stock, on a one-for-one basis at target, or up to 120% with respect to the 2020 grant, for certain specified thresholds. For the years ended December 31, 2022 and 2021, the Company recognized stock based compensation expense of $0.2 million and $0.5 million, respectively, and vested 64 thousand and 85 thousand shares, respectively, pursuant to these arrangements.

 

Unrecognized compensation expense related to performance stock units and restricted stock at December 31, 2022 was immaterial.

 

While there were no stock options granted during 2022 and 2021, the Company had outstanding options that vest based on two different types of vesting schedules:

 

1) performance-based; and

 

2) service-based.

 

Performance-based option awards also entitled participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company upon the sale, merger or other exit transaction of certain identified companies. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated.  The Company did not issue any performance-based units during the years ended December 31, 2022 and 2021.  During the years ended December 31, 2022 and 2021, respectively, 0 thousand and 1 thousand performance-based options vested and an immaterial amount of compensation cost was recognized.  During the years ended December 31, 2022 and 2021, respectively, 11 thousand and 11 thousand performance-based options were canceled or forfeited. The maximum number of unvested options at December 31, 2022 attainable under these grants was zero shares.

 

Service-based awards generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the years ended December 31, 2022 and 2021, respectively, the Company issued no service-based options to employees and recorded zero compensation expense from the vesting of previously issued awards. During the years ended December 31, 2022 and 2021, respectively, 0 thousand and 5 thousand service-based options were canceled or forfeited.  

 

34
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

Option activity of the Company is summarized below: 

 

  

Shares

  Weighted Average Exercise Price  

Weighted Average Remaining Contractual Life

  Aggregate Intrinsic Value 
  

(In thousands)

      

(In years)

  

(In thousands)

 

Outstanding at January 1, 2021

  45   14.20         

Options granted

  —   —         

Options exercised

  —   —         

Options canceled/forfeited

  (16)  14.20         

Outstanding at December 31, 2021

  29   14.20         

Options granted

  —   —         

Options exercised

  —   —         

Options canceled/forfeited

  (11)  14.48         

Outstanding at December 31, 2022

  18   14.05   1.50  $— 

Options exercisable at December 31, 2022

  18   14.05   1.50   — 

Shares available for future grant

  2,134             

 

At December 31, 2022, total unrecognized compensation cost related to non-vested service-based options was immaterial. At December 31, 2022, total unrecognized compensation cost related to non-vested performance-based options was immaterial.

 

35
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

Deferred stock unit, performance-based stock unit and restricted stock activity are summarized below: 

 

  

Shares

  Weighted Average Grant Date Fair Value 
  

(In thousands)

     

Unvested at January 1, 2021

  287  $8.78 

Granted

  163   7.21 

Vested

  (242)  6.82 

Forfeited

  (6)  14.99 

Unvested at December 31, 2021

  202   9.70 

Granted

  343   5.60 

Vested

  (293)  5.77 

Forfeited

  (92)  13.90 

Unvested at December 31, 2022

  160   5.70 

 
 

7. Employee Benefit Plan

 

The Company maintains a qualified 401(k) retirement plan for eligible employees. The Plan’s matching formula is 100% of the first 5% of participants’ qualified compensation. Compensation expense related to our matching contributions to the Plan for the years ended December 31, 2022 and 2021, were $0.1 million and $0.1 million, respectively.

 
 

8. Income Taxes

 

The federal and state provision (benefit) for income taxes was $0.0 million for the years ended December 31, 2022 and 2021.

 

The total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal income tax rate of 21.0% for the years ended December 31, 2022 and 2021 to net income (loss) before income taxes as a result of the following:

 

  

Year Ended December 31,

 
  

2022

  

2021

 

Statutory tax expense (benefit)

  (21.0)%  21.0%

Increase (decrease) in taxes resulting from:

        

Nondeductible expenses

  (2.6)  3.3 

Valuation allowance

  23.6   (24.3)
   0.0%  0.0%

 

36
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: 

 

  

As of December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Deferred tax asset:

        

Carrying values of ownership interests and other holdings

 $33,222  $31,985 

Tax loss and credit carryforwards

  68,492   77,045 

Disallowed interest carryforwards

  6,891   7,120 

Accrued expenses

  47   24 

Stock-based compensation

  180   268 

Other

  (106)  136 
   108,726   116,578 

Valuation allowance

  (108,726)  (116,578)

Net deferred tax asset

 $—  $— 

 

As of December 31, 2022, the Company and its subsidiaries had federal net operating and capital loss carryforwards for tax purposes of approximately $326 million, of which approximately $60 million have an indefinite life. These carryforwards expire as follows: 

 

  

Total

 
  

(In thousands)

 

2023

 $45,830 

2024

  50,140 

2025

  17,266 

2026

  7,648 

2027 and thereafter

  145,275 
  $266,159 

 

In assessing the recoverability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that it is more likely than not that certain future tax benefits may not be realized as a result of current and future income. Accordingly, a valuation allowance has been recorded against substantially all of the Company’s deferred tax assets.

 

The Company recognizes in its Consolidated Financial Statements the impact of a tax position if that position is more likely than not to be sustained upon examination, based on the technical merits of the position. All uncertain tax positions relate to unrecognized tax benefits that would impact the effective tax rate when recognized.

 

The Company does not expect any material increase or decrease in its income tax expense, in the next twelve months, related to examinations or changes in uncertain tax positions.

 

There were no changes in the Company’s uncertain tax positions for the years ended December 31, 2022 and 2021.

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. Tax years 2015 and forward remain open for examination for federal tax purposes and the Company’s more significant state tax jurisdictions. To the extent utilized in future years’ tax returns, net operating loss carryforwards at December 31, 2022 will remain subject to examination until the respective tax year is closed. The Company recognizes penalties and interest accrued related to income tax liabilities in income tax benefit (expense) in the Consolidated Statements of Operations.

 

37
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 
 

9. Net Income (Loss) Per Share

 

The calculations of net income (loss) per share were: 

 

  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands, except per share data)

 

Basic:

        

Net income (loss)

 $(14,263) $27,004 

Weighted average common shares outstanding

  16,337   19,827 

Net income (loss) per share

 $(0.87) $1.36 

Diluted:

        

Net income (loss)

 $(14,263) $27,004 

Weighted average common shares outstanding

  16,337   19,827 

Net income (loss) per share

 $(0.87) $1.36 

 

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

 

If an equity method company has dilutive stock options, unvested restricted stock, DSUs, or warrants, diluted net income (loss) per share is computed by first deducting from net income (loss) the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.

 

Diluted income (loss) per share for the years ended December 31, 2022 and 2021 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:

 

 

•

At December 31, 2022 and 2021, options to purchase 18 thousand and 29 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 per share, and $10.37 to $17.11 per share per share, respectively, were excluded from the calculation.

 

 

•

At December 31, 2022 and 2021, unvested restricted stock, performance-based stock units and DSUs convertible into 0.2 million and 0.2 million shares of stock, respectively, were excluded from the calculations.

 
 

10. Related Party Transactions

 

In the normal course of business, the Company’s officers and employees hold board positions with companies in which the Company has a direct or indirect ownership interest.

 
 

11. Commitments and Contingencies

 

The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its companies. The Company records costs associated with legal fees as such services are rendered.

 

38
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

 

The Company has provided a guarantee, which is fully funded by escrowed funds held by a third party, of $3.8 million at December 31, 2022 which related to one of the Company's private equity holdings.

 

The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under severance agreements for remaining employees is approximately $1.1 million at December 31, 2022 and 250,000 common shares.

 

In 2018, the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in February 2019 and June 2020, known as the Amended and Restated Safeguard Scientifics Transaction Bonus Plan (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the business strategy that the Company adopted and announced in January 2018. The June 2020 amendment lowered the level of the first threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consistent with the business strategy.  Under the LTIP, participants, which includes certain current and former employees, have received awards that may result in cash payments in connection with sales of the Company’s ownership interests (“Sale Transaction(s)”). The LTIP provides for a bonus pool corresponding to: (i) specified vesting thresholds or (ii) specified events. In the first case, the bonus pool will range from an amount equal to 0.2% (previously 1.0%) of received proceeds at the first threshold to 1.3% at higher thresholds. In the second case, a minimum pool will be created and paid under specified circumstances. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in cash within 60 days of the applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company recorded compensation expense of zero and $0.7 million during the years ended December 31, 2022 and 2021, respectively.  The Company paid $2.5 million during the year ended December 31, 2021 and has no amounts accrued under the LTIP as of   December 31, 2022.

 

In June 2011, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.

 
 

12. Supplemental Cash Flow Information

 

During the years ended December 31, 2022 and 2021, the Company converted zero and $1.0 million, respectively, of advances into ownership interests. 

 

39
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 
 

13. Segment Reporting

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

As of December 31, 2022 and 2021, all of the Company’s assets were located in the United States.

 

40
Table of Contents
 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

  
 

14. Selected Quarterly Financial Information (Unaudited)  

 

  

Three Months Ended

 
  

March 31

  

June 30

  

September 30

  

December 31

 
  

(In thousands, except per share data)

 

2022:

                

General and administrative expense

 $1,234  $1,146  $1,360  $1,035 

Operating loss

  (1,234)  (1,146)  (1,360)  (1,035)

Other income (loss), net

  (1,997)  30   (1,012)  (318)

Interest income

  101   145   230   318 

Equity income (loss), net

  (3,579)  1,454   (1,022)  (3,838)

Net loss before income taxes

  (6,709)  483   (3,164)  (4,873)

Income tax benefit (expense)

  —   —   —   — 

Net loss

 $(6,709) $483  $(3,164) $(4,873)

Net loss per share (a)

                

Basic

 $(0.40) $0.03  $(0.19) $(0.30)

Diluted

 $(0.40) $0.03  $(0.19) $(0.30)

2021:

                

General and administrative expense

 $2,463  $1,991  $1,564  $1,135 

Operating loss

  (2,463)  (1,991)  (1,564)  (1,135)

Other income (loss), net

  706   6,733   20,588   (5,992)

Interest income

  53   74   70   79 

Equity income (loss), net

  19,329   (5,136)  (761)  (1,586)

Net income (loss) before income taxes

  17,625   (320)  18,333   (8,634)

Income tax benefit (expense)

  —   —   —   — 

Net income (loss)

 $17,625  $(320) $18,333  $(8,634)

Net income (loss) per share (a)

                

Basic

 $0.84  $(0.02) $0.88  $(0.51)

Diluted

 $0.84  $(0.02) $0.88  $(0.51)

 

 

(a)

Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.

 

41
Table of Contents
  
 

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

(a) Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of December 31, 2022 are functioning effectively.

 

(b) Management’s Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022. In making this assessment, management used the framework established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). As a result of this assessment and based on the criteria in the COSO framework, management has concluded that, as of December 31, 2022, the Company’s internal control over financial reporting was effective.

 

 

(c) Change in Internal Control over Financial Reporting

 

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

42
Table of Contents

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Incorporated by reference to the portions of our Definitive Proxy Statement entitled “Election of Directors,” “Corporate Governance and Board Matters” and “Section 16(a) Beneficial Ownership Reporting Compliance.” Information about our Executive Officers is included in Annex to Part I above.

 

Item 11. Executive Compensation

 

Incorporated by reference to the portions of our Definitive Proxy Statement entitled “Compensation Discussion and Analysis,” “Compensation Committee Report” and “Executive Compensation.”

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The material features of our equity compensation plans are described in Note 7 to the Consolidated Financial Statements filed as part of our Annual Report on Form 10-K for the year ended December 31, 2022.

 

 

43
Table of Contents

 

 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

Incorporated by reference to the portions of the Definitive Proxy Statement entitled “Corporate Governance Principles and Board Matters – ‘Board Independence’ and “Review and Approval of Transactions with Related Persons.”

 

Item 14. Principal Accountant Fees and Services

 

Incorporated by reference to the portion of the Definitive Proxy Statement entitled “Independent Public Accountant – Audit Fees.”

 

44
Table of Contents

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) Consolidated Financial Statements and Schedules

 

Incorporated by reference to Item 8 of this Report on Form 10-K.

 

(b) Exhibits

 

The exhibits required to be filed as part of this Report are listed in the exhibit index below.

 

(c) Financial Statement Schedules

 

None.

 

Exhibits

 

The following is a list of exhibits required by Item 601 of Regulation S-K filed as part of this Report. For exhibits that previously have been filed, the Registrant incorporates those exhibits herein by reference. The exhibit table below includes the Form Type and Filing Date of the previous filing and the location of the exhibit in the previous filing which is being incorporated by reference herein. Documents which are incorporated by reference to filings by parties other than the Registrant are identified in footnotes to this table.

 

 

  

 

Incorporated Filing Reference

Exhibit

Number

  

Description

Form Type & Filing

Date

  

Original

Exhibit Number

1.a

 

Description

 

 

 

3.1.1

  

Seconded Amended and Restated Articles of Incorporation of Safeguard Scientifics, Inc.

Form 8-K

10/25/07

  

3.1

3.1.2

  

Amendment to Seconded Amended and Restated Articles of Incorporation of Safeguard Scientifics, Inc.

Form 8-K

8/27/09

  

3.1

3.1.3

  

Statement with Respect to Shares

Form 10-Q

4/25/14

 

3.1

3.1.4

 

Statement of Designation of Series B Junior Participating Preferred Stock

Form 8-K

2/20/18

  

3.1

3.2

  

Third Amended and Restated By-laws of Safeguard Scientifics, Inc.

Form 8-K

2/13/18

 

3.1

10.1*

  

Safeguard Scientifics, Inc. 1999 Equity Compensation Plan, as amended and restated on October 21, 2008

Form 10-Q

11/6/08

 

10.4

10.2

  

Safeguard Scientifics, Inc. 2001 Associates Equity Compensation Plan, as amended and restated on October 21, 2008

Form 10-Q

11/6/08

 

10.5

10.3*

  

Safeguard Scientifics, Inc. 2014 Equity Compensation Plan, as amended and restated on March 5, 2014

Form 10-Q

7/25/14

 

10.1

10.4*

  

Safeguard Scientifics, Inc. Executive Deferred Compensation Plan (amended and restated as of January 1, 2009)

Form 10-K

3/19/09

 

10.4

10.5*

  

Management Incentive Plan

Form 8-K

4/25/08

 

10.1

10.6*

 

Amended and Restated Safeguard Scientifics, Inc. Transaction bonus plan

Form 10-Q

8/12/20

 

10.6

10.7

  

Compensation Summary — Non-employee Directors

Form 10-K

3/11/22

   10.7

10.9.2*

 

 Letter Agreement between Safeguard Scientifics, Inc. and Eric Salzman dated January 1, 2023

Form 8-K

1/4/23

 

10.1

 

45
Table of Contents

 

10.12*

 

Compensation Agreement by and between Safeguard Scientifics, Inc. and Mark Herndon dated September 17, 2018

Form 8-K

9/18/18

 

99.1

10.13*

 

Key Employee Compensation Recoupment Policy

Form 10-Q

7/26/13

 

10.2

10.14

 

Purchase and Sale Agreement dated as of December 9, 2005 by and among HarbourVest VII Venture Ltd., Dover Street VI L.P. and several subsidiaries and affiliated limited partnerships of Safeguard Scientifics, Inc.

Form 10-K

3/13/06

 

10.36

10.15

 

Consent Agreement, dated as of May 17, 2011, by and among Shire Pharmaceuticals, Inc. and certain stockholders of Advanced BioHealing, Inc.

Form 8-K

5/18/11

 

10.1

10.16

 

Lease Agreement, effective February 2, 2015, between Safeguard Scientifics, Inc., a Pennsylvania corporation, and Radnor Properties-SDC, L.P., a Delaware limited partnership

Form 10-Q

4/24/15

 

10.1

10.17

 

Sublease Agreement, effective March 15, 2019, by and between Safeguard Scientifics, Inc., a Pennsylvania corporation and the subtenant named therein

Form 8-K

3/20/19

 

10.1

14.1

 

Code of Business Conduct and Ethics

—

 

—

21.1 †

 

List of Subsidiaries

—

 

—

23.1 †

 

Consent of Independent Registered Public Accounting Firm — Grant Thornton LLP

—

 

—

31.1 †

 

Certification of Eric C. Salzman pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934

—

 

—

31.2 †

 

Certification of Mark A. Herndon pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934

—

 

—

32.1 ‡

 

Certification of Eric C. Salzman pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

—

 

—

32.2 ‡

 

Certification of Mark A. Herndon pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

—

 

—

101

 

The following materials from Safeguard Scientifics, Inc. Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language); (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Comprehensive Income (Loss); (iv) Consolidated Statements of Changes in Shareholders' Equity; (v) Consolidated Statements of Cash Flows; and (vi) Notes to Consolidated Financial Statements.

—

 

—
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). —   —

 

†

Filed herewith
 

‡

Furnished herewith
   

*

These exhibits relate to management contracts or compensatory plans, contracts or arrangements in which directors and/or executive officers of the Registrant may participate.

 

46
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

SAFEGUARD SCIENTIFICS, INC.

 

 

 

 

By:

 

 /s/ ERIC C. SALZMAN

 

 

 

 

Eric C. Salzman

 

 

 

 

Chief Executive Officer

 

Dated: March 10, 2023

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature

Title

Date

 

 

 

/s/ ERIC C. SALZMAN

  Chief Executive Officer
(Principal Executive Officer)

March 10, 2023

Eric C. Salzman

  

 

/s/ MARK A. HERNDON

Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)  

 March 10, 2023

Mark A. Herndon

  

 

/s/ ROSS D. DEMONT

Director

 March 10, 2023

Ross D. DeMont

 

 

/s/ RUSSELL D. GLASS

Director

 March 10, 2023

Russell D. Glass

 

 

/s/ BETH S. MICHELSON

Director

 March 10, 2023

Beth S. Michelson

 

 
/s/ JOSEPH M. MANKO, JR. Chairman of the Board of Directors March 10, 2023
Joseph M. Manko, Jr.    

/s/ MAUREEN F. MORRISON

Director

 March 10, 2023

Maureen F. Morrison

 

 

 

47
EX-14.1 2 ex_477546.htm EXHIBIT 14.1 ex_477546.htm

Exhibit 14.1

logo.jpg 

 

SAFEGUARD SCIENTIFICS, INC.

CODE OF BUSINESS CONDUCT AND ETHICS

 

I.

Background - Administration

 

The reputation and integrity of Safeguard Scientifics, Inc. (“Company” or “Safeguard”) is a valuable asset that is vital to our success.

 

Each Company employee, including each of the Company’s officers, and each Company director is responsible for conducting the Company’s business in a manner that demonstrates a commitment to the highest standards of integrity. This Code of Business Conduct and Ethics (“Code”), which applies to all directors, officers and employees of the Company (collectively referred to as “Company Personnel”), has been adopted to help Company Personnel meet these standards. Specifically, the purpose of this Code is to:

 

●

encourage among Company Personnel a culture of honesty, accountability and mutual respect;

●

provide guidance to help Company Personnel recognize and deal with ethical issues; and

●

provide mechanisms for Company Personnel to report unethical conduct.

 

While this Code is designed to provide helpful guidelines, it is not intended to address every specific situation. Nevertheless, in every instance, we require that Company Personnel act honestly, fairly and with a view towards “doing the right thing.”

 

The Safeguard Scientifics, Inc. Board of Directors (“Safeguard Board”) is ultimately responsible for oversight of the Code. The Safeguard Board has designated G. Matthew Barnard, or his successor, to be the compliance officer (the “Compliance Officer”) for the implementation and administration of the Code. Company Personnel should feel free to direct questions concerning this Code to the Compliance Officer:

 

Safeguard Scientifics, Inc.

Attention: Compliance Officer

150 N. Radnor Chester Rd., STE F-200

Radnor, PA 19087

e-mail address: complianceofficer@safeguard.com

 

II.

Overview

 

It is the policy of the Company to: (a) comply with all applicable governmental laws, rules and regulations; (b) expect that all Company Personnel at all times observe honest and ethical conduct in the performance of their responsibilities, including the avoidance of conflicts of interest; (c) expect all Company Personnel to treat others with dignity, including other employees, shareholders, customers and vendors; and (d) encourage and support internal disclosure of any violation of this Code for appropriate action.

 

The Code governs the business-related conduct of all Company Personnel, including, but not limited to, the chief executive officer, chief financial officer and all other officers of Safeguard. Directors of the Company who are not employees are subject to this Code only as it relates to their capacities as directors.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 1
 
 

 

III.

Compliance With Law

 

A variety of laws apply to the Company and its operations. Company Personnel are expected to comply with all such laws, as well as rules and regulations adopted under such laws. Examples of criminal violations under these laws include:

 

●

stealing, embezzling or misapplying corporate or bank funds;

●

using threats, physical force or other unauthorized means to collect money;

●

making false entries in the books and records of the Company, or engaging in any conduct that results in the making of such false entries;

●

making a payment for an express purpose on the Company’s behalf to an individual who intends to use it for a different purpose;

●

utilizing the Company’s funds or other assets or services to make a political contribution or expenditure; and

●

making payments, whether corporate or personal, of cash or other items of value that are intended to influence the judgment or actions of political candidates, government officials or businesses in connection with any of the Company’s activities.

 

The Company must and will report all suspected criminal violations to the appropriate authorities for possible prosecution and will investigate, address and report to governmental or other authorities, as appropriate, non-criminal violations.

 

IV.

Conflicts of Interest

 

Company Personnel are expected to make or participate in business decisions and actions in the course of their service to the Company based on the best interests of the Company as a whole, and not based on personal relationships or personal benefits. A conflict of interest, which can occur or appear to occur in a wide variety of situations, can compromise the business ethics of Company Personnel. Generally speaking, a conflict of interest occurs when the personal interest of Company Personnel or members of their immediate family interferes with, or has the potential to interfere with, the interests or business of the Company. For example, a conflict of interest may occur where Company Personnel or a family member receives a gift, a unique advantage, or an improper personal benefit as a result of the Company Personnel’s position at the Company. A conflict of interest could make it difficult for such person to perform corporate duties objectively and effectively because he or she is involved in a competing interest. The following is a discussion of certain common areas that raise conflict of interest issues. However, a conflict of interest can occur in a variety of situations. Company Personnel must be alert to recognize any situation that may raise conflict of interest issues and must disclose to the Compliance Officer any material transaction or relationship that reasonably could be expected to give rise to actual or apparent conflicts of interest with the Company.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 2
 
 

 

Outside Activities/Employment – Any outside activity must not significantly encroach on the time and attention Company Personnel devote to their corporate duties and must not adversely affect the quality or quantity of their work. In addition, Company Personnel may not make use of corporate equipment, facilities or supplies for, or imply (without the Company’s approval) the Company’s sponsorship or endorsement of, any outside activity, and under no circumstances are Company Personnel permitted to take for themselves or their family members business opportunities that are discovered or made available by virtue of their positions at the Company. Moreover, unless the Audit Committee of the Company’s Board of Directors shall have approved or ratified a particular transaction or situation in accordance with the Company’s Statement of Policy with Respect to Related Party Transactions, Company Personnel may not (i) have any financial or economic interest in (a) any entity that is, or to such person’s knowledge may become, a vendor to, or a customer or competitor of, the Company or any of the companies in which the Company has an interest; or (b) any entity that otherwise has or may have a relationship with, or might expect financial or other support from, the Company or any of the companies in which the Company has an interest; or (ii) provide services to or perform services for the benefit of any such entity, other than services performed at the request of or on behalf of the Company. For purposes of clarity and consistency, the preceding sentence shall be interpreted to include the purchase or other acquisition by any Company Personnel of any financial or economic interest in the companies in which the Company has, or is proposed to have, an interest, whether directly or through a public market transaction, or otherwise. Company employees are prohibited from taking part in any outside employment without Safeguard’s prior written approval.

 

Notwithstanding the foregoing, other than relating to the companies in which the Company has an interest, Company Personnel generally may have (i) a passive investment in up to five percent of the total outstanding shares of an entity that is listed on a national or international exchange, the OTC Bulletin Board or a similar quotation service or (ii) a limited partnership interest in a private equity, venture capital or similar fund constituting less than five percent of such fund’s committed capital, provided that the investment is not so large financially either in absolute dollars or as a percentage of the person’s total net worth that it creates the appearance of a conflict of interest.

 

Directors of the Company who are not employees of the Company must be sensitive to situations in which they may be associated with, or have business or financial interests in, corporations or other business entities that, from time to time, have business dealings with the Company or which may compete with the Company. While these relationships and interests are not prohibited, they should be avoided where reasonably practicable. Any Company director who becomes engaged in such a relationship or interest must promptly bring it to the attention of the Chairperson of the Safeguard Board. The Chairperson shall promptly refer such matter to the full Safeguard Board or an appropriately authorized committee of the Safeguard Board for consideration and appropriate disposition. If a conflict cannot be avoided, it must be managed in an ethical and responsible manner.

 

Civic/Political Activities – Company Personnel are encouraged to participate in civic, charitable or political activities so long as such participation does not encroach on the time and attention they are expected to devote to their Company-related duties. Such activities are to be conducted in a manner that does not involve the Company or its assets or facilities and does not create an appearance of the Company’s sponsorship or endorsement.

 

Inventions, Books and Publications – Company employees must receive written permission from the Compliance Officer before developing, outside of the Company, any products, software or intellectual property that may be related to the Company’s current or potential business.

 

Proper Payments – Company Personnel shall pay for and receive only that which is proper. Company Personnel must not make or promise payments to influence another’s acts or decisions, and Company employees must not give gifts beyond those extended in normal business.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 3
 
 

 

Gifts – Company Personnel and members of their families must not give or receive valuable gifts (including gifts of equipment or money, discounts, or favored personal treatment) to or from any person associated with Safeguard’s vendors or customers. Acceptance of a gift in the nature of a memento, such as a conference gift or other inconsequential gift valued at less than five hundred dollars ($500), is permitted. Engaging in normal, occasional business-related entertainment, such as meals or the use of sporting, theatrical or other public event tickets, is permissible with the understanding that it is expected that Company Personnel will exercise sound judgment in reliance on this exception so as to avoid any situation that may otherwise be subject to question.

 

Loans to Directors and Employees – The Company will not make loans or extend credit guarantees to or for the personal benefit of directors and executive officers except as permitted by law and the listing standards of any exchange or quotation system on which the Company’s common stock is listed. Loans or guarantees may be extended to other employees only with the Company’s approval.

 

Insider Trading – Company Personnel are prohibited from trading in securities while in possession of material, nonpublic information. Among other things, trading while in possession of material, nonpublic information can subject the person to criminal or civil penalties. The Company has adopted a Statement of Company Policy for Insider Trading and Disclosure and requires all Company Personnel to sign a statement acknowledging that they have read, understand and will comply with the policies set forth therein.

 

V.

Fair Dealing

 

Company Personnel shall deal fairly and in good faith with each other and the Company’s customers, suppliers, regulators, business partners and others. Company Personnel may not take unfair advantage of anyone through manipulation, misrepresentation, inappropriate threats, fraud, abuse of confidential information or other related conduct.

 

VI.

Proper Use of Company Assets

 

As a general rule, Company assets, including facilities, equipment, materials, supplies, time, information, intellectual property, software, and other assets owned or leased by the Company, or that are otherwise in the Company’s possession, may be used only for legitimate business purposes. However, the Company makes an exception for incidental personal use (e.g., telephone calls to a friend or family member, sending a personal e-mail message, accessing the Web, etc.) provided that such incidental personal use is legal, ethical, appropriate and does not interfere with the conscientious performance of an employee's duties.

 

VII.

Delegation of Authority

 

Company Personnel, and particularly each of the Company’s officers and other managerial employees, must exercise due care to ensure that any delegation of authority is reasonable and appropriate in scope and includes appropriate and continuous monitoring.

 

VIII.

Handling Confidential Information

 

Company Personnel have an obligation to protect and keep confidential all nonpublic information related to the Company (“Confidential Information”) unless and until its disclosure is approved by the Company and one full business day has passed following its disclosure by the Company in publicly filed SEC reports, press releases, external website, other institutionalized methods of electronic communication, or where disclosure is otherwise mandated by law or regulation. Confidential Information includes all nonpublic information entrusted to or obtained by Company Personnel by virtue of their affiliation with or employment by the Company or their service on the Company’s Board of Directors. Confidential Information includes but is not limited to information relating to:

 

 

●

the Company’s strategy, business, finances, prospects, plans, and operations;

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 4
 
 

 

 

●

proposed mergers, acquisitions, divestitures, new business ventures, opportunities, partnerships or agreements;

 

 

●

news of a pending initial or secondary public offering of securities, other public or private sales of securities, stock splits or tender offers;

 

 

●

products, orders, contracts, customers, vendors or competitors;

 

 

●

employee records;

 

 

●

the proceedings, discussions and deliberations of the Board and its committees;

 

 

●

discussions relating to the Company by and among employees, officers and directors; and

 

 

●

third party confidential and proprietary information that has been provided to the Company and which the Company is under an obligation to maintain as confidential.

 

In addition, Company Personnel must safeguard proprietary information, which includes information that is not generally known to the public and has commercial value in the Company’s business. Proprietary information includes, among other things, software programs, source and object codes, trade secrets, ideas, techniques, inventions (whether patentable or not) and other information relating to designs, algorithms and research. It also includes information relating to marketing, pricing, customers, and terms of compensation for Company Personnel. The obligation to safeguard proprietary information continues even after employment or service with the Company ends.

 

Please keep in mind the following guidelines in order to protect Confidential Information:

 

 

●

Do not discuss Confidential Information in public places.

 

 

●

Do not forward Confidential Information or proprietary information to non-Company email accounts.

 

 

●

Beware of informal telephone or email requests from outsiders requesting information (including but not limited to requests for comments on expected financial performance, information about current or former employees, or requests from the media).

 

The Company’s Statement of Company Policy on Insider Trading and Disclosure contains additional information concerning confidentiality obligations for Company Personnel.

 

IX.

Public Disclosures

 

As a public company, the Company must ensure that its filings and submissions with the SEC and other public communications provide full, fair, timely, accurate and understandable disclosure. Company Personnel engaged in the preparation of these filings, submissions and communications (“Public Disclosure Personnel”) must endeavor to ensure that the Company’s filings, submissions, and communications meet these objectives. Depending on their duties and responsibilities, other employees may be called upon to provide information to assure that the Company’s reports are complete, fair and understandable. To this end, all transactions affecting assets, liabilities, stockholders’ equity, revenues and expenses must be recorded on a timely basis in detailed journals and must be traceable through the general ledger and resulting financial statements. Accounting and financial reporting practices must be fair and proper, in accordance with generally accepted accounting principles.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 5
 
 

 

Company Personnel are expected to take this responsibility very seriously. Company Personnel are prohibited from (i) directly or indirectly taking any action to influence, coerce, manipulate or mislead the Company’s independent registered public accounting firm in the performance of an audit of the Company’s financial statements for the purpose of rendering the Company’s financial statements materially misleading; (ii) altering, mutilating or concealing a record, document or other object, or attempting to do so with intent to impair the object’s integrity or availability for use in an official proceeding; and (iii) using Company funds for any purpose other than as described in the documents supporting the disbursement.

 

If requested by Public Disclosure Personnel to provide information for use in such filings, submissions or communications, Company Personnel will provide, as promptly as practicable, accurate, understandable and complete information on a timely basis.

 

Complaints or concerns regarding accounting, internal accounting controls or audit matters must be reported to the Compliance Officer, to the Audit Committee of the Safeguard Board or through our external reporting system, MySafeWorkplace, as indicated in Article X of this Code. Company Personnel may choose to submit such complaints or concerns anonymously. However, we encourage Company Personnel to supply contact information with their submission to facilitate follow-up, clarification and assistance with any investigation, if necessary.

 

Special Ethics Guidelines for the Chief Executive Officer and Employees with Financial Reporting Responsibilities

 

The Chief Executive Officer and employees with financial reporting responsibilities bear a special responsibility for promoting integrity throughout the organization and have a special role both to adhere to these principles themselves and also to ensure that a culture exists throughout the Company as a whole that ensures the fair and timely reporting of Company financial results and condition, as well as other information required by SEC regulations. Because of this special role, the Chief Executive Officer and employees with financial reporting responsibilities are bound by the following additional specific policies.

 

The Chief Executive Officer and employees with financial reporting responsibilities shall:

 

 

●

Act with honesty and integrity, avoiding actual or apparent conflicts of interest in personal and professional relationships.

 

 

●

Provide to the Company’s other employees, consultants and advisors who are engaged in filing reports and documents with the SEC (“SEC Reports”) or in disseminating other public communications such as press releases, information that is accurate, complete, relevant, timely and understandable.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 6
 
 

 

 

●

Endeavor to ensure full, fair, timely, accurate and understandable disclosure in SEC Reports.

 

 

●

Comply with laws, rules and regulations of federal, state and local governments, and appropriate self-regulatory organizations.

 

 

●

Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing one’s independent judgment to be subordinated.

 

 

●

Respect the confidentiality of information acquired in the course of one’s work except when authorized or otherwise legally obligated to disclose.

 

 

●

Refrain from using Confidential Information acquired in the course of employment for personal advantage.

 

 

●

Proactively promote and be an example of ethical behavior as a responsible partner among peers in the work environment.

 

 

●

Endeavor to ensure responsible use of and control over all assets and resources employed or entrusted.

 

 

●

Record or participate in the recording of entries in the Company’s books and records that are accurate to the best of his or her knowledge.

 

Promptly report to the Compliance Officer, the Audit Committee of the Safeguard Board, or through our external reporting system, MySafeWorkplace, any conduct that he or she believes to be a violation of law or business ethics or of any provision of this Code, including any transaction or relationship that reasonably could be expected to give rise to such a violation.

 

Violations of these Special Ethics Guidelines for the Chief Executive Officer and employees with financial reporting responsibilities, including failures to report violations or suspected violations by others, will be viewed as a severe disciplinary matter that may result in personnel action, including termination of employment.

 

X.

Report of Violations

 

Administration – General Policy Regarding Report of Violations – Company Personnel who observe, learn of, or, in good faith, suspect a violation of the Code must immediately report the violation or suspected violation either to his or her immediate supervisor (who in turn is responsible for informing the Compliance Officer of such report) or to the Compliance Officer. Complaints or concerns regarding accounting, internal accounting controls or audit matters, must be reported to the Compliance Officer, to the Audit Committee of the Safeguard Board or through our external reporting system, MySafeWorkplace, as indicated in this Article X. You may be subject to disciplinary action, including termination of employment, for failure to do so.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 7
 
 

 

Complaint Procedure

 

●

Notification of Complaint

 

 

●

To report a violation, suspected violation, complaint or concern to the Compliance Officer, provide the report to the following address or e-mail address:
   

 
   

Safeguard Scientifics, Inc.

Attention: Compliance Officer

150 N. Radnor Chester Rd., STE F-200

Radnor, PA 19087

e-mail address: complianceofficer@safeguard.com

 

 

●

To report a violation, suspected violation, complaint or concern to the Audit Committee of the Safeguard Board, provide the report to the following address:
   

 
   

Safeguard Scientifics, Inc.

Attention: Audit Committee - CONFIDENTIAL

c/o Corporate Secretary

150 N. Radnor Chester Rd., STE F-200

Radnor, PA 19087

 

 

●

If Company Personnel are not comfortable using the procedures and protocols outlined above, they can report a violation, suspected violation, complaint or concern by providing a report via our external, anonymous and confidential reporting system, MySafeWorkplace. Such report should be provided using the following internet address or telephone number:
   

 
   

Via Internet:            www.MySafeWorkplace.com

Via telephone:         800-461-9330

 

 

●

Whenever practical, the complaint should be made in writing.

 

 

●

You may choose to submit violations, suspected violations, complaints or concerns anonymously. However, we encourage Company Personnel to supply contact information with their submission to facilitate follow-up, clarification and assistance with any investigation, if necessary. Confidentiality is respected and an individual’s identity will only be shared on a “need-to-know” basis.

 

 

●

Nothing in this Code prevents Company Personnel from reporting violations or suspected violations of law to relevant government authorities.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 8
 
 

 

●

Investigation and Corrective Action

 

Reports of violations, suspected violations, complaints or concerns will promptly be investigated under the supervision of the Compliance Officer or, where appropriate, the Audit Committee of the Safeguard Board. Company Personnel are required to cooperate fully in such investigations and to provide truthful, complete and accurate information. The investigation will be handled as discreetly as reasonably possible, allowing for a fair investigation and any necessary corrective action. Appropriate corrective action will be taken whenever a violation of this Code is determined to have occurred. Depending on the nature of the violation, the offending individual can be subject to disciplinary action, which may include termination of employment. In addition, anyone who interferes with an investigation, or provides information in an investigation that the individual knows to be untrue or inaccurate, will be subject to disciplinary action, which may include termination of employment. Any employee who submits a complaint or concern relating to the handling of accounting, internal accounting controls or audit matters in good faith should have no fear of dismissal or retaliation of any kind. Retaliation against employees who, for lawful purposes, file a complaint or participate in an investigation is strictly prohibited.

 

The Audit Committee of the Safeguard Board will be responsible for the acceptance, investigation and management of reports of suspected violations of this Code by the Chief Executive Officer, the Compliance Officer and employees with financial reporting responsibilities and complaints or concerns regarding accounting, internal accounting controls or audit matters.

 

The Company’s Compliance Officer will be responsible for the acceptance, investigation and management of reports by attorneys regarding material violations of securities laws, fiduciary duties or similar laws.

 

●

Confidentiality 

 

Except as may be required by law or by the requirements of the resulting investigation or the corrective action, all notices, reports and information received under this process will be treated in a confidential manner. Every reasonable effort will be made to handle the matter with discretion and to protect the identity of those who make reports as well as those who are being investigated. However, the Compliance Officer regularly will report to the Audit Committee of the Safeguard Board any violations that have been reported. Further, if necessary to conduct a proper review or to comply with legal requirements, the Audit Committee of the Safeguard Board, the Company’s independent registered public accounting firm or others may become involved in the review process. Also, as noted above, the Company must and will report all suspected criminal violations to the appropriate authorities for possible prosecution and will investigate, address and report to governmental or other authorities, as appropriate, non-criminal violations.

 

XI.

Protection Against Retaliation

 

Policy - The Company prohibits any form of retaliation against employees who, for lawful purposes, report to the Company any conduct or activity that may violate this Code, any law or regulation applicable to the Company, or any other suspected improper, unethical or illegal conduct or activities by anyone at the Company. The Company also prohibits any form of retaliation against employees who provide information, cause information to be provided, or assist in an investigation conducted by the Company or any governmental body regarding a possible violation of any law or regulation relating to fraud, any labor law, or any rule or regulation of the SEC, or who file, cause to be filed, or assist, participate or give testimony in any proceeding relating to an alleged violation of any such law, rule or regulation.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 9
 
 

 

Management Responsibility - All Company officers and other managerial employees are responsible for ensuring adherence to this Code. In addition, each Company officer and managerial employee is responsible for communicating this Code to employees under his or her supervision and for supporting programs and practices designed to develop understanding of, commitment to and compliance with this Code. In the event that any Company officer, other managerial employee or supervisor believes that a violation of this Code has occurred or receives a report of a violation, he or she must immediately contact the Compliance Officer or the Audit Committee of the Safeguard Board.

 

Procedures for Reporting Policy Violations - If an employee believes that he or she has been retaliated against (including threatened or harassed) in violation of this Code, he or she should immediately report the retaliation either to his or her immediate supervisor (who in turn is responsible for informing the Compliance Officer of such report) or to the Compliance Officer in accordance with the contact procedures for the Compliance Officer set forth above. In connection with retaliation related to complaints or concerns regarding accounting, internal accounting controls or audit matters, any retaliation in violation of this Code must be reported to the Compliance Officer, the Audit Committee of the Safeguard Board or through our external reporting system, MySafeWorkplace, in accordance with the contact procedures set forth above. Once an employee reports retaliation prohibited by this Code, the Company will promptly investigate the matter in accordance with the procedures described in Article X of this Code.

 

XII.

Waivers

 

Requests for a waiver of a provision of the Code must be submitted in writing to the Compliance Officer or the Audit Committee of the Safeguard Board for appropriate review, and the Compliance Officer or the Audit Committee of the Safeguard Board will decide the outcome. For conduct involving directors and executive officers, only the Audit Committee of the Safeguard Board has the authority to waive a provision of the Code. The Audit Committee of the Safeguard Board must review and approve any “related party” transaction as defined in Item 404 of Regulation S-K, promulgated by the SEC, before it is consummated. In the event of an approved waiver involving the conduct of a director or executive officer, appropriate and prompt disclosure must be made to the Company’s shareholders as required by the SEC or other regulation or by applicable listing standards of the principal exchange or interdealer quotation system on which the Company’s common stock is listed.

 

Statements in the Code to the effect that certain actions may be taken only with “the Company’s approval” or that certain items will be “designated by the Company” will be interpreted to mean that appropriate executive officers of Safeguard Scientifics, Inc. or members of the Safeguard Board must give prior written approval or make such designation before the proposed action may be undertaken or the proposed designation may be made.

 

Violations of the Special Ethics Guidelines for the Chief Executive Officer and employees with financial reporting responsibilities contained in this Code that go unaddressed are treated by the SEC as implicit waivers of this Code. Accordingly, any violation that is discovered and not addressed will have to be disclosed in accordance with the rules and regulations of the SEC and applicable listing standards with respect to a waiver of this Code. In such cases, the applicable SEC rules will require disclosure of the nature of any violation, the date of the violation and the name of the person who committed the violation. Such disclosure would not only be harmful to the Company, but also to an individual either as one who is responsible for monitoring the enforcing compliance with this Code or as one who has violated it. In either case, depending on the nature of the violation, an individual may be dismissed or his or her duties and responsibilities with the Company may be changed.

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 10
 
 

 

XIII.

Compliance

 

Adherence to Code; Disciplinary Action – All Company Personnel have a responsibility to understand and follow this Code. In addition, all Company Personnel are expected to perform their work with honesty and integrity in all areas not specifically addressed in this Code. A violation of this Code may result in appropriate disciplinary action, including the possible termination from employment with the Company.

 

Communications; Training; Annual Certification – The Company strongly encourages dialogue among employees and their supervisors to make everyone aware of situations that give rise to ethical questions and to articulate acceptable ways of handling those situations. Company employees will receive periodic training on the contents and importance of the Code and related policies and the manner in which violations must be reported and waivers must be requested. All Company Personnel must certify that they have read this Code and to the best of their knowledge are in compliance with all its provisions. In addition, each director, officer and other managerial employee of the Company, as may be designated by the Company from time to time, has an obligation to annually certify that he or she has reviewed this Code with his or her subordinates. Forms of these certifications are attached to this Code as Appendices I and II.

 

Responsibility of Senior Employees – All Company officers and other managerial employees will be responsible for the enforcement of, and compliance with, this Code, including necessary distribution to assure Company employee knowledge and compliance. Directors, officers and other managerial employees are expected to promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships. Managerial employees may be disciplined if they condone misconduct, do not report misconduct, do not take reasonable measures to detect misconduct, or do not demonstrate the appropriate leadership to insure compliance.

 

XIV.

Related Policies; Enforceable by Company Only

 

This Code should be read in conjunction with Safeguard’s other policy statements, including but not limited to the Statement of Company Policy on Insider Trading and Disclosure. This Code is for the benefit of the Company, and no other person or entity is entitled to enforce this Code. This Code does not, and should not be interpreted to, create any private cause of action or remedy in any other person or entity for a violation of the Code. In addition, this Code should not be construed as a contract of employment and does not change any person's employment status.

 

 

Adopted:              April 8, 2004

 

Last Approved:    November 1, 2022

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 11
 
 

 

APPENDIX I

 

INITIAL CODE OF BUSINESS CONDUCT AND ETHICS DISCLOSURE STATEMENT

 

 

As a director, officer or other employee of Safeguard Scientifics, Inc. (“Company”), I have read and understand the Company’s Code of Business Conduct and Ethics (“Code”), and I hereby affirm my agreement to comply with its terms. I hereby certify as follows:

 

1.

I have received a copy of the Code.

 

2.

I have read, understand and agree to comply with the Code.

 

3.

I am currently in compliance and, as applicable, members of my family are in compliance, with the terms of the Code and all obligations imposed by it, except as disclosed to the Compliance Officer or as otherwise disclosed in accordance with the procedures contained in Article X of the Code.

 

4.

I am not aware of any conduct on the part of any person associated with the Company that may constitute a violation of the Code, except with respect to any matters that I may have disclosed to the Compliance Officer or otherwise disclosed in accordance with the procedures contained in Article X of the Code.

 

5.

I understand that none of the benefits, policies, programs, procedures or statements in the Code are intended to confer any rights or privileges upon me or entitle me to be or remain an employee of the Company. I am aware that the Code is not a contract and is subject to change at any time, without notice, at the sole discretion of the Company.

 

I understand that all Disclosure Statements may be available to the Compliance Officer, the Company’s Board of Directors, and internal and external legal counsel. Such information shall otherwise be held in confidence in accordance with Article X of the Code.

 

Each person signing a Disclosure Statement is responsible for keeping his/her Disclosure Statement current. These statements will be kept in Safeguard’s Legal Department.

 

 

____________________________

Signature

 

 

____________________________

Name

 

 

____________________________

Date

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 12
 
 

 

APPENDIX II

 

ANNUAL CODE OF BUSINESS CONDUCT AND ETHICS DISCLOSURE STATEMENT

 

 

As a director, officer or other employee of Safeguard Scientifics, Inc. (“Company”), I have read and understand the Company’s Code of Business Conduct and Ethics (“Code”), and I hereby reaffirm my agreement to comply with its terms. With respect to the last 12 months, I hereby certify as follows:

 

1.

I have complied and, as applicable, members of my family have complied, with the terms of the Code and all obligations imposed by it, except as disclosed to the Compliance Officer or as otherwise disclosed in accordance with the procedures contained in Article X of the Code.

 

2.

I have reviewed the Code with my subordinates and I am not aware of any conduct on the part of any person associated with the Company that may constitute a violation of the Code, except with respect to any matters that I may have disclosed to the Compliance Officer or otherwise disclosed in accordance with the procedures contained in Article X of the Code.

 

3.

I understand that none of the benefits, policies, programs, procedures or statements in the Code are intended to confer any rights or privileges upon me or entitle me to be or remain an employee of the Company. I am aware that the Code is not a contract and is subject to change at any time, without notice, at the sole discretion of the Company.

 

I understand that all Disclosure Statements may be available to the Compliance Officer, the Company’s Board of Directors, and internal and external legal counsel. Such information shall otherwise be held in confidence except in accordance with Article X of the Code.

 

Each person signing a Disclosure Statement is responsible for keeping his/her Disclosure Statement current. These statements will be kept in Safeguard’s Legal Department.

 

 

 

____________________________

Signature

 

 

____________________________

Name

 

 

____________________________

Date

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 13
 
 EX-21.1 3 ex_449898.htm EXHIBIT 21.1 ex_449898.htm

EXHIBIT 21.1

 

SUBSIDIARIES OF SAFEGUARD SCIENTIFICS, INC.

 

Exclusive of immaterial subsidiaries and companies in which the Registrant holds a minority interest, as of March 10, 2023, the Registrant had the following subsidiaries:

 

NAME

PLACE OF INCORPORATION

Bonfield VII, Ltd.

British Virgin Islands

Novitas Capital II Management, L.P.

Pennsylvania

Safeguard Capital Management, Inc.

Delaware

Safeguard Delaware, Inc.

Delaware

Safeguard Delaware II, Inc.

Delaware

Safeguard Fund Management, Inc.

Delaware

Safeguard PM SPV, Inc.

Delaware

Safeguard Scientifics (Delaware), Inc.

Delaware

Safeguard Technologies, Inc.

Delaware

SFE Properties, Inc.

Delaware

SSI Management Company, Inc.

Delaware

SSI Partnership Holdings (Pennsylvania), Inc.

Pennsylvania

 

 
 EX-23.1 4 ex_449899.htm EXHIBIT 23.1 ex_449899.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We have issued our report dated March 10, 2023, with respect to the consolidated financial statements included in the Annual Report of Safeguard Scientifics, Inc. on Form 10-K for the year ended December 31, 2022. We consent to the incorporation by reference of said report in the Registration Statements of Safeguard Scientifics, Inc. on Forms S-8 (File Nos. 333-86777, 333-118046, 333-171226 and 333-198783). 

 

 

 

/s/ GRANT THORNTON LLP

 

Philadelphia, Pennsylvania
March 10, 2023

 

 

 
 EX-31.1 5 ex_449901.htm EXHIBIT 31.1 ex_449901.htm

Exhibit 31.1

   

CERTIFICATION

   

I, Eric C. Salzman, certify that:

   

1.

I have reviewed this Annual Report on Form 10-K of Safeguard Scientifics, Inc.;

   

   

   

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

   

   

   

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

   

   

   

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   

   

   

   

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   

   

   

   

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   

   

   

   

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   

   

   

   

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

   

   

   

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

   

   

   

   

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

   

   

   

   

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

   

 

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

 March 10, 2023

/s/ Eric C. Salzman

   

 

Eric C. Salzman

   

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 
 EX-31.2 6 ex_449902.htm EXHIBIT 31.2 ex_449902.htm

Exhibit 31.2

   

CERTIFICATION

   

I, Mark A. Herndon, certify that:

   

1.

I have reviewed this Annual Report on Form 10-K of Safeguard Scientifics, Inc.;

   

   

   

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

   

   

   

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

   

   

   

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   

   

   

   

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   

   

   

   

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   

   

   

   

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   

   

   

   

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

   

   

   

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

   

   

   

   

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

   

   

   

   

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date

 March 10, 2023

/s/ Mark A. Herndon

   

 

Mark A. Herndon

   

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

 
 EX-32.1 7 ex_449903.htm EXHIBIT 32.1 ex_449903.htm

Exhibit 32.1

   

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

   

In connection with the Annual Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric C. Salzman, Chief Executive Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

   

1.

The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and

   

   

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.

   

   

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

 March 10, 2023

/s/ Eric C. Salzman

   

 

Eric C. Salzman

   

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 
 EX-32.2 8 ex_449904.htm EXHIBIT 32.2 ex_449904.htm

Exhibit 32.2

   

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

   

In connection with the Annual Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark A. Herndon, Senior Vice President and Chief Financial Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

   

1.

The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and

   

   

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.

   

   

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

March 10, 2023

/s/ Mark A. Herndon

   

 

Mark A. Herndon

   

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

 
 EX-101.SCH 9 sfe-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - General link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Ownership Interests and Advances link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Acquisitions of Ownership Interests link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Equity link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Stock-Based Compensation link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Employee Benefit Plan link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Net Income (Loss) Per Share link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Supplemental Cash Flow Information link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Segment Reporting link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - General (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Ownership Interests and Advances (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 6 - Stock-Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Net Income (Loss) Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 1 - General (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 1 - General - Schedule of Leases (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 2 - Ownership Interests and Advances (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Acquisitions of Ownership Interests (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 5 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 6 - Stock-Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Employee Benefit Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 8 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 9 - Net Income (Loss) Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 12 - Supplemental Cash Flow Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 13 - Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 10 sfe-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 sfe-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 sfe-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - General Note 2 - Ownership Interests and Advances Note 4 - Fair Value Measurements Note 6 - Stock-Based Compensation Note 8 - Income Taxes Note 9 - Net Income (Loss) Per Share Note 14 - Selected Quarterly Financial Information (Unaudited) Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) Income Tax Disclosure [Text Block] Note 1 - General - Schedule of Leases (Details) Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) us-gaap_GuaranteeObligationsCurrentCarryingValue Guarantor Obligations, Current Carrying Value Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details) Current liabilities Total current liabilities Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details) Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details) Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Share-Based Payment Arrangement, Activity [Table Text Block] Proceeds, from sales and maturities in marketable securities Granted (in dollars per share) Vested (in dollars per share) Forfeited (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance (in dollars per share) Balance (in dollars per share) US Treasury Securities [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) Forfeited (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance (in shares) Balance (in shares) Granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) Vested (in shares) Options exercisable , weighted average exercise price (in dollars per share) Options exercisable, weighted average remaining contractual life (Year) Options exercisable, aggregative intrinsic value us-gaap_PaymentsForAdvanceToAffiliate Advances and loans to ownership interests us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total Equity Balance Balance Options exercisable, shares (in shares) Balance, weighted average remaining contractual life (Year) Balance, aggregative intrinsic value us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares (in shares) Private Equity Funds [Member] us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balance, weighted average exercise price (in dollars per share) Balance, weighted average exercise price (in dollars per share) Options canceled/forfeited, weighted average exercise price (in dollars per share) Financial Instrument [Axis] Options granted, weighted average exercise price (in dollars per share) Options exercised, weighted average exercise price (in dollars per share) Accrued expenses and other current liabilities Accrued compensation and benefits Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Balance, shares (in shares) Balance, shares (in shares) sfe_GainLossFromObservablePriceChanges Gain from observable price changes Represents gain (loss) from observable price changes. us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) Shares available for future grant, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) AdvantEdge Healthcare Solutions, Inc. [Member] Represents information pertaining to AdvantEdge Healthcare Solutions, Inc. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) sfe_LongtermIncentivePlanBonusPoolPercent Long-term Incentive Plan, Bonus Pool Percent Represents bonus pool percent for long-term incentive plan. Weighted average shares used in computing net income (loss) per share: Equity Method Investment Partner Company Results Of Operation [Table Text Block] Tabular disclosure for results of operation for a partnering company under the equity method investment. Current Liabilities: sfe_EquityMethodInvestmentAssetsExceedCarryingValueOfInvestment Equity Method Investment Assets Exceed Carrying Value Of Investment Represents the value by which the carrying value exceeded the company's assets under the equity method investment. sfe_EquityMethodInvestmentAllocationOfExcessFairValue Equity Method Investment Allocation of Excess Fair Value Represents the allocation of excess fair value under the equity method investment. Intangible Assets [Member] Represents intangible assets. us-gaap_Assets Total Assets Plan Name [Axis] Plan Name [Domain] Compensation and Employee Benefit Plans [Text Block] Number of equity method ownership interests Represents the number of equity method ownership interests. High Traction Stage [Member] Information pertaining to high traction stage. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement [Text Block] Bright Health [Member] Represents Bright Health. Credit Facility [Member] represents credit facility. Award Type [Domain] Award Type [Axis] Net loss Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net The value of shares issued for restricted stock awards withheld for taxes. sfe_LongTermIncentivePlanPayments Long-term Incentive Plan, Payments Represents amount of payments under long-term incentive plan. Restricted Stock [Member] Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) The number of shares issued for restricted stock awards and withheld for taxes. Performance Shares [Member] Share-Based Payment Arrangement, Option [Member] Performance Stock Unit [Member] Represents performance stock unit. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] 2028, operating lease payments Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year. 2014 Equity Compensation Plan [Member] Represents the 2014 equity compensation plan. 2028, expected sublease receipts Amount of lease payments to be received by lessor in sixth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date. Commitments and Contingencies Disclosure [Text Block] sfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationTerm Share Based Compensation Arrangement, By Share Based Payment Award, Expiration Term (Year) Represents the share based compensation arrangement by share based payment award expiration term. Service Based Award [Member] Represents the service based award. sfe_ConvertibleBridgeLoan Convertible Bridge Loan The amount of funding for convertible bridge loans in the period. Clutch Holdings [Member] Related to the entity Clutch Holdings. Syapse, Inc. [Member] Related to the entity Syapse, Inc. Zipnosis [Member] Related to the entity Zipnosis. sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAwardVestingTypes Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types Represents the number of award vesting types under share-based compensation arrangement by share-based payment award. WebLinc, Inc. [Member] Related to the entity WebLinc, Inc. Moxe Health Corporation [Member] Related to the entity Moxe Health Corporation. Aktana, Inc. [Member] Related to the entity Aktana, Inc. meQuilibrium [Member] Related to the entity meQuilibrium. Share Repurchase Program Authorized in July 2015 [Member] Represents share repurchase program authorized in July 2015. sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent Investments and Advances to Affiliates, Current and Noncurrent Represents Investments and Advances to Affiliates, Current and Noncurrent. sfe_RestrictedCashAndCashEquivalentsFairValue Restricted cash Fair value portion of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Disallowed interest carryforwards Represents the deferred tax assets, disallowed interest carryforwards. sfe_NetOperatingLossCarryforwardsExpiringInYearOne 2023 Represents net operating loss carryforwards expiring in year one. Share Repurchase Program Authorized in May 2021 [Member] Represents share repurchase program authorized in May 2021. Ownership Interest Equity Method Investment, Ownership Percentage Schedule Of Activity For Restricted Stock Units Deferred Stock Units And Performance Units [Table Text Block] Tabular disclosure of activity for restricted stock unity. deferred stock units and performance units. Net income (loss) Net income (loss) Net income (loss) sfe_NetOperatingLossCarryforwardsExpiringInYearTwo 2024 Represents net operating loss carryforwards expiring in year two. Investments in and Advances to Affiliates, Schedule of Investments [Text Block] sfe_NetOperatingLossCarryforwardsExpiringInYearThree 2025 Represents net operating loss carryforwards expiring in year three. Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] us-gaap_MarketableSecurities Marketable Securities, Total sfe_LesseeOperatingLeaseLiabilityToBePaidAfterYearSix Thereafter, operating lease payments Represents the amount of lessee's undiscounted obligation for lease payment for operating lease due after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Cash Flows from Investing Activities: sfe_LessorOperatingLeasePaymentToBeReceivedAfterYearSix Thereafter, expected sublease receipts Represents amount of lease payment to be received by lessor for operating lease after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach) Other Method, fair value measurement alternative Equity Securities without Readily Determinable Fair Value, Amount Net income (loss) per share: Earnings Per Share [Text Block] Advances to companies Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] Represents restricted stock, performance-based stock units, and deferred stock units. Ownership interests and advances Accounts payable, accrued expenses, and other current liabilities Equity income (loss), net Equity income (loss), net Equity Method Companies Equity Method Investments Related Party Transactions Disclosure [Text Block] Income tax benefit (expense) Flashtalking [Member] Related to the entity Flashtalking. Prognos Health, Inc. [Member] Related to the entity Prognos Health, Inc. Lumesis, Inc. [Member] Related to the entity Lumesis, Inc. InfoBionic, Inc. [Member] Related to the entity InfoBionic, Inc. us-gaap_OtherNonoperatingGainsLosses Other, net Trice Medical, Inc. [Member] Related to the entity Trice Medical, Inc. sfe_TradingSecurityUnrealizedGainLoss Trading Security, Unrealized Gain (Loss) The amount of gain (loss) from change in fair value for trading securities. sfe_OtherMethodInvestmentRealizedGainLoss Other Method Investment, Realized Gain (Loss) Amount of gain (loss) from sale of other method investment. sfe_ContingentProceedsFromOtherMethodInvestment Contingent Proceeds from Other Method Investment The amount of contingent proceeds from other method investment. us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost General and administrative expense General and administrative expense us-gaap_RestrictedCash Restricted cash us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match sfe_IncomeLossFromEquityMethodInvestmentsExcludingImpairments Equity (income) loss, net Amount of income (loss) for proportionate share of equity method investee's income (loss), excluding impairments. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax Share-Based Payment Arrangement, Expense, after Tax General and administrative expense us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Equity Method Investment, Realized Gain (Loss) on Disposal Repurchases of common stock (in shares) Treasury Stock, Shares, Acquired (in shares) us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) sfe_ImpairmentOfOtherMethodSecurities Impairment of Other Method Securities The amount of impairment of other method securities. Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus us-gaap_OperatingLeaseCost Operating Lease, Cost Document Fiscal Year Focus Document Period End Date sfe_TradingSecuritiesFairValueDisclosure Ownership interests Amount of fair value for investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Entity File Number Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Share Repurchase Program Authorized in March 2022 [Member] Represents the share repurchase programmed that was authorized in March 2022. Equity Method and Other Investments Disclosure [Text Block] The entire disclosure for equity method and other investments. Document Information [Line Items] Document Information [Table] Entity Public Float Entity Filer Category us-gaap_InvestmentOwnedBalanceShares Investment Owned, Balance, Shares (in shares) sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposureShares Employee and Severance Agreement, Maximum Aggregate Exposure, Shares (in shares) Represents maximum aggregate shares exposure for employee and severance agreement. Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer us-gaap_LessorOperatingLeasePaymentsToBeReceived Total future minimum lease payments, expected sublease receipts us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears 2027, expected sublease receipts Stock-based compensation Quarterly Financial Information [Text Block] Entity Tax Identification Number Entity Central Index Key us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths 2023, expected sublease receipts Entity Registrant Name us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears 2024, expected sublease receipts us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears 2025, expected sublease receipts us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears 2026, expected sublease receipts Entity [Domain] Legal Entity [Axis] Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Entity Address, Address Line One us-gaap_TreasuryStockValueAcquiredCostMethod Treasury Stock, Value, Acquired, Cost Method Repurchases of common stock Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province us-gaap_TreasuryStockValue Treasury stock, at cost; 5,478 and 5,068 shares at December 31, 2022 and 2021, respectively Entity Common Stock, Shares Outstanding Investments [Domain] Trading Symbol Investment Type [Axis] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number Equity Method Investee [Member] Options exercised, shares (in shares) Options exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables Related Party [Axis] Related Party [Domain] Options granted, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares) Options canceled/forfeited, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) Collaborative Arrangement and Arrangement Other than Collaborative [Domain] us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Equity Reported Value Measurement [Member] Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Accumulated other comprehensive loss Non-current assets Changes in assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements sfe_CommitmentToFundConvertibleBridgeLoan Commitment To Fund Convertible Bridge Loan Represents commitment to fund convertible bridge loan. Subsequent Event [Member] Lease liability - non-current Restrictions on Cash and Cash Equivalents [Table Text Block] us-gaap_OperatingLeaseLiability Total operating lease liabilities Subsequent Event Type [Axis] Lease liability - current Subsequent Event Type [Domain] Right-of-use asset, net us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total future minimum lease payments, operating lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less imputed interest us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2025, operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2026, operating lease payments us-gaap_UnrealizedGainLossOnInvestments Impairments of ownership interests and advances us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2027, operating lease payments Fair Value of Financial Instruments, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2023, operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2024, operating lease payments Segment Reporting, Policy [Policy Text Block] us-gaap_DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount Other assets Stock-based compensation, including liability classified awards Lessee, Leases [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Schedule of Other Ownership Interests [Table Text Block] Revenue Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Ownership interests Debt Securities, Trading, and Equity Securities, FV-NI, Total sfe_EquityMethodInvestmentRealizedGainLossOnDisposalOtherReceivableRelatedToIndemnificationEscrow "Equity Method Investment, Realized Gain (Loss) on Disposal, Other Receivable Related to Indemnification Escrow Amount of other receivable related to indemnification escrow for realized gain or loss on disposal under equity method investments. Preferred Equity in Acquiror in Connection with Sale of Zipnosis, Inc [Member] Represents the preferred equity in acquiror in connection with the sale of Zipnosis, Inc. sfe_EquityMethodInvestmentDilutionGain Equity Method Investment, Dilution Gain Amount of gain related to the equity issuance of equity method investee. Current assets Total current assets us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash and cash equivalents Stockholders' Equity Note Disclosure [Text Block] us-gaap_InvestmentsFairValueDisclosure U.S. Government securities Velano Vascular [Member] Represents Velano Vascular. Treasury stock, shares (in shares) Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2022 and 2021, respectively Adjustments to reconcile to net cash used in operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Common stock, par value (in dollars per share) us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) us-gaap_DeferredTaxAssetsValuationAllowance Valuation allowance us-gaap_OperatingLeasePayments Operating Lease, Payments Statistical Measurement [Domain] Maximum [Member] sfe_IncreaseDecreaseInFairValueOfOwnershipInterests Change in fair value of ownership interests The amount of increase (decrease) in the fair value of ownership interests as of the end of the reporting period. Minimum [Member] sfe_GainFromSaleOfOwnershipInterests Gain from sales of ownership interests The amount of gain from the sale of ownership interest as of the end of the reporting period. us-gaap_DeferredTaxAssetsNet Net deferred tax asset Statistical Measurement [Axis] Investment, Name [Domain] T-Rex Group, Inc [Member] Represents information related to T-Rex Group, Inc. Preferred stock, $0.10 par value; 1,000 shares authorized Investment, Name [Axis] Cash Flow, Supplemental Disclosures [Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Other Amended and Restated Safeguard Scientifics Transaction Bonus Plan [Member] Represents amended and restated safeguard scientifics transaction bonus plan. us-gaap_DeferredTaxAssetsGross Deferred Tax Assets, Gross, Total Preferred stock, shares authorized (in shares) Portion at Fair Value Measurement [Member] [Default] Carrying values of ownership interests and other holdings Preferred stock, par value (in dollars per share) sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposure Employee and Severance Agreement, Maximum Aggregate Exposure Represents maximum aggregate exposure for employee and severance agreement. Estimate of Fair Value Measurement [Member] Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Accrued expenses Non-Employee [Member] Represents non-employee. The 2020 Award [Member] Represents the 2020 award. Cash Flows from Operating Activities: Other Management [Member] Represents other management. Statement [Line Items] sfe_ContingentProceedsFromSaleOfEquityMethodInvestments Contingent Proceeds from Sale of Equity Method Investments The amount of contingent proceeds received from the sale of equity method investments. Performance Based Options [Member] Represents performance based options. us-gaap_NumberOfOperatingSegments Number of Operating Segments us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Stock-based compensation Dutch Auction Self-tender [Member] Represents Dutch auction self-tender. Marketable securities Additional paid-in capital AOCI Attributable to Parent [Member] Other income (loss), net Other income (loss), net Segment Reporting Disclosure [Text Block] Equity: Tax loss and credit carryforwards us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards, Total Restricted cash sfe_ProceedsFromSaleOfOtherMethodInvestment Proceeds From Sale of Other Method Investment The amount of cash inflow from the sale of other method investment during the period. Current Assets: Fair Value Disclosures [Text Block] us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Total cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash equivalents at beginning of period Cash, cash equivalents and restricted cash at end of period Interest income Interest income us-gaap_Liabilities Total Liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and contingencies (Note 11) us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Net change in cash, cash equivalents and restricted cash Director [Member] Operating loss us-gaap_OperatingIncomeLoss Operating loss us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Gross profit us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent Deferred Compensation Liability, Current and Noncurrent, Total Partnership Interest [Member] Investment, Policy [Policy Text Block] us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Tax withholdings related to equity-based awards Equity Method Investments [Table Text Block] us-gaap_PaymentsForRepurchaseOfCommonStock Repurchases of common stock Retained Earnings [Member] us-gaap_TreasuryStockAcquiredAverageCostPerShare Treasury Stock Acquired, Average Cost Per Share (in dollars per share) Title of Individual [Domain] Title of Individual [Axis] Treasury Stock [Member] us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock Additional Paid-in Capital [Member] Share Repurchase Program [Domain] Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations Federal Income Tax Expense (Benefit), Continuing Operations, Total Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedAndVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued and Vested in Period (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that issued and vested during the reporting period. Net loss before income taxes us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Net income (loss) before income taxes ICFR Auditor Attestation Flag Right-of-use Assets [Policy Text Block] Disclosure for the accounting policy for right-of-use assets. sfe_CompensationCashAward Compensation, Cash Award The value of the cash award for compensation. Statutory tax expense (benefit) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate (Negative Rate), Percent Percentage of domestic federal statutory tax rate applicable to pretax income (loss). Document Annual Report Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Entity Interactive Data Current us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease Unrecognized Tax Benefits, Period Increase (Decrease), Total Security Exchange Name Title of 12(b) Security Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Equity Method Investment, Nonconsolidated Investee [Domain] Income Statement Location [Axis] Income Statement Location [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Auditor Name Auditor Firm ID Auditor Location us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Goodwill [Member] Asset Class [Axis] Asset Class [Domain] Summary of Operating Loss Carryforwards [Table Text Block] Statement [Table] Statement of Financial Position [Abstract] Diluted (in dollars per share) Diluted (in dollars per share) Basic (in shares) Diluted: us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total Basic (in dollars per share) Basic (in dollars per share) Valuation allowance Basic: Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Quarterly Financial Information [Table Text Block] Amortization of right of use asset Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Nondeductible expenses Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Non-current liabilities Cash Flows from Financing Activities: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other long-term liabilities Proceeds from sales and distributions from ownership interests us-gaap_ProceedsFromSaleOfEquityMethodInvestments Proceeds from Sale of Equity Method Investments Shareholders’ deficit Class of Stock [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) sfe_NetOperatingLossCarryforwardsExpiringInYearFiveAndThereafter 2027 and thereafter Represent net operating loss carryforwards expiring in year five and thereafter. sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumTargetPercentage Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Target Percentage the maximum target percentage for equity instruments other then options under share based payment arrangement. us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) sfe_NetOperatingLossCarryforwardsExpiringInYearFour 2026 Represents net operating loss carryforwards expiring in year four. EX-101.PRE 13 sfe-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 logo.jpg begin 644 logo.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 06, 2023
Jun. 30, 2022
Document Information [Line Items]      
Entity Central Index Key 0000086115    
Entity Registrant Name SAFEGUARD SCIENTIFICS INC    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 1-5620    
Entity Incorporation, State or Country Code PA    
Entity Tax Identification Number 23-1609753    
Entity Address, Address Line One 150 N. Radnor Chester Road    
Entity Address, City or Town Radnor    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19087    
City Area Code 610    
Local Phone Number 293-0600    
Title of 12(b) Security Common Stock ($.10 par value)    
Trading Symbol SFE    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Small Business true    
Entity Filer Category Non-accelerated Filer    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 50,494,095
Entity Common Stock, Shares Outstanding   16,268,270  
Auditor Firm ID 248    
Auditor Name GRANT THORNTON LLP    
Auditor Location Philadelphia, Pennsylvania    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Preferred stock, par value (in dollars per share) $ 0.10 $ 0.10
Current Assets:    
Cash and cash equivalents $ 13,331 $ 24,739
Restricted cash 25 25
Marketable securities 5,956 0
Ownership interests 860 4,549
Prepaid expenses and other current assets 1,251 965
Total current assets 21,423 30,278
Right-of-use asset, net 1,290 1,561
Ownership interests and advances 14,545 21,972
Other assets 434 217
Total Assets 37,692 54,028
Current Liabilities:    
Accounts payable 16 41
Accrued compensation and benefits 507 794
Accrued expenses and other current liabilities 865 524
Lease liability - current 429 375
Total current liabilities 1,817 1,734
Lease liability - non-current 1,249 1,678
Other long-term liabilities 50 50
Total Liabilities 3,116 3,462
Commitments and contingencies (Note 11)
Equity:    
Preferred stock, $0.10 par value; 1,000 shares authorized 0 0
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2022 and 2021, respectively 2,157 2,157
Additional paid-in capital 804,752 806,638
Treasury stock, at cost; 5,478 and 5,068 shares at December 31, 2022 and 2021, respectively (48,410) (48,569)
Accumulated deficit (723,898) (709,635)
Accumulated other comprehensive loss (25) (25)
Total Equity 34,576 50,566
Total Liabilities and Equity $ 37,692 $ 54,028
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets (Parentheticals) - $ / shares
shares in Thousands
Dec. 31, 2022
Dec. 31, 2021
Preferred stock, par value (in dollars per share) $ 0.10 $ 0.10
Preferred stock, shares authorized (in shares) 1,000 1,000
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
Common stock, shares authorized (in shares) 83,333 83,333
Common stock, shares issued (in shares) 21,573 21,573
Treasury stock, shares (in shares) 5,478 5,068
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
General and administrative expense $ 4,775 $ 7,153
Operating loss (4,775) (7,153)
Other income (loss), net (3,297) 22,035
Interest income 794 276
Equity income (loss), net (6,985) 11,846
Net income (loss) before income taxes (14,263) 27,004
Income tax benefit (expense) 0 0
Net income (loss) $ (14,263) $ 27,004
Net income (loss) per share:    
Basic (in dollars per share) $ (0.87) $ 1.36
Diluted (in dollars per share) $ (0.87) $ 1.36
Weighted average shares used in computing net income (loss) per share:    
Basic (in shares) 16,337 19,827
Diluted (in shares) 16,337 19,827
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Total
Balance at Dec. 31, 2020 $ (736,639) $ (25) $ 2,157 $ 807,582 $ (10,200) $ 62,875
Balance (in shares) at Dec. 31, 2020     21,573   688  
Net income (loss) 27,004 0 $ 0 0 $ 0 27,004
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 (1,550) $ 2,286 736
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)     0   (161)  
Stock-based compensation 0 0 $ 0 606 $ 0 606
Repurchases of common stock 0 0 $ 0 0 $ (40,655) (40,655)
Repurchases of common stock (in shares)     0   4,541  
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (0) (0) $ (0) 1,550 $ (2,286) (736)
Balance at Dec. 31, 2021 (709,635) (25) $ 2,157 806,638 $ (48,569) 50,566
Balance (in shares) at Dec. 31, 2021     21,573   5,068  
Net income (loss) (14,263) 0 $ 0 0 $ 0 (14,263)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 2,622 $ (3,099) (477)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)     0   (302)  
Stock-based compensation 0 0 $ 0 736 $ 0 736
Repurchases of common stock 0 0 $ 0 0 $ (2,940) (2,940)
Repurchases of common stock (in shares)     0   712  
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 (2,622) $ 3,099 477
Balance at Dec. 31, 2022 $ (723,898) $ (25) $ 2,157 $ 804,752 $ (48,410) $ 34,576
Balance (in shares) at Dec. 31, 2022     21,573   5,478  
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities:    
Net income (loss) $ (14,263) $ 27,004
Adjustments to reconcile to net cash used in operating activities:    
Amortization of right of use asset 271 229
Equity (income) loss, net 6,985 (11,846)
Impairments of ownership interests and advances 0 2,521
Gain from observable price changes (553) (8,505)
Gain from sales of ownership interests 0 (35,284)
Change in fair value of ownership interests 3,689 19,255
Other, net 76 (22)
Stock-based compensation, including liability classified awards 1,445 1,779
Changes in assets and liabilities:    
Prepaid expenses and other current assets (534) (238)
Accounts payable, accrued expenses, and other current liabilities (374) (3,045)
Net cash used in operating activities (3,258) (8,152)
Cash Flows from Investing Activities:    
Proceeds from sales and distributions from ownership interests 6,879 60,832
Advances and loans to ownership interests (5,670) (2,718)
Purchase of marketable securities (11,871) 0
Proceeds, from sales and maturities in marketable securities 6,000 0
Net cash (used in) provided by investing activities (4,662) 58,114
Cash Flows from Financing Activities:    
Repurchases of common stock (2,939) (40,655)
Tax withholdings related to equity-based awards (549) (144)
Net cash used in financing activities (3,488) (40,799)
Net change in cash, cash equivalents and restricted cash (11,408) 9,163
Cash, cash equivalents and restricted cash equivalents at beginning of period 24,764 15,601
Cash, cash equivalents and restricted cash at end of period $ 13,356 $ 24,764
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - General
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. General

 

Liquidity And Capital Resources

 

As of December 31, 2022, Safeguard Scientifics, Inc. ("the Company") had $13.3 million of cash and cash equivalents and $6.0 million of marketable securities.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders.   We have considered and taken action on various initiatives including the sale of our ownership interests, the sale of certain or all of our ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value. As we seek to provide additional funding to existing companies where we have an ownership interest, we may be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    

 

The Company believes that its cash and cash equivalents at December 31, 2022 will be sufficient to fund operations past one year from the issuance of these consolidated financial statements. 

 

Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

 

Principles of Accounting for Ownership Interests in Companies

 

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

 

In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost.  Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations.  The Company also adjust the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative.  Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interests of the same issuer.  Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  Under this method, the changes in fair value are reflected in Other income (loss), net. As of December 31, 2022 those ownership interests consist of approximately 1.3 million common shares of Bright Health Group ("Bright Health") valued at $0.9 million.  

 

Comprehensive Income (loss) 

 

During the years ended December 31, 2022 or 2021, there were no items of comprehensive income (loss).

 

 

 

Accounting Estimates

 

The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

 

Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may require adjustments in the future when audits of these entities’ financial statements are completed.

 

It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2022, the Company believes the carrying value of the Company’s ownership interests and advances is not impaired, although there can be no assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will not be required in the future or that a significant loss will not be recorded in the future upon the sale of a company.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits that are readily convertible into cash.  The Company has not experienced any significant losses on cash equivalents and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

 

Restricted Cash

 

Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows:

 

  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Cash and cash equivalents

 $13,331  $24,739 

Restricted cash

  25   25 

Total cash, cash equivalents and restricted cash

 $13,356  $24,764 

 

Financial Instruments

 

The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. 

 

Right-of-use asset

 

Right-of-use assets represent an operating lease for office facilities.  The right-of-use assets are reduced over the remaining term of the applicable lease (principally April 2026) in a manner that results in a straight-line lease expense, when combined with the interest factor on the lease liability.     

 

 

 

Lease liability

 

The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 associated with the Company's prior corporate headquarters operating office lease. The discount rate used to calculate the lease liability was based on the Company's incremental borrowing rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease, which was approximately 12%, at the transition to the guidance of ASU No. 2016-02, Leases. Subsequent values of the lease liability reflect the reduction in the lease liability for operating lease payments less an amount representing interest, which is included in the straight-line lease expense. There is no residual value guarantee associated with this operating lease arrangement. The Company has incurred operating lease expenses and operating cash outflows of $0.5 million for each of the years ended December 31, 2022 and 2021, respectively, and $0.6 million for each of the years ended December 31, 2022 and 2021.

 

 

In March 2019, the Company entered into a sublease of its prior corporate headquarters office space. The term of the sublease is through April 2026, the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.

 

A summary of the Company's operating lease cash flows at December 31, 2022 follows:

 

  Operating lease payments  

Expected sublease receipts

 
  

(In thousands)

 

2023

 $607  $556 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

  —   — 

2028

  —   — 

Thereafter

  —   — 

Total future minimum lease payments

  2,046   1,918 

Less imputed interest

  (368)    

Total operating lease liabilities

 $1,678     

 

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

 

 

 

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations.

 

The reduced cost basis of a previously impaired company accounted for using the Equity method are not written-up if circumstances suggest the value of the company has subsequently recovered.

 

Income Taxes

 

The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not considered more likely than not to be realized.

 

Net Income (Loss) Per Share

 

The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.

 

Segment Information

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

 
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

2. Ownership Interests and Advances

 

The following summarizes the carrying value of the Company’s ownership interests and advances.

 

  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Equity Method:

        

Companies

 $8,749  $21,091 

Private equity funds

  97   117 
   8,846   21,208 

Other Method:

        

Companies, fair value

  860   4,549 

Companies, fair value measurement alternative

  1,067   514 

Private equity funds, fair value measurement alternative

  250   250 
   2,177   5,313 

Advances to companies

  4,382   — 
  $15,405  $26,521 

 

In September 2022, Lumesis, Inc. was acquired by another entity for cash.  The Company received $5.5 million in cash proceeds in connection with this transaction, excluding holdbacks and escrows.  This transaction resulted in a gain of $4.9 million, including $0.8 million other receivable related to an indemnification escrow during the year ended December 31, 2022.   

 

In March 2021, Zipnosis, Inc. was acquired by another entity, Bright Health.  The Company received $3.5 million in cash proceeds, including escrows, and $15.3 million in preferred equity in the acquiror in connection with this transaction.  This ownership interest represented a security that did not have a readily determinable fair value.  Due to the inherent uncertainty of determining the fair value of ownership interests that do not have a readily determinable fair value, this estimated value  may differ significantly from the value that would have been reported had a ready market for the security existed, and it is reasonably possible that the difference could be material.  The Company recognized a $17.3 million gain on the sale, which is included in Equity income (loss), net in the Consolidated Statements of Operations.  The fair value of the ownership interest received as a result of the acquisition was estimated based on evaluating several valuation methods available, including the value at which independent third parties have recently invested, the valuation of comparable public companies, and the present value of our expected outcomes.  Assumptions considered within these methods include determining which public companies are comparable, projecting forward revenues, selecting an appropriate valuation multiple, discounts to apply for the lack of marketability or lack of comparability, other factors and the relative weight to apply to each valuation method available.  Due to the unobservable nature of some of these inputs, we determined this initial estimate to be a Level 3 fair value measurement.  During the three months ended June 30, 2021, Bright Health completed an initial public offering that resulted in our ownership interest converting into approximately 1.3 million common shares.  Accordingly, the Bright Health common shares represent an ownership interest with a readily determinable fair value (Level 1), which will subsequently be measured at fair value with unrealized gains (losses) being reported as a component of Other income (loss), net.  As a result, the Company recognized a $10.8 million unrealized loss, net, on Bright Health subsequent to the initial public offering during the year ended December 31, 2021. The Company recognized a $3.7 million unrealized loss on Bright Health during the year ended December 31, 2022.

 

In August 2021, Flashtalking was acquired by another entity.  The Company has received $45.0 million in cash proceeds, including escrows, and included a $32.5 million gain in Other income (loss), net, during the year ended December 31, 2021.  The Company may receive additional amounts of up to approximately $0.5 million over the next 12 months from the resolution of escrow contingencies.  

 

In January 2021, WebLinc, Inc. was acquired by another entity.  The Company has received $3.6 million in cash proceeds to-date, which could be partially offset by indemnifiable claims.  The Company has recognized a $0.1 million loss on the sale during the year ended December 31, 2021, which is included in Equity income (loss), as certain contingencies were resolved.  During the year ended December 31, 2022, the Company recognized $0.5 million as gain on sale as the result of the collection of additional amounts and as contingencies were resolved, those amounts were recorded as gain on the sale and included within Equity income (loss). 

 

QuanticMind and Hoopla were acquired in separate transactions during the first quarter of 2021 by other entities, however there were no resultant proceeds to the Company.  There was no resulting gain or loss due to this equity method ownership interest being impaired during the prior year.

 

In March 2021, the Company's ownership interest in T-REX Group, Inc., which was accounted for using the fair value measurement alternative, was acquired for $3.0 million in cash.  The Company recognized a $0.9 million gain, which is included in Other income (loss), net.  

 

In April 2021, Velano Vascular was acquired by another entity.  The Company has received $4.0 million in cash proceeds, including escrows, and included a $1.9 million gain in Other income (loss), net, for the year ended December 31, 2021.  

 

In December 2021, the Company received $2 million of contingent proceeds resulting from resolution of certain valuation thresholds remaining from the 2018 sale of AdvantEdge Healthcare Solutions.

 

During the year ended December 31, 2021, the Company recorded an impairment of $2.5 million related to reduced expectations for certain Other ownership interests, which is included in Other income (loss), net. 

 

 

 

As of December 31, 2022, the Company held ownership interests accounted for using the equity method in 8 non-consolidated companies. 

 

Certain of the Company’s ownership interests as of December 31, 2022 and 2021 included the following:

 

  

Safeguard Primary Ownership as of December 31,

  

Company Name

 

2022

  

2021

 

Accounting Method

Aktana, Inc.

  13.6%  13.4%

Equity

Clutch Holdings, Inc.

  41.7%  41.7%

Equity

InfoBionic, Inc.

  25.2%  25.2%

Equity

meQuilibrium

  31.3%  31.9%

Equity

Moxe Health Corporation

  19.3%  27.6%

Equity

Prognos Health Inc.

  28.4%  28.5%

Equity

Syapse, Inc.

  11.0%  11.1%

Equity

Trice Medical, Inc.

  11.6%  12.6%

Equity

 

Summarized Financial Information

 

The following table provides summarized financial information for ownership interests accounted for under the equity method for the periods presented and has been compiled from respective company financial statements, reflect certain historical adjustments, and are reported on a one quarter lag. Results of operations are excluded for periods prior to their acquisition and subsequent to their disposition. Historical results are not adjusted when the Company exits or writes-off a company. 

 

  

As of December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Balance Sheets:

        

Current assets

 $126,042  $127,651 

Non-current assets

  55,073   53,220 

Total assets

 $181,115  $180,871 

Current liabilities

 $92,990  $62,538 

Non-current liabilities

  220,681   158,975 

Shareholders’ deficit

  (132,556)  (40,642)

Total liabilities and shareholders’ deficit

 $181,115  $180,871 
         

Number of equity method ownership interests

  8   9 

 

  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Results of Operations:

        

Revenue

 $144,771  $140,670 

Gross profit

 $88,666  $90,388 

Net loss

 $(152,936) $(106,363)

 

As of December 31, 2022, the Company’s carrying value in equity method companies, in the aggregate, exceeded the Company’s share of the net assets of such companies by approximately $2.7 million. Of this excess, $2.5 million was allocated to goodwill and $0.2 million was allocated to intangible assets.

 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Acquisitions of Ownership Interests
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Equity Method and Other Investments Disclosure [Text Block]

3. Acquisitions of Ownership Interests

 

2022 Transactions

 

The Company funded $1.6 million of convertible loans to Syapse, Inc.  The Company had previously deployed an aggregate of $25.0 million.  Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models.

 

The Company funded $2.0 million of convertible loans to Prognos Health Inc.  The Company had previously deployed an aggregate of $12.6 million.  Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with life sciences brands, payers, and clinical diagnostics organizations.  Prognos' innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.

 

The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million.  Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. 

 

The Company funded $0.5 million of convertible loans to meQuilibrium.  The Company had previously deployed an aggregate of $14.0 million.  meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers, and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being.

 

The Company funded $0.1 million of convertible loans to Trice Medical.  The Company had previously deployed an aggregate of $11.8 million.  Trice Medical is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians.  The Company also committed to provide another $0.3 million under certain conditions pursuant to a subordinated line of credit.  The Company's obligation under this line of credit is included in accrued expenses. Subsequent to the year end, the Company funded $0.3 million in accordance with this line of credit.

 

2021 Transactions

 

The Company funded $1.7 million to Aktana, Inc. during the three months ended September 30, 2021. The Company had previously deployed an aggregate of $14.2 million. Aktana helps its customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions and providing insight regarding which strategies work best for which customers under which conditions.

 

Syapse raised $68 million of preferred equity during the three months ended March 31, 2021, which reduced the Company's ownership interest to approximately 11.1%.  The Company recorded a $7.3 million dilution gain as a result of this transaction, which is included in Equity income (loss), net in the Consolidated Statements of Operation.  

 

The Company funded $1 million of convertible loans to Trice Medical, Inc. during the three months ended June 30, 2021.  During the three months ended September 30, 2021, Trice Medical raised additional preferred equity which reduced the Company's ownership interest to 12.6%.  The Company's existing convertible loans and related interest in Trice Medical were also converted into this new class of preferred equity.  As a result of this transaction, the Company recorded a $2.0 million dilution gain for the year ended December 31, 2021.

 

 

 

 

 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

4. Fair Value Measurements

 

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.

 

Cash, cash equivalents and restricted cash approximate fair value due to their short term nature.  The Company did not have any Level 2 or Level 3 financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022.

 

  

Carrying

  

Fair Value Measurement at December 31, 2022

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(in thousands)

 

Cash and cash equivalents

 $13,331  $13,331  $—  $— 
                 

Restricted cash

 $25  $25  $—  $— 
                 

Marketable securities—held-to-maturity:

                

U.S. Government securities

 $5,956  $5,956  $—  $— 
                 

Ownership interests

 $860  $860  $—  $— 

 

  

Carrying

  

Fair Value Measurement at December 31, 2021

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(In thousands)

 

Cash and cash equivalents

 $24,739  $24,739  $—  $— 
                 

Restricted cash equivalents

 $25  $25  $—  $— 
                 

Ownership interests

 $4,549  $4,549  $—  $— 
                 
                 

 

Ownership interests accounted for at fair value as of December 31, 2022 consist of approximately 1.3 million common shares of Bright Health. The securities are carried at fair value based on the closing stock price on the last trading day of the reporting period. The Company was restricted from trading these securities until December 2021 as a result of a lock-up agreement from the Bright Health Group initial public offering.

 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Equity
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

5. Equity

 

In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended December 31, 2022 and 2021, the Company did not repurchase any shares under the existing authorization. 

 

In May 2021, the Company's Board of Directors authorized a $6.0 million share repurchase program (the "2021 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2021, the Company purchased 236,159 shares under the 2021 Plan at an aggregate cost of $1.6 million, or $6.94 per share.  During October 2021, the Company suspended the 2021 Plan and completed a modified Dutch auction self-tender that resulted in the repurchase of 4.3 million common shares for an aggregate price of $38.7 million, or $9.00 per share.

 

In March 2022, the Company's Board of Directors replaced the 2021 Plan and authorized a separate $3.0 million share repurchase program (the "2022 Plan") using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  During the year ended December 31, 2022, the Company purchased 711,481 shares under the 2022 Plan at an aggregate cost of $2.9 million, or $4.13 per share.  The Company completed the 2022 Plan in January 2023 by purchasing an additional 25,096 shares, resulting in an average price of $4.09 for the 2022 Program.

 

 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Stock-Based Compensation
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

6. Stock-Based Compensation

 

Equity Compensation Plans

 

The 2014 Equity Compensation Plan has 4.1 million shares authorized for issuance. During 2022 and 2021, the Company issued no stock-based awards outside of existing plans. To the extent allowable, service-based options are incentive stock options. Options granted under the plans are at prices equal to or greater than the fair market value at the date of grant. Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares. At December 31, 2022, the Company had reserved 2.2 million shares of common stock for possible future issuance under its 2014 Equity Compensation Plan and other previously expired equity compensation plans.

 

Classification of Stock-Based Compensation Expense

 

Stock-based compensation consists of time based awards to employees, financial liability based awards to employees and non-employees to be settled in stock, performance based awards to employees, and financial liability based awards to Directors for quarterly and annual services. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: 

 

  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

General and administrative expense

 $1,445  $1,779 
  $1,445  $1,779 

 

Stock-based compensation expense of $1.2 million and $1.2 million was recognized during the years ended  December 31, 2022 and 2021, respectively, related to annual and quarterly Board fees, time based management awards and management bonuses earned during the year that were subsequently settled in stock.  For the years ended December 31, 2022 and 2021, respectively, the Company issued 165 thousand and 83 thousand of restricted shares to Directors for their annual and quarterly services.  The annual grants vest over a one year period, or are vested at issuance for directors 65 or older, while quarterly amounts are paid in arrears.  The Company vested 110 thousand and 95 thousand shares during the years ended December 31, 2022 and 2021.  The Company vested 22 thousand and 67 thousand shares during the years ended December 31, 2022 and 2021, respectively, for time based management compensation.  The Company settled in stock other management bonuses resulting in the issuance of 82 thousand and 60 thousand vested shares for the years ended December 31, 2022 and 2021, respectively.  The Company issued 15 thousand and 20 thousand vested shares to a non-employee for services during the years ended December 31, 2022 and 2021. The Company had liabilities of $0.4 million and $0.8 million as of December 31, 2022 and 2021, respectively, that were settled through the issuance of common stock in the subsequent period. 

 

The Company has previously granted certain performance-based stock units that vest based on the achievement of targeted capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified companies. The requisite service periods for these performance-based awards were based on the Company’s estimate of when the performance conditions will be met. Compensation expense was recognized for performance-based awards for which the performance condition is considered probable of achievement. During the years ended December 31, 2022 and 2021, respectively, 92 thousand and 6 thousand performance-based stock units pursuant to these targeted capital return pools were canceled or forfeited. The Company recorded a reduction of compensation expense related to these performance-based awards of zero and $0.1 million for the years ended December 31, 2022 and 2021, respectively. During October 2020 and in January 2022, the Company granted the CEO restricted stock units that may vest based on certain performance targets and criteria determined by the Board of Directors.  Such performance-based stock units represent the right to receive shares of the Company’s common stock, on a one-for-one basis at target, or up to 120% with respect to the 2020 grant, for certain specified thresholds. For the years ended December 31, 2022 and 2021, the Company recognized stock based compensation expense of $0.2 million and $0.5 million, respectively, and vested 64 thousand and 85 thousand shares, respectively, pursuant to these arrangements.

 

Unrecognized compensation expense related to performance stock units and restricted stock at December 31, 2022 was immaterial.

 

While there were no stock options granted during 2022 and 2021, the Company had outstanding options that vest based on two different types of vesting schedules:

 

1) performance-based; and

 

2) service-based.

 

Performance-based option awards also entitled participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company upon the sale, merger or other exit transaction of certain identified companies. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated.  The Company did not issue any performance-based units during the years ended December 31, 2022 and 2021.  During the years ended December 31, 2022 and 2021, respectively, 0 thousand and 1 thousand performance-based options vested and an immaterial amount of compensation cost was recognized.  During the years ended December 31, 2022 and 2021, respectively, 11 thousand and 11 thousand performance-based options were canceled or forfeited. The maximum number of unvested options at December 31, 2022 attainable under these grants was zero shares.

 

Service-based awards generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the years ended December 31, 2022 and 2021, respectively, the Company issued no service-based options to employees and recorded zero compensation expense from the vesting of previously issued awards. During the years ended December 31, 2022 and 2021, respectively, 0 thousand and 5 thousand service-based options were canceled or forfeited.  

 

 

 

Option activity of the Company is summarized below: 

 

  

Shares

  Weighted Average Exercise Price  

Weighted Average Remaining Contractual Life

  Aggregate Intrinsic Value 
  

(In thousands)

      

(In years)

  

(In thousands)

 

Outstanding at January 1, 2021

  45   14.20         

Options granted

  —   —         

Options exercised

  —   —         

Options canceled/forfeited

  (16)  14.20         

Outstanding at December 31, 2021

  29   14.20         

Options granted

  —   —         

Options exercised

  —   —         

Options canceled/forfeited

  (11)  14.48         

Outstanding at December 31, 2022

  18   14.05   1.50  $— 

Options exercisable at December 31, 2022

  18   14.05   1.50   — 

Shares available for future grant

  2,134             

 

At December 31, 2022, total unrecognized compensation cost related to non-vested service-based options was immaterial. At December 31, 2022, total unrecognized compensation cost related to non-vested performance-based options was immaterial.

 

 

 

Deferred stock unit, performance-based stock unit and restricted stock activity are summarized below: 

 

  

Shares

  Weighted Average Grant Date Fair Value 
  

(In thousands)

     

Unvested at January 1, 2021

  287  $8.78 

Granted

  163   7.21 

Vested

  (242)  6.82 

Forfeited

  (6)  14.99 

Unvested at December 31, 2021

  202   9.70 

Granted

  343   5.60 

Vested

  (293)  5.77 

Forfeited

  (92)  13.90 

Unvested at December 31, 2022

  160   5.70 

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Employee Benefit Plan
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Compensation and Employee Benefit Plans [Text Block]

7. Employee Benefit Plan

 

The Company maintains a qualified 401(k) retirement plan for eligible employees. The Plan’s matching formula is 100% of the first 5% of participants’ qualified compensation. Compensation expense related to our matching contributions to the Plan for the years ended December 31, 2022 and 2021, were $0.1 million and $0.1 million, respectively.

 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

8. Income Taxes

 

The federal and state provision (benefit) for income taxes was $0.0 million for the years ended December 31, 2022 and 2021.

 

The total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal income tax rate of 21.0% for the years ended December 31, 2022 and 2021 to net income (loss) before income taxes as a result of the following:

 

  

Year Ended December 31,

 
  

2022

  

2021

 

Statutory tax expense (benefit)

  (21.0)%  21.0%

Increase (decrease) in taxes resulting from:

        

Nondeductible expenses

  (2.6)  3.3 

Valuation allowance

  23.6   (24.3)
   0.0%  0.0%

 

 

 

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: 

 

  

As of December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Deferred tax asset:

        

Carrying values of ownership interests and other holdings

 $33,222  $31,985 

Tax loss and credit carryforwards

  68,492   77,045 

Disallowed interest carryforwards

  6,891   7,120 

Accrued expenses

  47   24 

Stock-based compensation

  180   268 

Other

  (106)  136 
   108,726   116,578 

Valuation allowance

  (108,726)  (116,578)

Net deferred tax asset

 $—  $— 

 

As of December 31, 2022, the Company and its subsidiaries had federal net operating and capital loss carryforwards for tax purposes of approximately $326 million, of which approximately $60 million have an indefinite life. These carryforwards expire as follows: 

 

  

Total

 
  

(In thousands)

 

2023

 $45,830 

2024

  50,140 

2025

  17,266 

2026

  7,648 

2027 and thereafter

  145,275 
  $266,159 

 

In assessing the recoverability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that it is more likely than not that certain future tax benefits may not be realized as a result of current and future income. Accordingly, a valuation allowance has been recorded against substantially all of the Company’s deferred tax assets.

 

The Company recognizes in its Consolidated Financial Statements the impact of a tax position if that position is more likely than not to be sustained upon examination, based on the technical merits of the position. All uncertain tax positions relate to unrecognized tax benefits that would impact the effective tax rate when recognized.

 

The Company does not expect any material increase or decrease in its income tax expense, in the next twelve months, related to examinations or changes in uncertain tax positions.

 

There were no changes in the Company’s uncertain tax positions for the years ended December 31, 2022 and 2021.

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. Tax years 2015 and forward remain open for examination for federal tax purposes and the Company’s more significant state tax jurisdictions. To the extent utilized in future years’ tax returns, net operating loss carryforwards at December 31, 2022 will remain subject to examination until the respective tax year is closed. The Company recognizes penalties and interest accrued related to income tax liabilities in income tax benefit (expense) in the Consolidated Statements of Operations.

 

 
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Net Income (Loss) Per Share
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

9. Net Income (Loss) Per Share

 

The calculations of net income (loss) per share were: 

 

  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands, except per share data)

 

Basic:

        

Net income (loss)

 $(14,263) $27,004 

Weighted average common shares outstanding

  16,337   19,827 

Net income (loss) per share

 $(0.87) $1.36 

Diluted:

        

Net income (loss)

 $(14,263) $27,004 

Weighted average common shares outstanding

  16,337   19,827 

Net income (loss) per share

 $(0.87) $1.36 

 

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

 

If an equity method company has dilutive stock options, unvested restricted stock, DSUs, or warrants, diluted net income (loss) per share is computed by first deducting from net income (loss) the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.

 

Diluted income (loss) per share for the years ended December 31, 2022 and 2021 do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:

 

 

•

At December 31, 2022 and 2021, options to purchase 18 thousand and 29 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 per share, and $10.37 to $17.11 per share per share, respectively, were excluded from the calculation.

 

 

•

At December 31, 2022 and 2021, unvested restricted stock, performance-based stock units and DSUs convertible into 0.2 million and 0.2 million shares of stock, respectively, were excluded from the calculations.

 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

10. Related Party Transactions

 

In the normal course of business, the Company’s officers and employees hold board positions with companies in which the Company has a direct or indirect ownership interest.

 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

11. Commitments and Contingencies

 

The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its companies. The Company records costs associated with legal fees as such services are rendered.

 

 

 

The Company has provided a guarantee, which is fully funded by escrowed funds held by a third party, of $3.8 million at December 31, 2022 which related to one of the Company's private equity holdings.

 

The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under severance agreements for remaining employees is approximately $1.1 million at December 31, 2022 and 250,000 common shares.

 

In 2018, the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in February 2019 and June 2020, known as the Amended and Restated Safeguard Scientifics Transaction Bonus Plan (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the business strategy that the Company adopted and announced in January 2018. The June 2020 amendment lowered the level of the first threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consistent with the business strategy.  Under the LTIP, participants, which includes certain current and former employees, have received awards that may result in cash payments in connection with sales of the Company’s ownership interests (“Sale Transaction(s)”). The LTIP provides for a bonus pool corresponding to: (i) specified vesting thresholds or (ii) specified events. In the first case, the bonus pool will range from an amount equal to 0.2% (previously 1.0%) of received proceeds at the first threshold to 1.3% at higher thresholds. In the second case, a minimum pool will be created and paid under specified circumstances. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in cash within 60 days of the applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company recorded compensation expense of zero and $0.7 million during the years ended December 31, 2022 and 2021, respectively.  The Company paid $2.5 million during the year ended December 31, 2021 and has no amounts accrued under the LTIP as of   December 31, 2022.

 

In June 2011, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.

 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Cash Flow, Supplemental Disclosures [Text Block]

12. Supplemental Cash Flow Information

 

During the years ended December 31, 2022 and 2021, the Company converted zero and $1.0 million, respectively, of advances into ownership interests. 

 

 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Segment Reporting
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

13. Segment Reporting

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

As of December 31, 2022 and 2021, all of the Company’s assets were located in the United States.

 

  
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Selected Quarterly Financial Information (Unaudited)
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Quarterly Financial Information [Text Block]

14. Selected Quarterly Financial Information (Unaudited)  

 

  

Three Months Ended

 
  

March 31

  

June 30

  

September 30

  

December 31

 
  

(In thousands, except per share data)

 

2022:

                

General and administrative expense

 $1,234  $1,146  $1,360  $1,035 

Operating loss

  (1,234)  (1,146)  (1,360)  (1,035)

Other income (loss), net

  (1,997)  30   (1,012)  (318)

Interest income

  101   145   230   318 

Equity income (loss), net

  (3,579)  1,454   (1,022)  (3,838)

Net loss before income taxes

  (6,709)  483   (3,164)  (4,873)

Income tax benefit (expense)

  —   —   —   — 

Net loss

 $(6,709) $483  $(3,164) $(4,873)

Net loss per share (a)

                

Basic

 $(0.40) $0.03  $(0.19) $(0.30)

Diluted

 $(0.40) $0.03  $(0.19) $(0.30)

2021:

                

General and administrative expense

 $2,463  $1,991  $1,564  $1,135 

Operating loss

  (2,463)  (1,991)  (1,564)  (1,135)

Other income (loss), net

  706   6,733   20,588   (5,992)

Interest income

  53   74   70   79 

Equity income (loss), net

  19,329   (5,136)  (761)  (1,586)

Net income (loss) before income taxes

  17,625   (320)  18,333   (8,634)

Income tax benefit (expense)

  —   —   —   — 

Net income (loss)

 $17,625  $(320) $18,333  $(8,634)

Net income (loss) per share (a)

                

Basic

 $0.84  $(0.02) $0.88  $(0.51)

Diluted

 $0.84  $(0.02) $0.88  $(0.51)

 

 

(a)

Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.

 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

 
Investment, Policy [Policy Text Block]

Principles of Accounting for Ownership Interests in Companies

 

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

 

In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost.  Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations.  The Company also adjust the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative.  Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interests of the same issuer.  Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  Under this method, the changes in fair value are reflected in Other income (loss), net. As of December 31, 2022 those ownership interests consist of approximately 1.3 million common shares of Bright Health Group ("Bright Health") valued at $0.9 million.  

 
Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (loss) 

 

During the years ended December 31, 2022 or 2021, there were no items of comprehensive income (loss).

 

 

 
Use of Estimates, Policy [Policy Text Block]

Accounting Estimates

 

The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.

 

Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may require adjustments in the future when audits of these entities’ financial statements are completed.

 

It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2022, the Company believes the carrying value of the Company’s ownership interests and advances is not impaired, although there can be no assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will not be required in the future or that a significant loss will not be recorded in the future upon the sale of a company.

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits that are readily convertible into cash.  The Company has not experienced any significant losses on cash equivalents and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

 
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

 

Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows:

 

  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Cash and cash equivalents

 $13,331  $24,739 

Restricted cash

  25   25 

Total cash, cash equivalents and restricted cash

 $13,356  $24,764 

 
Fair Value of Financial Instruments, Policy [Policy Text Block]

Financial Instruments

 

The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. 

 
Right-of-use Assets [Policy Text Block]

Right-of-use asset

 

Right-of-use assets represent an operating lease for office facilities.  The right-of-use assets are reduced over the remaining term of the applicable lease (principally April 2026) in a manner that results in a straight-line lease expense, when combined with the interest factor on the lease liability.     

 

 

 
Lessee, Leases [Policy Text Block]

Lease liability

 

The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 associated with the Company's prior corporate headquarters operating office lease. The discount rate used to calculate the lease liability was based on the Company's incremental borrowing rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease, which was approximately 12%, at the transition to the guidance of ASU No. 2016-02, Leases. Subsequent values of the lease liability reflect the reduction in the lease liability for operating lease payments less an amount representing interest, which is included in the straight-line lease expense. There is no residual value guarantee associated with this operating lease arrangement. The Company has incurred operating lease expenses and operating cash outflows of $0.5 million for each of the years ended December 31, 2022 and 2021, respectively, and $0.6 million for each of the years ended December 31, 2022 and 2021.

 

 

In March 2019, the Company entered into a sublease of its prior corporate headquarters office space. The term of the sublease is through April 2026, the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.

 

A summary of the Company's operating lease cash flows at December 31, 2022 follows:

 

  Operating lease payments  

Expected sublease receipts

 
  

(In thousands)

 

2023

 $607  $556 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

  —   — 

2028

  —   — 

Thereafter

  —   — 

Total future minimum lease payments

  2,046   1,918 

Less imputed interest

  (368)    

Total operating lease liabilities

 $1,678     

 
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

 

 

 

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations.

 

The reduced cost basis of a previously impaired company accounted for using the Equity method are not written-up if circumstances suggest the value of the company has subsequently recovered.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not considered more likely than not to be realized.

 
Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) Per Share

 

The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.

 
Segment Reporting, Policy [Policy Text Block]

Segment Information

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - General (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Restrictions on Cash and Cash Equivalents [Table Text Block]
  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Cash and cash equivalents

 $13,331  $24,739 

Restricted cash

  25   25 

Total cash, cash equivalents and restricted cash

 $13,356  $24,764 
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]
  Operating lease payments  

Expected sublease receipts

 
  

(In thousands)

 

2023

 $607  $556 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

  —   — 

2028

  —   — 

Thereafter

  —   — 

Total future minimum lease payments

  2,046   1,918 

Less imputed interest

  (368)    

Total operating lease liabilities

 $1,678     
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]
  

December 31, 2022

  

December 31, 2021

 
  

(In thousands)

 

Equity Method:

        

Companies

 $8,749  $21,091 

Private equity funds

  97   117 
   8,846   21,208 

Other Method:

        

Companies, fair value

  860   4,549 

Companies, fair value measurement alternative

  1,067   514 

Private equity funds, fair value measurement alternative

  250   250 
   2,177   5,313 

Advances to companies

  4,382   — 
  $15,405  $26,521 
Schedule of Other Ownership Interests [Table Text Block]
  

Safeguard Primary Ownership as of December 31,

  

Company Name

 

2022

  

2021

 

Accounting Method

Aktana, Inc.

  13.6%  13.4%

Equity

Clutch Holdings, Inc.

  41.7%  41.7%

Equity

InfoBionic, Inc.

  25.2%  25.2%

Equity

meQuilibrium

  31.3%  31.9%

Equity

Moxe Health Corporation

  19.3%  27.6%

Equity

Prognos Health Inc.

  28.4%  28.5%

Equity

Syapse, Inc.

  11.0%  11.1%

Equity

Trice Medical, Inc.

  11.6%  12.6%

Equity
Equity Method Investment Partner Company Results Of Operation [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Balance Sheets:

        

Current assets

 $126,042  $127,651 

Non-current assets

  55,073   53,220 

Total assets

 $181,115  $180,871 

Current liabilities

 $92,990  $62,538 

Non-current liabilities

  220,681   158,975 

Shareholders’ deficit

  (132,556)  (40,642)

Total liabilities and shareholders’ deficit

 $181,115  $180,871 
         

Number of equity method ownership interests

  8   9 
Equity Method Investments [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Results of Operations:

        

Revenue

 $144,771  $140,670 

Gross profit

 $88,666  $90,388 

Net loss

 $(152,936) $(106,363)
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
  

Carrying

  

Fair Value Measurement at December 31, 2022

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(in thousands)

 

Cash and cash equivalents

 $13,331  $13,331  $—  $— 
                 

Restricted cash

 $25  $25  $—  $— 
                 

Marketable securities—held-to-maturity:

                

U.S. Government securities

 $5,956  $5,956  $—  $— 
                 

Ownership interests

 $860  $860  $—  $— 
  

Carrying

  

Fair Value Measurement at December 31, 2021

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(In thousands)

 

Cash and cash equivalents

 $24,739  $24,739  $—  $— 
                 

Restricted cash equivalents

 $25  $25  $—  $— 
                 

Ownership interests

 $4,549  $4,549  $—  $— 
                 
                 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Share-Based Payment Arrangement, Activity [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

General and administrative expense

 $1,445  $1,779 
  $1,445  $1,779 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Shares

  Weighted Average Exercise Price  

Weighted Average Remaining Contractual Life

  Aggregate Intrinsic Value 
  

(In thousands)

      

(In years)

  

(In thousands)

 

Outstanding at January 1, 2021

  45   14.20         

Options granted

  —   —         

Options exercised

  —   —         

Options canceled/forfeited

  (16)  14.20         

Outstanding at December 31, 2021

  29   14.20         

Options granted

  —   —         

Options exercised

  —   —         

Options canceled/forfeited

  (11)  14.48         

Outstanding at December 31, 2022

  18   14.05   1.50  $— 

Options exercisable at December 31, 2022

  18   14.05   1.50   — 

Shares available for future grant

  2,134             
Schedule Of Activity For Restricted Stock Units Deferred Stock Units And Performance Units [Table Text Block]
  

Shares

  Weighted Average Grant Date Fair Value 
  

(In thousands)

     

Unvested at January 1, 2021

  287  $8.78 

Granted

  163   7.21 

Vested

  (242)  6.82 

Forfeited

  (6)  14.99 

Unvested at December 31, 2021

  202   9.70 

Granted

  343   5.60 

Vested

  (293)  5.77 

Forfeited

  (92)  13.90 

Unvested at December 31, 2022

  160   5.70 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

 

Statutory tax expense (benefit)

  (21.0)%  21.0%

Increase (decrease) in taxes resulting from:

        

Nondeductible expenses

  (2.6)  3.3 

Valuation allowance

  23.6   (24.3)
   0.0%  0.0%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 
  

(In thousands)

 

Deferred tax asset:

        

Carrying values of ownership interests and other holdings

 $33,222  $31,985 

Tax loss and credit carryforwards

  68,492   77,045 

Disallowed interest carryforwards

  6,891   7,120 

Accrued expenses

  47   24 

Stock-based compensation

  180   268 

Other

  (106)  136 
   108,726   116,578 

Valuation allowance

  (108,726)  (116,578)

Net deferred tax asset

 $—  $— 
Summary of Operating Loss Carryforwards [Table Text Block]
  

Total

 
  

(In thousands)

 

2023

 $45,830 

2024

  50,140 

2025

  17,266 

2026

  7,648 

2027 and thereafter

  145,275 
  $266,159 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Net Income (Loss) Per Share (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

 
  

(In thousands, except per share data)

 

Basic:

        

Net income (loss)

 $(14,263) $27,004 

Weighted average common shares outstanding

  16,337   19,827 

Net income (loss) per share

 $(0.87) $1.36 

Diluted:

        

Net income (loss)

 $(14,263) $27,004 

Weighted average common shares outstanding

  16,337   19,827 

Net income (loss) per share

 $(0.87) $1.36 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Quarterly Financial Information [Table Text Block]
  

Three Months Ended

 
  

March 31

  

June 30

  

September 30

  

December 31

 
  

(In thousands, except per share data)

 

2022:

                

General and administrative expense

 $1,234  $1,146  $1,360  $1,035 

Operating loss

  (1,234)  (1,146)  (1,360)  (1,035)

Other income (loss), net

  (1,997)  30   (1,012)  (318)

Interest income

  101   145   230   318 

Equity income (loss), net

  (3,579)  1,454   (1,022)  (3,838)

Net loss before income taxes

  (6,709)  483   (3,164)  (4,873)

Income tax benefit (expense)

  —   —   —   — 

Net loss

 $(6,709) $483  $(3,164) $(4,873)

Net loss per share (a)

                

Basic

 $(0.40) $0.03  $(0.19) $(0.30)

Diluted

 $(0.40) $0.03  $(0.19) $(0.30)

2021:

                

General and administrative expense

 $2,463  $1,991  $1,564  $1,135 

Operating loss

  (2,463)  (1,991)  (1,564)  (1,135)

Other income (loss), net

  706   6,733   20,588   (5,992)

Interest income

  53   74   70   79 

Equity income (loss), net

  19,329   (5,136)  (761)  (1,586)

Net income (loss) before income taxes

  17,625   (320)  18,333   (8,634)

Income tax benefit (expense)

  —   —   —   — 

Net income (loss)

 $17,625  $(320) $18,333  $(8,634)

Net income (loss) per share (a)

                

Basic

 $0.84  $(0.02) $0.88  $(0.51)

Diluted

 $0.84  $(0.02) $0.88  $(0.51)
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - General (Details Textual) - USD ($)
$ in Thousands, shares in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Total $ 13,331 $ 24,739  
Marketable Securities, Total 6,000    
Debt Securities, Trading, and Equity Securities, FV-NI, Total 860 4,549  
Lessee, Operating Lease, Discount Rate     12.00%
Operating Lease, Cost 500 500  
Operating Lease, Payments $ 600 $ 600  
Bright Health [Member]      
Investment Owned, Balance, Shares (in shares) 1.3    
Debt Securities, Trading, and Equity Securities, FV-NI, Total $ 900    
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Total $ 13,331 $ 24,739  
Restricted cash 25 25  
Total cash, cash equivalents and restricted cash $ 13,356 $ 24,764 $ 15,601
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - General - Schedule of Leases (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
2023, operating lease payments $ 607
2023, expected sublease receipts 556
2024, operating lease payments 613
2024, expected sublease receipts 573
2025, operating lease payments 619
2025, expected sublease receipts 590
2026, operating lease payments 207
2026, expected sublease receipts 199
2027, operating lease payments 0
2027, expected sublease receipts 0
2028, operating lease payments 0
2028, expected sublease receipts 0
Thereafter, operating lease payments 0
Thereafter, expected sublease receipts 0
Total future minimum lease payments, operating lease payments 2,046
Total future minimum lease payments, expected sublease receipts 1,918
Less imputed interest (368)
Total operating lease liabilities $ 1,678
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances (Details Textual) - USD ($)
$ in Thousands, shares in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Equity Securities without Readily Determinable Fair Value, Amount   $ 5,313   $ 2,177 $ 5,313
Impairment of Other Method Securities         2,500
Equity Method Investment Assets Exceed Carrying Value Of Investment       2,700  
Goodwill [Member]          
Equity Method Investment Allocation of Excess Fair Value       2,500  
Intangible Assets [Member]          
Equity Method Investment Allocation of Excess Fair Value       $ 200  
Preferred Equity in Acquiror in Connection with Sale of Zipnosis, Inc [Member]          
Equity Securities without Readily Determinable Fair Value, Amount     $ 15,300    
Lumesis, Inc. [Member]          
Proceeds from Sale of Equity Method Investments $ 5,500        
Equity Method Investment, Realized Gain (Loss) on Disposal 4,900        
"Equity Method Investment, Realized Gain (Loss) on Disposal, Other Receivable Related to Indemnification Escrow $ 800        
Zipnosis [Member]          
Proceeds from Sale of Equity Method Investments     3,500    
Equity Method Investment, Realized Gain (Loss) on Disposal     $ 17,300    
Investment Owned, Balance, Shares (in shares)     1.3    
Bright Health [Member]          
Investment Owned, Balance, Shares (in shares)       1.3  
Trading Security, Unrealized Gain (Loss)       $ 3,700 (10,800)
Flashtalking [Member]          
Proceeds From Sale of Other Method Investment         45,000
Other Method Investment, Realized Gain (Loss)         32,500
Contingent Proceeds from Other Method Investment         500
WebLinc, Inc. [Member]          
Proceeds from Sale of Equity Method Investments         3,600
Equity Method Investment, Realized Gain (Loss) on Disposal       $ 500 100
T-Rex Group, Inc [Member]          
Equity Method Investment, Realized Gain (Loss) on Disposal     $ 900    
Proceeds From Sale of Other Method Investment     $ 3,000    
Velano Vascular [Member]          
Proceeds from Sale of Equity Method Investments         4,000
Equity Method Investment, Realized Gain (Loss) on Disposal         $ 1,900
AdvantEdge Healthcare Solutions, Inc. [Member]          
Contingent Proceeds from Sale of Equity Method Investments   $ 2,000      
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Equity Method Companies $ 8,846 $ 21,208
Ownership interests 860 4,549
Other Method, fair value measurement alternative 2,177 5,313
Advances to companies 4,382 0
Investments and Advances to Affiliates, Current and Noncurrent 15,405 26,521
Partnership Interest [Member]    
Equity Method Companies 8,749 21,091
Ownership interests 860 4,549
Other Method, fair value measurement alternative 1,067 514
Private Equity Funds [Member]    
Equity Method Companies 97 117
Other Method, fair value measurement alternative $ 250 $ 250
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2021
Aktana, Inc. [Member]        
Ownership Interest 13.60% 13.40%    
Clutch Holdings [Member]        
Ownership Interest 41.70% 41.70%    
InfoBionic, Inc. [Member]        
Ownership Interest 25.20% 25.20%    
meQuilibrium [Member]        
Ownership Interest 31.30% 31.90%    
Moxe Health Corporation [Member]        
Ownership Interest 19.30% 27.60%    
Prognos Health, Inc. [Member]        
Ownership Interest 28.40% 28.50%    
Syapse, Inc. [Member]        
Ownership Interest 11.00% 11.10%   11.10%
Trice Medical, Inc. [Member]        
Ownership Interest 11.60% 12.60% 12.60%  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Current assets $ 21,423 $ 30,278
Total Assets 37,692 54,028
Current liabilities 1,817 1,734
Total Liabilities and Equity 37,692 54,028
High Traction Stage [Member]    
Current assets 126,042 127,651
Non-current assets 55,073 53,220
Total Assets 181,115 180,871
Current liabilities 92,990 62,538
Non-current liabilities 220,681 158,975
Shareholders’ deficit (132,556) (40,642)
Total Liabilities and Equity $ 181,115 $ 180,871
Number of equity method ownership interests 8 9
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue $ 144,771 $ 140,670
Gross profit 88,666 90,388
Net loss $ (152,936) $ (106,363)
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Jan. 31, 2023
Equity Method Investments       $ 8,846 $ 21,208  
Syapse, Inc. [Member]            
Convertible Bridge Loan       1,600    
Equity Method Investments       $ 25,000    
Proceeds from Issuance of Preferred Stock and Preference Stock     $ 68,000      
Equity Method Investment, Ownership Percentage     11.10% 11.00% 11.10%  
Equity Method Investment, Dilution Gain     $ 7,300      
Prognos Health, Inc. [Member]            
Convertible Bridge Loan       $ 2,000    
Equity Method Investments       $ 12,600    
Equity Method Investment, Ownership Percentage       28.40% 28.50%  
Clutch Holdings [Member]            
Convertible Bridge Loan       $ 1,400    
Equity Method Investments       $ 16,900    
Equity Method Investment, Ownership Percentage       41.70% 41.70%  
meQuilibrium [Member]            
Convertible Bridge Loan       $ 500    
Equity Method Investments       $ 14,000    
Equity Method Investment, Ownership Percentage       31.30% 31.90%  
Trice Medical, Inc. [Member]            
Convertible Bridge Loan   $ 1,000   $ 100    
Equity Method Investments       $ 11,800    
Equity Method Investment, Ownership Percentage 12.60%     11.60% 12.60%  
Equity Method Investment, Dilution Gain         $ 2,000  
Trice Medical, Inc. [Member] | Equity Method Investee [Member] | Credit Facility [Member]            
Commitment To Fund Convertible Bridge Loan       $ 300    
Trice Medical, Inc. [Member] | Equity Method Investee [Member] | Credit Facility [Member] | Subsequent Event [Member]            
Commitment To Fund Convertible Bridge Loan           $ 300
Aktana, Inc. [Member]            
Convertible Bridge Loan $ 1,700          
Equity Method Investments $ 14,200          
Equity Method Investment, Ownership Percentage       13.60% 13.40%  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements (Details Textual)
shares in Millions
Dec. 31, 2022
shares
Bright Health [Member]  
Investment Owned, Balance, Shares (in shares) 1.3
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Reported Value Measurement [Member]    
Cash and cash equivalents $ 13,331 $ 24,739
Restricted cash 25 25
Ownership interests 860 4,549
Reported Value Measurement [Member] | US Treasury Securities [Member]    
U.S. Government securities 5,956  
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents 13,331 24,739
Restricted cash 25 25
Ownership interests 860 4,549
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]    
U.S. Government securities 5,956  
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents 0 0
Restricted cash 0 0
Ownership interests 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]    
U.S. Government securities 0  
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents 0 0
Restricted cash 0 0
Ownership interests 0 $ 0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]    
U.S. Government securities $ 0  
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Equity (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2023
Oct. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Mar. 31, 2022
May 31, 2021
Jul. 31, 2015
Treasury Stock, Value, Acquired, Cost Method     $ 2,940 $ 40,655      
Share Repurchase Program Authorized in July 2015 [Member]              
Stock Repurchase Program, Authorized Amount             $ 25,000
Treasury Stock, Shares, Acquired (in shares)     0 0      
Share Repurchase Program Authorized in May 2021 [Member]              
Stock Repurchase Program, Authorized Amount           $ 6,000  
Treasury Stock, Shares, Acquired (in shares)       236,159      
Treasury Stock, Value, Acquired, Cost Method       $ 1,600      
Treasury Stock Acquired, Average Cost Per Share (in dollars per share)       $ 6.94      
Dutch Auction Self-tender [Member]              
Treasury Stock, Shares, Acquired (in shares)   4,300,000          
Treasury Stock, Value, Acquired, Cost Method   $ 38,700          
Treasury Stock Acquired, Average Cost Per Share (in dollars per share)   $ 9.00          
Share Repurchase Program Authorized in March 2022 [Member]              
Stock Repurchase Program, Authorized Amount         $ 3,000    
Treasury Stock, Shares, Acquired (in shares)     711,481        
Treasury Stock, Value, Acquired, Cost Method     $ 2,900        
Treasury Stock Acquired, Average Cost Per Share (in dollars per share)     $ 4.13        
Share Repurchase Program Authorized in March 2022 [Member] | Subsequent Event [Member]              
Treasury Stock, Shares, Acquired (in shares) 25,096            
Treasury Stock Acquired, Average Cost Per Share (in dollars per share) $ 4.09            
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Stock-Based Compensation (Details Textual)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
Share-Based Payment Arrangement, Expense | $ $ 1,445 $ 1,779  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types 2    
Director [Member]      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ $ 400 800  
Performance Shares [Member]      
Share-Based Payment Arrangement, Expense | $ 1,200 1,200  
Share-Based Payment Arrangement, Expense, after Tax | $ $ 0 $ 100  
Restricted Stock [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) 22,000 67,000  
Restricted Stock [Member] | Director [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) 165,000 83,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) 110,000 95,000  
Restricted Stock [Member] | Other Management [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued and Vested in Period (in shares) 82,000 60,000  
Restricted Stock [Member] | Non-Employee [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued and Vested in Period (in shares) 15,000 20,000  
Performance Stock Unit [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) 0 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) 0 1  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) 92,000 6,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Target Percentage     120.00%
Performance Based Options [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares (in shares) 11,000 11,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) 0    
Service Based Award [Member]      
Share-Based Payment Arrangement, Expense, after Tax | $ $ 0 $ 0  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 4 years    
Share Based Compensation Arrangement, By Share Based Payment Award, Expiration Term (Year) 8 years    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) 0 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares) 0 5,000  
2014 Equity Compensation Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 4,100,000    
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 2,200,000    
The 2020 Award [Member]      
Share-Based Payment Arrangement, Expense | $ $ 200 $ 500  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) 64,000 85,000  
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
General and administrative expense $ 1,445 $ 1,779
General and Administrative Expense [Member]    
General and administrative expense $ 1,445 $ 1,779
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance, shares (in shares) 29 45
Balance, weighted average exercise price (in dollars per share) $ 14.20 $ 14.20
Options granted, shares (in shares) 0 0
Options granted, weighted average exercise price (in dollars per share) $ 0 $ 0
Options exercised, shares (in shares) 0 0
Options exercised, weighted average exercise price (in dollars per share) $ 0 $ 0
Options canceled/forfeited, shares (in shares) (11) (16)
Options canceled/forfeited, weighted average exercise price (in dollars per share) $ 14.48 $ 14.20
Options exercised, shares (in shares) 0 (0)
Balance, shares (in shares) 18 29
Balance, weighted average exercise price (in dollars per share) $ 14.05 $ 14.20
Balance, weighted average remaining contractual life (Year) 1 year 6 months  
Balance, aggregative intrinsic value $ 0  
Options exercisable, shares (in shares) 18  
Options exercisable , weighted average exercise price (in dollars per share) $ 14.05  
Options exercisable, weighted average remaining contractual life (Year) 1 year 6 months  
Options exercisable, aggregative intrinsic value $ 0  
Shares available for future grant, shares (in shares) 2,134  
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details) - Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance (in shares) 202 287
Balance (in dollars per share) $ 9.70 $ 8.78
Granted (in shares) 343 163
Granted (in dollars per share) $ 5.60 $ 7.21
Vested (in shares) (293) (242)
Vested (in dollars per share) $ 5.77 $ 6.82
Forfeited (in shares) (92) (6)
Forfeited (in dollars per share) $ 13.90 $ 14.99
Balance (in shares) 160 202
Balance (in dollars per share) $ 5.70 $ 9.70
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Employee Benefit Plan (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Defined Contribution Plan, Employer Matching Contribution, Percent of Match 100.00%  
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 5.00%  
Defined Contribution Plan, Cost $ 0.1 $ 0.1
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Federal Income Tax Expense (Benefit), Continuing Operations, Total $ 0 $ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate (Negative Rate), Percent 21.00% 21.00%
Deferred Tax Assets, Operating Loss Carryforwards, Total $ 326,000  
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration 60,000  
Unrecognized Tax Benefits, Period Increase (Decrease), Total $ 0 $ 0
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Statutory tax expense (benefit) 21.00% 21.00%
Nondeductible expenses (2.60%) 3.30%
Valuation allowance 23.60% (24.30%)
Effective Income Tax Rate Reconciliation, Percent, Total 0.00% 0.00%
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Carrying values of ownership interests and other holdings $ 33,222 $ 31,985
Tax loss and credit carryforwards 68,492 77,045
Disallowed interest carryforwards 6,891 7,120
Accrued expenses 47 24
Stock-based compensation 180 268
Other (106) 136
Deferred Tax Assets, Gross, Total 108,726 116,578
Valuation allowance (108,726) (116,578)
Net deferred tax asset $ 0 $ 0
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
2023 $ 45,830
2024 50,140
2025 17,266
2026 7,648
2027 and thereafter 145,275
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $ 266,159
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Net Income (Loss) Per Share (Details Textual) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 18,000 29
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) $ 10.37 $ 10.37
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) $ 17.11 $ 17.11
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 200,000 200,000
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Basic:                    
Net income (loss) $ (4,873) $ (3,164) $ 483 $ (6,709) $ (8,634) $ 18,333 $ (320) $ 17,625 $ (14,263) $ 27,004
Basic (in shares)                 16,337 19,827
Basic (in dollars per share) $ (0.30) [1] $ (0.19) [1] $ 0.03 [1] $ (0.40) [1] $ (0.51) [1] $ 0.88 [1] $ (0.02) [1] $ 0.84 [1] $ (0.87) $ 1.36
Diluted:                    
Net income (loss) $ (4,873) $ (3,164) $ 483 $ (6,709) $ (8,634) $ 18,333 $ (320) $ 17,625 $ (14,263) $ 27,004
Diluted (in shares)                 16,337 19,827
Diluted (in dollars per share) $ (0.30) [1] $ (0.19) [1] $ 0.03 [1] $ (0.40) [1] $ (0.51) [1] $ 0.88 [1] $ (0.02) [1] $ 0.84 [1] $ (0.87) $ 1.36
[1] Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Commitments and Contingencies (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Employee and Severance Agreement, Maximum Aggregate Exposure $ 1,100  
Employee and Severance Agreement, Maximum Aggregate Exposure, Shares (in shares) 250,000  
Long-term Incentive Plan, Payments   $ 2,500
Deferred Compensation Liability, Current and Noncurrent, Total $ 0  
Amended and Restated Safeguard Scientifics Transaction Bonus Plan [Member]    
Compensation, Cash Award $ 0 $ 700
Minimum [Member]    
Long-term Incentive Plan, Bonus Pool Percent 0.20% 1.00%
Maximum [Member]    
Long-term Incentive Plan, Bonus Pool Percent 1.30%  
Private Equity Funds [Member]    
Guarantor Obligations, Current Carrying Value $ 3,800  
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Supplemental Cash Flow Information (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Debt Conversion, Converted Instrument, Amount $ 0 $ 1,000
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Segment Reporting (Details Textual)
 12 Months Ended
Dec. 31, 2022
Number of Operating Segments 1
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
General and administrative expense $ 1,035 $ 1,360 $ 1,146 $ 1,234 $ 1,135 $ 1,564 $ 1,991 $ 2,463 $ 4,775 $ 7,153
Operating loss (1,035) (1,360) (1,146) (1,234) (1,135) (1,564) (1,991) (2,463) (4,775) (7,153)
Other income (loss), net (318) (1,012) 30 (1,997) (5,992) 20,588 6,733 706 (3,297) 22,035
Interest income 318 230 145 101 79 70 74 53 794 276
Equity income (loss), net (3,838) (1,022) 1,454 (3,579) (1,586) (761) (5,136) 19,329 (6,985) 11,846
Net loss before income taxes (4,873) (3,164) 483 (6,709) (8,634) 18,333 (320) 17,625 (14,263) 27,004
Net income (loss) $ (4,873) $ (3,164) $ 483 $ (6,709) $ (8,634) $ 18,333 $ (320) $ 17,625 $ (14,263) $ 27,004
Basic (in dollars per share) $ (0.30) [1] $ (0.19) [1] $ 0.03 [1] $ (0.40) [1] $ (0.51) [1] $ 0.88 [1] $ (0.02) [1] $ 0.84 [1] $ (0.87) $ 1.36
Diluted (in dollars per share) $ (0.30) [1] $ (0.19) [1] $ 0.03 [1] $ (0.40) [1] $ (0.51) [1] $ 0.88 [1] $ (0.02) [1] $ 0.84 [1] $ (0.87) $ 1.36
[1] Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.
XML 70 sfe20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0000086115 2022-01-01 2022-12-31 0000086115 2022-06-30 0000086115 2023-03-06 0000086115 2022-12-31 0000086115 2021-12-31 0000086115 2021-01-01 2021-12-31 0000086115 2020-12-31 0000086115 us-gaap:RetainedEarningsMember 2020-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000086115 us-gaap:CommonStockMember 2020-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000086115 us-gaap:TreasuryStockMember 2020-12-31 0000086115 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000086115 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000086115 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000086115 us-gaap:RetainedEarningsMember 2021-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000086115 us-gaap:CommonStockMember 2021-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000086115 us-gaap:TreasuryStockMember 2021-12-31 0000086115 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000086115 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000086115 us-gaap:TreasuryStockMember 2022-01-01 2022-12-31 0000086115 us-gaap:RetainedEarningsMember 2022-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000086115 us-gaap:CommonStockMember 2022-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000086115 us-gaap:TreasuryStockMember 2022-12-31 0000086115 sfe:BrightHealthMember 2022-12-31 0000086115 srt:PartnershipInterestMember 2022-12-31 0000086115 srt:PartnershipInterestMember 2021-12-31 0000086115 us-gaap:PrivateEquityFundsMember 2022-12-31 0000086115 us-gaap:PrivateEquityFundsMember 2021-12-31 0000086115 sfe:LumesisIncMember 2022-09-01 2022-09-30 0000086115 sfe:LumesisIncMember 2022-09-30 0000086115 sfe:ZipnosisMember 2021-03-01 2021-03-31 0000086115 sfe:PreferredEquityInAcquirorInConnectionWithSaleOfZipnosisIncMember 2021-03-31 0000086115 sfe:ZipnosisMember 2021-03-31 0000086115 sfe:BrightHealthMember 2021-01-01 2021-12-31 0000086115 sfe:BrightHealthMember 2022-01-01 2022-12-31 0000086115 sfe:FlashtalkingMember 2021-01-01 2021-12-31 0000086115 sfe:WebLincIncMember 2021-01-01 2021-12-31 0000086115 sfe:WebLincIncMember 2022-01-01 2022-12-31 0000086115 sfe:TrexGroupIncMember 2021-03-01 2021-03-31 0000086115 sfe:VelanoVascularMember 2021-01-01 2021-12-31 0000086115 sfe:AdvantedgeHealthcareSolutionsIncMember 2021-12-01 2021-12-31 0000086115 sfe:AktanaIncMember 2022-12-31 0000086115 sfe:AktanaIncMember 2021-12-31 0000086115 sfe:ClutchHoldingsMember 2022-12-31 0000086115 sfe:ClutchHoldingsMember 2021-12-31 0000086115 sfe:InfoBionicIncMember 2022-12-31 0000086115 sfe:InfoBionicIncMember 2021-12-31 0000086115 sfe:meQuilibriumMember 2022-12-31 0000086115 sfe:meQuilibriumMember 2021-12-31 0000086115 sfe:MoxeHealthCorporationMember 2022-12-31 0000086115 sfe:MoxeHealthCorporationMember 2021-12-31 0000086115 sfe:PrognosHealthIncMember 2022-12-31 0000086115 sfe:PrognosHealthIncMember 2021-12-31 0000086115 sfe:SyapseIncMember 2022-12-31 0000086115 sfe:SyapseIncMember 2021-12-31 0000086115 sfe:TriceMedicalIncMember 2022-12-31 0000086115 sfe:TriceMedicalIncMember 2021-12-31 0000086115 sfe:HighTractionStageMember 2022-12-31 0000086115 sfe:HighTractionStageMember 2021-12-31 0000086115 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2022-01-01 2022-12-31 0000086115 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-12-31 0000086115 us-gaap:GoodwillMember 2022-12-31 0000086115 sfe:IntangibleAssetsMember 2022-12-31 0000086115 sfe:SyapseIncMember 2022-01-01 2022-12-31 0000086115 sfe:PrognosHealthIncMember 2022-01-01 2022-12-31 0000086115 sfe:ClutchHoldingsMember 2022-01-01 2022-12-31 0000086115 sfe:meQuilibriumMember 2022-01-01 2022-12-31 0000086115 sfe:TriceMedicalIncMember 2022-01-01 2022-12-31 0000086115 sfe:TriceMedicalIncMember sfe:CreditFacilityMember us-gaap:EquityMethodInvesteeMember 2022-12-31 0000086115 sfe:TriceMedicalIncMember sfe:CreditFacilityMember us-gaap:EquityMethodInvesteeMember us-gaap:SubsequentEventMember 2023-01-31 0000086115 sfe:AktanaIncMember 2021-07-01 2021-09-30 0000086115 sfe:AktanaIncMember 2021-09-30 0000086115 sfe:SyapseIncMember 2021-01-01 2021-03-31 0000086115 sfe:SyapseIncMember 2021-03-31 0000086115 sfe:TriceMedicalIncMember 2021-04-01 2021-06-30 0000086115 sfe:TriceMedicalIncMember 2021-09-30 0000086115 sfe:TriceMedicalIncMember 2021-01-01 2021-12-31 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member 2015-07-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member 2022-01-01 2022-12-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member 2021-01-01 2021-12-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMay2021Member 2021-05-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMay2021Member 2021-01-01 2021-12-31 0000086115 sfe:DutchAuctionSelftenderMember 2021-10-01 2021-10-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMarch2022Member 2022-03-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMarch2022Member 2022-01-01 2022-12-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMarch2022Member us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 0000086115 sfe:EquityCompensationPlanMember 2022-12-31 0000086115 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000086115 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000086115 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000086115 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000086115 srt:DirectorMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000086115 srt:DirectorMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000086115 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000086115 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000086115 sfe:OtherManagementMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000086115 sfe:OtherManagementMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000086115 sfe:NonemployeeMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000086115 sfe:NonemployeeMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000086115 srt:DirectorMember 2022-12-31 0000086115 srt:DirectorMember 2021-12-31 0000086115 sfe:PerformanceStockUnitMember 2022-01-01 2022-12-31 0000086115 sfe:PerformanceStockUnitMember 2021-01-01 2021-12-31 0000086115 sfe:PerformanceStockUnitMember 2020-12-31 0000086115 sfe:The2020AwardMember 2022-01-01 2022-12-31 0000086115 sfe:The2020AwardMember 2021-01-01 2021-12-31 0000086115 sfe:PerformanceBasedOptionsMember 2022-01-01 2022-12-31 0000086115 sfe:PerformanceBasedOptionsMember 2021-01-01 2021-12-31 0000086115 sfe:PerformanceBasedOptionsMember 2022-12-31 0000086115 sfe:ServiceBasedAwardMember 2022-01-01 2022-12-31 0000086115 sfe:ServiceBasedAwardMember 2021-01-01 2021-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2020-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2021-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2022-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2020-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2021-01-01 2021-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2021-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2022-01-01 2022-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2022-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000086115 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000086115 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000086115 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000086115 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000086115 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2022-01-01 2022-12-31 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2021-01-01 2021-12-31 0000086115 srt:MinimumMember 2022-01-01 2022-12-31 0000086115 srt:MinimumMember 2021-01-01 2021-12-31 0000086115 srt:MaximumMember 2022-01-01 2022-12-31 0000086115 sfe:AmendedAndRestatedSafeguardScientificsTransactionBonusPlanMember 2022-01-01 2022-12-31 0000086115 sfe:AmendedAndRestatedSafeguardScientificsTransactionBonusPlanMember 2021-01-01 2021-12-31 0000086115 2022-01-01 2022-03-31 0000086115 2022-04-01 2022-06-30 0000086115 2022-07-01 2022-09-30 0000086115 2022-10-01 2022-12-31 0000086115 2021-01-01 2021-03-31 0000086115 2021-04-01 2021-06-30 0000086115 2021-07-01 2021-09-30 0000086115 2021-10-01 2021-12-31 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y 0000086115 SAFEGUARD SCIENTIFICS INC false --12-31 FY 2022 0.10 0.10 0.10 0.10 1000000 1000000 0.10 0.10 83333000 83333000 21573000 21573000 2157000 2157000 5478000 5068000 500000 600000 2500000 0 0 0 2 0 0 P4Y P8Y 0 0 0 0.0 0.210 0.210 0.210 0 0 0 1 10-K true 2022-12-31 false 1-5620 PA 23-1609753 150 N. Radnor Chester Road Radnor PA 19087 610 293-0600 Common Stock ($.10 par value) SFE NASDAQ No No Yes Yes true Non-accelerated Filer false false false 50494095 16268270 248 GRANT THORNTON LLP Philadelphia, Pennsylvania 13331000 24739000 25000 25000 5956000 0 860000 4549000 1251000 965000 21423000 30278000 1290000 1561000 14545000 21972000 434000 217000 37692000 54028000 16000 41000 507000 794000 865000 524000 429000 375000 1817000 1734000 1249000 1678000 50000 50000 3116000 3462000 0 0 804752000 806638000 48410000 48569000 -723898000 -709635000 -25000 -25000 34576000 50566000 37692000 54028000 4775000 7153000 -4775000 -7153000 -3297000 22035000 794000 276000 -6985000 11846000 -14263000 27004000 0 0 -14263000 27004000 -0.87 1.36 -0.87 1.36 16337000 19827000 16337000 19827000 62875000 -736639000 -25000 21573000 2157000 807582000 688000 -10200000 27004000 27004000 0 0 0 0 -736000 -0 -0 0 -0 1550000 -161000 -2286000 606000 0 0 0 606000 0 40655000 -0 -0 0 -0 -0 4541000 40655000 50566000 -709635000 -25000 21573000 2157000 806638000 5068000 -48569000 -14263000 -14263000 0 0 0 0 477000 0 0 0 0 -2622000 -302000 3099000 736000 0 0 0 736000 0 2940000 -0 -0 0 -0 -0 712000 2940000 34576000 -723898000 -25000 21573000 2157000 804752000 5478000 -48410000 -14263000 27004000 271000 229000 -6985000 11846000 -0 -2521000 553000 8505000 -0 35284000 -3689000 -19255000 -76000 22000 1445000 1779000 534000 238000 -374000 -3045000 -3258000 -8152000 6879000 60832000 5670000 2718000 11871000 -0 6000000 0 -4662000 58114000 2939000 40655000 549000 144000 -3488000 -40799000 -11408000 9163000 24764000 15601000 13356000 24764000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> General</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><b>Liquidity And Capital Resources </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">As of <em style="font: inherit;"> December 31, 2022</em>, Safeguard Scientifics, Inc. ("the Company") had $13.3 million of cash and cash equivalents and $6.0 million of marketable securities.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 24pt; text-align: left;">In <em style="font: inherit;"> January 2018, </em>Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders.   We have considered and taken action on various initiatives including the sale of our ownership interests, the sale of certain or all of our ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value. As we seek to provide additional funding to existing companies where we have an ownership interest, we <em style="font: inherit;"> may </em>be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company believes that its cash and cash equivalents at <em style="font: inherit;"> December 31, 2022</em> will be sufficient to fund operations past <em style="font: inherit;">one</em> year from the issuance of these consolidated financial statements. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Principles of Consolidation</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Principles of Accounting for Ownership Interests in Companies</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company accounts for its ownership interests using <em style="font: inherit;">one</em> of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"><i>Equity Method.</i> The Company accounts for ownership interests whose results are <em style="font: inherit;">not</em> consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or <em style="font: inherit;">not</em> the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a <em style="font: inherit;">20%</em> to <em style="font: inherit;">50%</em> interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost.  Under the equity method of accounting, the Company does <em style="font: inherit;">not</em> reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations.  The Company also adjust the carrying value to reflect <em style="font: inherit;">third</em> party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a <em style="font: inherit;">one</em> quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">When the Company’s carrying value in an equity method company is reduced to zero, the Company records <em style="font: inherit;">no</em> further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will <em style="font: inherit;">not</em> record its share of such income until it exceeds the amount of the Company’s share of losses <em style="font: inherit;">not</em> previously recognized.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"><i>Other Method. </i>We account for ownership interests in companies that are <em style="font: inherit;">not</em> accounted for under the equity method that do <em style="font: inherit;">not</em> have a readily determinable fair value under the fair value measurement alternative.  Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interests of the same issuer.  Under this method, our share of the income or losses of such companies is <em style="font: inherit;">not</em> included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company accounts for ownership interests that are <em style="font: inherit;">not</em> accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  Under this method, the changes in fair value are reflected in Other income (loss), net. As of <em style="font: inherit;"> December 31, 2022 </em>those ownership interests consist of approximately 1.3 million common shares of Bright Health Group ("Bright Health") valued at $0.9 million.  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"><i><b/></i></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"><i><b>Comprehensive Income (loss) </b></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">During the years ended <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;">2021,</em> there were <em style="font: inherit;">no</em> items of comprehensive income (loss).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Accounting Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results <em style="font: inherit;"> may </em>differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and <em style="font: inherit;"> may </em>require adjustments in the future when audits of these entities’ financial statements are completed.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At <em style="font: inherit;"> December 31, 2022</em>, the Company believes the carrying value of the Company’s ownership interests and advances is <em style="font: inherit;">not</em> impaired, although there can be <em style="font: inherit;">no</em> assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will <em style="font: inherit;">not</em> be required in the future or that a significant loss will <em style="font: inherit;">not</em> be recorded in the future upon the sale of a company.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Cash and Cash Equivalents</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company considers all highly liquid instruments with an original maturity of <em style="font: inherit;">90</em> days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits that are readily convertible into cash.  The Company has <em style="font: inherit;">not</em> experienced any significant losses on cash equivalents and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Restricted Cash </b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;">Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total cash, cash equivalents and restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Financial Instruments</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Right-of-use asset</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Right-of-use assets represent an operating lease for office facilities.  The right-of-use assets are reduced over the remaining term of the applicable lease (principally <em style="font: inherit;"> April 2026) </em>in a manner that results in a straight-line lease expense, when combined with the interest factor on the lease liability. <b>    </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"><i><b>Lease liability</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The initial lease liability represents the present value of the fixed escalating lease payments through <em style="font: inherit;"> April 2026 </em>associated with the Company's prior corporate headquarters operating office lease. The discount rate used to calculate the lease liability was based on the Company's incremental borrowing rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease, which was approximately 12%, at the transition to the guidance of ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i>. Subsequent values of the lease liability reflect the reduction in the lease liability for operating lease payments less an amount representing interest, which is included in the straight-line lease expense. There is <em style="font: inherit;">no</em> residual value guarantee associated with this operating lease arrangement. The Company has incurred operating lease expenses and operating cash outflows of $0.5 million for each of the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, and $0.6 million for each of the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">In <em style="font: inherit;"> March 2019, </em>the Company entered into a sublease of its prior corporate headquarters office space. The term of the sublease is through <em style="font: inherit;"> April 2026, </em>the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">A summary of the Company's operating lease cash flows at <em style="font: inherit;"> December 31, 2022</em> follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Operating lease payments</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Expected sublease receipts</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 12pt;"/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 12pt;"><i><b/></i></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 12pt;"><i><b>Impairment of Ownership Interests and Advances </b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">On a periodic basis, but <em style="font: inherit;">no</em> less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are <em style="font: inherit;">not</em> primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The estimated fair value of privately held companies is generally determined based on the value at which independent <em style="font: inherit;">third</em> parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The reduced cost basis of a previously impaired company accounted for using the Equity method are <em style="font: inherit;">not</em> written-up if circumstances suggest the value of the company has subsequently recovered.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Income Taxes</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are <em style="font: inherit;">not</em> considered more likely than <em style="font: inherit;">not</em> to be realized.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Net Income (Loss) Per Share</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Segment Information</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company operates as <em style="font: inherit;">one</em> operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 13300000 6000000.0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Principles of Consolidation</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The consolidated financial statements include the accounts of Safeguard and all of its wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Principles of Accounting for Ownership Interests in Companies</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company accounts for its ownership interests using <em style="font: inherit;">one</em> of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"><i>Equity Method.</i> The Company accounts for ownership interests whose results are <em style="font: inherit;">not</em> consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or <em style="font: inherit;">not</em> the Company exercises significant influence with respect to an ownership interest depends on an evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a <em style="font: inherit;">20%</em> to <em style="font: inherit;">50%</em> interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost.  Under the equity method of accounting, the Company does <em style="font: inherit;">not</em> reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations.  The Company also adjust the carrying value to reflect <em style="font: inherit;">third</em> party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a <em style="font: inherit;">one</em> quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">When the Company’s carrying value in an equity method company is reduced to zero, the Company records <em style="font: inherit;">no</em> further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will <em style="font: inherit;">not</em> record its share of such income until it exceeds the amount of the Company’s share of losses <em style="font: inherit;">not</em> previously recognized.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"><i>Other Method. </i>We account for ownership interests in companies that are <em style="font: inherit;">not</em> accounted for under the equity method that do <em style="font: inherit;">not</em> have a readily determinable fair value under the fair value measurement alternative.  Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interests of the same issuer.  Under this method, our share of the income or losses of such companies is <em style="font: inherit;">not</em> included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company accounts for ownership interests that are <em style="font: inherit;">not</em> accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  Under this method, the changes in fair value are reflected in Other income (loss), net. As of <em style="font: inherit;"> December 31, 2022 </em>those ownership interests consist of approximately 1.3 million common shares of Bright Health Group ("Bright Health") valued at $0.9 million.  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"/> 1300000 900000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"><i><b>Comprehensive Income (loss) </b></i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 6pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">During the years ended <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;">2021,</em> there were <em style="font: inherit;">no</em> items of comprehensive income (loss).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Accounting Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results <em style="font: inherit;"> may </em>differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and <em style="font: inherit;"> may </em>require adjustments in the future when audits of these entities’ financial statements are completed.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At <em style="font: inherit;"> December 31, 2022</em>, the Company believes the carrying value of the Company’s ownership interests and advances is <em style="font: inherit;">not</em> impaired, although there can be <em style="font: inherit;">no</em> assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will <em style="font: inherit;">not</em> be required in the future or that a significant loss will <em style="font: inherit;">not</em> be recorded in the future upon the sale of a company.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Cash and Cash Equivalents</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company considers all highly liquid instruments with an original maturity of <em style="font: inherit;">90</em> days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits that are readily convertible into cash.  The Company has <em style="font: inherit;">not</em> experienced any significant losses on cash equivalents and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Restricted Cash </b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;">Restricted cash represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Cash Flows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total cash, cash equivalents and restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total cash, cash equivalents and restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 13331000 24739000 25000 25000 13356000 24764000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Financial Instruments</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Right-of-use asset</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Right-of-use assets represent an operating lease for office facilities.  The right-of-use assets are reduced over the remaining term of the applicable lease (principally <em style="font: inherit;"> April 2026) </em>in a manner that results in a straight-line lease expense, when combined with the interest factor on the lease liability. <b>    </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"><i><b>Lease liability</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The initial lease liability represents the present value of the fixed escalating lease payments through <em style="font: inherit;"> April 2026 </em>associated with the Company's prior corporate headquarters operating office lease. The discount rate used to calculate the lease liability was based on the Company's incremental borrowing rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease, which was approximately 12%, at the transition to the guidance of ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i>. Subsequent values of the lease liability reflect the reduction in the lease liability for operating lease payments less an amount representing interest, which is included in the straight-line lease expense. There is <em style="font: inherit;">no</em> residual value guarantee associated with this operating lease arrangement. The Company has incurred operating lease expenses and operating cash outflows of $0.5 million for each of the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, and $0.6 million for each of the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">In <em style="font: inherit;"> March 2019, </em>the Company entered into a sublease of its prior corporate headquarters office space. The term of the sublease is through <em style="font: inherit;"> April 2026, </em>the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">A summary of the Company's operating lease cash flows at <em style="font: inherit;"> December 31, 2022</em> follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Operating lease payments</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Expected sublease receipts</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 12pt;"/> 0.12 500000 600000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Operating lease payments</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Expected sublease receipts</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 607000 556000 613000 573000 619000 590000 207000 199000 0 0 0 0 0 0 2046000 1918000 368000 1678000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 12pt;"><i><b>Impairment of Ownership Interests and Advances </b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">On a periodic basis, but <em style="font: inherit;">no</em> less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are <em style="font: inherit;">not</em> primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The estimated fair value of privately held companies is generally determined based on the value at which independent <em style="font: inherit;">third</em> parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The reduced cost basis of a previously impaired company accounted for using the Equity method are <em style="font: inherit;">not</em> written-up if circumstances suggest the value of the company has subsequently recovered.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Income Taxes</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are <em style="font: inherit;">not</em> considered more likely than <em style="font: inherit;">not</em> to be realized.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Net Income (Loss) Per Share</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Segment Information</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company operates as <em style="font: inherit;">one</em> operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">2.</em> Ownership Interests and Advances </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The following summarizes the carrying value of the Company’s ownership interests and advances.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Equity Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,749</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Private equity funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,846</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,208</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Companies, fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Companies, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Private equity funds, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Advances to companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">15,405</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">26,521</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">In <em style="font: inherit;"> September 2022, </em>Lumesis, Inc. was acquired by another entity for cash.  The Company received $5.5 million in cash proceeds in connection with this transaction, excluding holdbacks and escrows.  This transaction resulted in a gain of $4.9 million, including $0.8 million other receivable related to an indemnification escrow during the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022.</em>   </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 24pt; text-align: left;">In <em style="font: inherit;"> March 2021, </em>Zipnosis, Inc. was acquired by another entity, Bright Health.  The Company received $3.5 million in cash proceeds, including escrows, and $15.3 million in preferred equity in the acquiror in connection with this transaction.  This ownership interest represented a security that did <em style="font: inherit;">not</em> have a readily determinable fair value.  Due to the inherent uncertainty of determining the fair value of ownership interests that do <em style="font: inherit;">not</em> have a readily determinable fair value, this estimated value <em style="font: inherit;"> may </em>differ significantly from the value that would have been reported had a ready market for the security existed, and it is reasonably possible that the difference could be material.  The Company recognized a $17.3 million gain on the sale, which is included in Equity income (loss), net in the Consolidated Statements of Operations.  The fair value of the ownership interest received as a result of the acquisition was estimated based on evaluating several valuation methods available, including the value at which independent <em style="font: inherit;">third</em> parties have recently invested, the valuation of comparable public companies, and the present value of our expected outcomes.  Assumptions considered within these methods include determining which public companies are comparable, projecting forward revenues, selecting an appropriate valuation multiple, discounts to apply for the lack of marketability or lack of comparability, other factors and the relative weight to apply to each valuation method available.  Due to the unobservable nature of some of these inputs, we determined this initial estimate to be a Level <em style="font: inherit;">3</em> fair value measurement.  During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2021, </em>Bright Health completed an initial public offering that resulted in our ownership interest converting into approximately 1.3 million common shares.  Accordingly, the Bright Health common shares represent an ownership interest with a readily determinable fair value (Level <em style="font: inherit;">1</em>), which will subsequently be measured at fair value with unrealized gains (losses) being reported as a component of Other income (loss), net.  As a result, the Company recognized a $10.8 million unrealized loss, net, on Bright Health subsequent to the initial public offering during the year ended <em style="font: inherit;"> December 31, 2021. </em>The Company recognized a $3.7 million unrealized loss on Bright Health during the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">In <em style="font: inherit;"> August 2021, </em>Flashtalking was acquired by another entity.  The Company has received $45.0 million in cash proceeds, including escrows, and included a $32.5 million gain in Other income (loss), net, during the year ended <em style="font: inherit;"> December 31, 2021.  </em>The Company <em style="font: inherit;"> may </em>receive additional amounts of up to approximately $0.5 million over the next <em style="font: inherit;">12</em> months from the resolution of escrow contingencies.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">In <em style="font: inherit;"> January 2021, </em>WebLinc, Inc. was acquired by another entity.  The Company has received $3.6 million in cash proceeds to-date, which could be partially offset by indemnifiable claims.  The Company has recognized a $0.1 million loss on the sale during the year ended <em style="font: inherit;"> December 31, 2021, </em>which is included in Equity income (loss), as certain contingencies were resolved.  During the year ended <em style="font: inherit;"> December 31, 2022, </em>the Company recognized $0.5 million as gain on sale as the result of the collection of additional amounts and as contingencies were resolved, those amounts were recorded as gain on the sale and included within Equity income (loss). </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">QuanticMind and Hoopla were acquired in separate transactions during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2021</em> by other entities, however there were <em style="font: inherit;">no</em> resultant proceeds to the Company.  There was <em style="font: inherit;">no</em> resulting gain or loss due to this equity method ownership interest being impaired during the prior year.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">In <em style="font: inherit;"> March 2021, </em>the Company's ownership interest in T-REX Group, Inc., which was accounted for using the fair value measurement alternative, was acquired for $3.0 million in cash.  The Company recognized a $0.9 million gain, which is included in Other income (loss), net.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">In <em style="font: inherit;"> April 2021, </em>Velano Vascular was acquired by another entity.  The Company has received $4.0 million in cash proceeds, including escrows, and included a $1.9 million gain in Other income (loss), net, for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021.</em>  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-indent: 18pt;">In <em style="font: inherit;"> December 2021, </em>the Company received $2 million of contingent proceeds resulting from resolution of certain valuation thresholds remaining from the <em style="font: inherit;">2018</em> sale of AdvantEdge Healthcare Solutions.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">During the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company recorded an impairment of $2.5 million related to reduced expectations for certain Other ownership interests, which is included in Other income (loss), net. </p> <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company held ownership interests accounted for using the equity method in <em style="font: inherit;">8</em> non-consolidated companies. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Certain of the Company’s ownership interests as of <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em> included the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Safeguard Primary Ownership as of December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 39.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Company Name</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 30.9%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accounting Method</em></b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Aktana, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Clutch Holdings, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">InfoBionic, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">meQuilibrium</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Moxe Health Corporation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prognos Health Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Syapse, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Trice Medical, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"><i><b>Summarized Financial Information </b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The following table provides summarized financial information for ownership interests accounted for under the equity method for the periods presented and has been compiled from respective company financial statements, reflect certain historical adjustments, and are reported on a <em style="font: inherit;">one</em> quarter lag. Results of operations are excluded for periods prior to their acquisition and subsequent to their disposition. Historical results are <em style="font: inherit;">not</em> adjusted when the Company exits or writes-off a company. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.75pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">As of December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Balance Sheets:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">127,651</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Non-current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,073</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">53,220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">181,115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">180,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,990</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">158,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Shareholders’ deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(132,556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(40,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total liabilities and shareholders’ deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">181,115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">180,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Number of equity method ownership interests</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Results of Operations:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">144,771</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,670</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">88,666</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(152,936</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(106,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company’s carrying value in equity method companies, in the aggregate, exceeded the Company’s share of the net assets of such companies by approximately $2.7 million. Of this excess, <span style="-sec-ix-hidden:c94272665">$2.5</span> million was allocated to goodwill and $0.2 million was allocated to intangible assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Equity Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,749</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Private equity funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">97</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,846</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,208</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Companies, fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Companies, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">1,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Private equity funds, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Advances to companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">15,405</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">26,521</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 8749000 21091000 97000 117000 8846000 21208000 860000 4549000 1067000 514000 250000 250000 2177000 5313000 4382000 0 15405000 26521000 5500000 4900000 800000 3500000 15300000 17300000 1300000 -10800000 3700000 45000000.0 32500000 500000 3600000 100000 500000 3000000.0 900000 4000000.0 1900000 2000000 2500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Safeguard Primary Ownership as of December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 39.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Company Name</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 30.9%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accounting Method</em></b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Aktana, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Clutch Holdings, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">InfoBionic, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">meQuilibrium</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Moxe Health Corporation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prognos Health Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Syapse, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Trice Medical, Inc.</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> </tbody></table> 0.136 0.134 0.417 0.417 0.252 0.252 0.313 0.319 0.193 0.276 0.284 0.285 0.110 0.111 0.116 0.126 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">As of December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Balance Sheets:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">127,651</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Non-current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,073</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">53,220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">181,115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">180,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,990</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">158,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Shareholders’ deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(132,556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(40,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Total liabilities and shareholders’ deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">181,115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">180,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Number of equity method ownership interests</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 126042000 127651000 55073000 53220000 181115000 180871000 92990000 62538000 220681000 158975000 -132556000 -40642000 181115000 180871000 8 9 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Results of Operations:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">144,771</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,670</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">88,666</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(152,936</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(106,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 144771000 140670000 88666000 90388000 -152936000 -106363000 2700000 200000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">3.</em> Acquisitions of Ownership Interests </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><em style="font: inherit;">2022</em> Transactions</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">The Company funded $1.6 million of convertible loans to Syapse, Inc.  The Company had previously deployed an aggregate of $25.0 million.  Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">The Company funded $2.0 million of convertible loans to Prognos Health Inc.  The Company had previously deployed an aggregate of $12.6 million.  Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with life sciences brands, payers, and clinical diagnostics organizations.  Prognos' innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million.  Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">The Company funded $0.5 million of convertible loans to meQuilibrium.  The Company had previously deployed an aggregate of $14.0 million.  meQuilibrium is a digital coaching platform that delivers clinically validated and highly personalized resilience solutions to employers, health plans, wellness providers, and consumers increasing engagement, productivity and performance, as well as improving outcomes in managing stress, health and well-being.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">The Company funded $0.1 million of convertible loans to Trice Medical.  The Company had previously deployed an aggregate of $11.8 million.  Trice Medical is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians.  The Company also committed to provide another $0.3 million under certain conditions pursuant to a subordinated line of credit.  The Company's obligation under this line of credit is included in accrued expenses. Subsequent to the year end, the Company funded $0.3 million in accordance with this line of credit.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><em style="font: inherit;">2021</em> Transactions</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company funded $1.7 million to Aktana, Inc. during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2021. </em>The Company had previously deployed an aggregate of $14.2 million. Aktana helps its customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions and providing insight regarding which strategies work best for which customers under which conditions.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Syapse raised $68 million of preferred equity during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021, </em>which reduced the Company's ownership interest to approximately 11.1%.  The Company recorded a $7.3 million dilution gain as a result of this transaction, which is included in Equity income (loss), net in the Consolidated Statements of Operation.  </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company funded $1 million of convertible loans to Trice Medical, Inc. during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2021.  </em>During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2021, </em>Trice Medical raised additional preferred equity which reduced the Company's ownership interest to 12.6%.  The Company's existing convertible loans and related interest in Trice Medical were also converted into this new class of preferred equity.  As a result of this transaction, the Company recorded a $2.0 million dilution gain for the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> 1600000 25000000.0 2000000.0 12600000 1400000 16900000 500000 14000000.0 100000 11800000 300000 300000 1700000 14200000 68000000 0.111 7300000 1000000 0.126 2000000.0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">4.</em> Fair Value Measurements</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company categorizes its financial instruments into a <em style="font: inherit;">three</em>-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level <em style="font: inherit;">1</em>) and the lowest priority to unobservable inputs (Level <em style="font: inherit;">3</em>). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Cash, cash equivalents and restricted cash approximate fair value due to their short term nature.  The Company did <em style="font: inherit;">not</em> have any Level <em style="font: inherit;">2</em> or Level <em style="font: inherit;">3</em> financial assets and liabilities measured at fair value on a recurring basis as of <em style="font: inherit;"> December 31, 2022</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at December 31, 2022</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Marketable securities—held-to-maturity:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">U.S. Government securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">5,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">5,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ownership interests</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at December 31, 2021</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Restricted cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Ownership interests</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Ownership interests accounted for at fair value as of <em style="font: inherit;"> December 31, 2022 </em>consist of approximately 1.3 million common shares of Bright Health. The securities are carried at fair value based on the closing stock price on the last trading day of the reporting period. The Company was restricted from trading these securities until <em style="font: inherit;"> December 2021 </em>as a result of a lock-up agreement from the Bright Health Group initial public offering.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at December 31, 2022</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Marketable securities—held-to-maturity:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">U.S. Government securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">5,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">5,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td><td style="padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ownership interests</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">860</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at December 31, 2021</em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">24,739</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Restricted cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Ownership interests</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table> 13331000 13331000 0 0 25000 25000 0 0 5956000 5956000 0 0 860000 860000 0 0 24739000 24739000 0 0 25000 25000 0 0 4549000 4549000 0 0 1300000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">5.</em> Equity</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">In <em style="font: inherit;"> July 2015, </em>the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, the Company did <span style="-sec-ix-hidden:c94272706"><span style="-sec-ix-hidden:c94272911">not</span></span> repurchase any shares under the existing authorization. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt;">In <em style="font: inherit;"> May 2021, </em>the Company's Board of Directors authorized a $6.0 million share repurchase program (the <em style="font: inherit;">"2021</em> Plan") using existing funds in accordance with the requirements of Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> and Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> under the Securities Exchange Act of <em style="font: inherit;">1934,</em> as amended.  During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company purchased 236,159 shares under the <em style="font: inherit;">2021</em> Plan at an aggregate cost of $1.6 million, or $6.94 per share.  During <em style="font: inherit;"> October 2021, </em>the Company suspended the <em style="font: inherit;">2021</em> Plan and completed a modified Dutch auction self-tender that resulted in the repurchase of 4.3 million common shares for an aggregate price of $38.7 million, or $9.00 per share.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">In <em style="font: inherit;"> March 2022, </em>the Company's Board of Directors replaced the <em style="font: inherit;">2021</em> Plan and authorized a separate $3.0 million share repurchase program (the <em style="font: inherit;">"2022</em> Plan") using existing funds in accordance with the requirements of Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> and Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> under the Securities Exchange Act of <em style="font: inherit;">1934,</em> as amended.  During the year ended <em style="font: inherit;"> December 31, 2022, </em>the Company purchased 711,481 shares under the <em style="font: inherit;">2022</em> Plan at an aggregate cost of $2.9 million, or $4.13 per share.  The Company completed the <em style="font: inherit;">2022</em> Plan in <em style="font: inherit;"> January 2023 </em>by purchasing an additional 25,096 shares, resulting in an average price of $4.09 for the <em style="font: inherit;">2022</em> Program.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> 25000000.0 6000000.0 236159 1600000 6.94 4300000 38700000 9.00 3000000.0 711481 2900000 4.13 25096 4.09 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">6.</em> Stock-Based Compensation</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Equity Compensation Plans</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The <em style="font: inherit;">2014</em> Equity Compensation Plan has 4.1 million shares authorized for issuance. During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em>, the Company issued <em style="font: inherit;">no</em> stock-based awards outside of existing plans. To the extent allowable, service-based options are incentive stock options. Options granted under the plans are at prices equal to or greater than the fair market value at the date of grant. Upon exercise of stock options, the Company issues shares <em style="font: inherit;">first</em> from treasury stock, if available, then from authorized but unissued shares. At <em style="font: inherit;"> December 31, 2022</em>, the Company had reserved 2.2 million shares of common stock for possible future issuance under its <em style="font: inherit;">2014</em> Equity Compensation Plan and other previously expired equity compensation plans.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Classification of Stock-Based Compensation Expense</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 24pt;">Stock-based compensation consists of time based awards to employees, financial liability based awards to employees and non-employees to be settled in stock, performance based awards to employees, and financial liability based awards to Directors for quarterly and annual services. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 22.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,445</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,445</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Stock-based compensation expense of $1.2 million and $1.2 million was recognized during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, related to annual and quarterly Board fees, time based management awards and management bonuses earned during the year that were subsequently settled in stock.  For the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively, the Company issued 165 thousand and 83 thousand of restricted shares to Directors for their annual and quarterly services.  The annual grants vest over a <em style="font: inherit;">one</em> year period, or are vested at issuance for directors <em style="font: inherit;">65</em> or older, while quarterly amounts are paid in arrears.  The Company vested 110 thousand and 95 thousand shares during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>.  The Company vested 22 thousand and 67 thousand shares during the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively, for time based management compensation.  The Company settled in stock other management bonuses resulting in the issuance of 82 thousand and 60 thousand vested shares for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively.  The Company issued 15 thousand and 20 thousand vested shares to a non-employee for services during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>. The Company had liabilities of $0.4 million and $0.8 million as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, that were settled through the issuance of common stock in the subsequent period. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company has previously granted certain performance-based stock units that vest based on the achievement of targeted capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified companies. The requisite service periods for these performance-based awards were based on the Company’s estimate of when the performance conditions will be met. Compensation expense was recognized for performance-based awards for which the performance condition is considered probable of achievement. During the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively, 92 thousand and 6 thousand performance-based stock units pursuant to these targeted capital return pools were canceled or forfeited. The Company recorded a reduction of compensation expense related to these performance-based awards of <span style="-sec-ix-hidden:c94272774">zero</span> and $0.1 million for the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively. During <em style="font: inherit;"> October 2020 </em>and in <em style="font: inherit;"> January 2022, </em>the Company granted the CEO restricted stock units that <em style="font: inherit;"> may </em>vest based on certain performance targets and criteria determined by the Board of Directors.  Such performance-based stock units represent the right to receive shares of the Company’s common stock, on a <em style="font: inherit;">one</em>-for-<em style="font: inherit;">one</em> basis at target, or up to 120% with respect to the <em style="font: inherit;">2020</em> grant, for certain specified thresholds. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company recognized stock based compensation expense of $0.2 million and $0.5 million, respectively, and vested 64 thousand and 85 thousand shares, respectively, pursuant to these arrangements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Unrecognized compensation expense related to performance stock units and restricted stock at <em style="font: inherit;"> December 31, 2022</em> was immaterial.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">While there were <em style="font: inherit;">no</em> stock options granted during <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em>, the Company had outstanding options that vest based on <span style="-sec-ix-hidden:c94272789">two</span> different types of vesting schedules:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72.75pt;"><em style="font: inherit;">1</em>) performance-based; and</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72.75pt;"><em style="font: inherit;">2</em>) service-based.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Performance-based option awards also entitled participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company upon the sale, merger or other exit transaction of certain identified companies. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated.  The Company did <span style="-sec-ix-hidden:c94272792"><span style="-sec-ix-hidden:c94320547">not</span></span> issue any performance-based units during the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>.  During the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively, 0 thousand and 1 thousand performance-based options vested and an immaterial amount of compensation cost was recognized.  During the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively, 11 thousand and 11 thousand performance-based options were canceled or forfeited. The maximum number of unvested options at <em style="font: inherit;"> December 31, 2022</em> attainable under these grants was zero shares.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Service-based awards generally vest over <span style="-sec-ix-hidden:c94272801">four</span> years after the date of grant and expire <span style="-sec-ix-hidden:c94272802">eight</span> years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, the Company issued no service-based options to employees and recorded <span style="-sec-ix-hidden:c94272805"><span style="-sec-ix-hidden:c94320549">zero</span></span> compensation expense from the vesting of previously issued awards. During the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, respectively, 0 thousand and 5 thousand service-based options were canceled or forfeited.  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Option activity of the Company is summarized below: </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Weighted Average Exercise Price</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options canceled/forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options canceled/forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Shares available for future grant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">At <em style="font: inherit;"> December 31, 2022</em>, total unrecognized compensation cost related to non-vested service-based options was immaterial. At <em style="font: inherit;"> December 31, 2022</em>, total unrecognized compensation cost related to non-vested performance-based options was immaterial.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Deferred stock unit, performance-based stock unit and restricted stock activity are summarized below: </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Weighted Average Grant Date Fair Value</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unvested at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(242</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unvested at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unvested at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> 4100000 2200000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,445</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,445</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1445000 1779000 1445000 1779000 1200000 1200000 165000 83000 110000 95000 22000 67000 82000 60000 15000 20000 400000 800000 92000 6000 100000 1.20 200000 500000 64000 85000 0 1 11000 11000 0 0 0 5000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Weighted Average Exercise Price</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Weighted Average Remaining Contractual Life</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options canceled/forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options canceled/forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Options exercisable at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Shares available for future grant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 45000 14.20 0 0 -0 0 16000 14.20 29000 14.20 0 0 0 0 11000 14.48 18000 14.05 P1Y6M 0 18000 14.05 P1Y6M 0 2134000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><em style="font: inherit;">Weighted Average Grant Date Fair Value</em></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unvested at January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(242</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unvested at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Unvested at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 287000 8.78 163000 7.21 242000 6.82 6000 14.99 202000 9.70 343000 5.60 293000 5.77 92000 13.90 160000 5.70 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">7.</em> Employee Benefit Pla</b><b>n</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company maintains a qualified <em style="font: inherit;">401</em>(k) retirement plan for eligible employees. The Plan’s matching formula is 100% of the <em style="font: inherit;">first</em> 5% of participants’ qualified compensation. Compensation expense related to our matching contributions to the Plan for the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, were $0.1 million and $0.1 million, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 1 0.05 100000 100000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">8.</em> Income Taxes</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The federal and state provision (benefit) for income taxes was $0.0 million for the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal income tax rate of 21.0% for the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em> to net income (loss) before income taxes as a result of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Statutory tax expense (benefit)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c94272420">(21.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c94272421">21.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Increase (decrease) in taxes resulting from:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Nondeductible expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">As of December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Deferred tax asset:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Carrying values of ownership interests and other holdings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Tax loss and credit carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77,045</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Disallowed interest carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,891</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">268</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">108,726</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116,578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(108,726</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(116,578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company and its subsidiaries had federal net operating and capital loss carryforwards for tax purposes of approximately $326 million, of which approximately $60 million have an indefinite life. These carryforwards expire as follows: </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,830</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,140</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,266</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2027 and thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">145,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">266,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In assessing the recoverability of deferred tax assets, the Company considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The Company has determined that it is more likely than <em style="font: inherit;">not</em> that certain future tax benefits <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be realized as a result of current and future income. Accordingly, a valuation allowance has been recorded against substantially all of the Company’s deferred tax assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company recognizes in its Consolidated Financial Statements the impact of a tax position if that position is more likely than <em style="font: inherit;">not</em> to be sustained upon examination, based on the technical merits of the position. All uncertain tax positions relate to unrecognized tax benefits that would impact the effective tax rate when recognized.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company does <em style="font: inherit;">not</em> expect any material increase or decrease in its income tax expense, in the next <em style="font: inherit;">twelve</em> months, related to examinations or changes in uncertain tax positions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">There were no changes in the Company’s uncertain tax positions for the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. Tax years <em style="font: inherit;">2015</em> and forward remain open for examination for federal tax purposes and the Company’s more significant state tax jurisdictions. To the extent utilized in future years’ tax returns, net operating loss carryforwards at <em style="font: inherit;"> December 31, 2022</em> will remain subject to examination until the respective tax year is closed. The Company recognizes penalties and interest accrued related to income tax liabilities in income tax benefit (expense) in the Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.0 0.210 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Statutory tax expense (benefit)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c94272420">(21.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c94272421">21.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Increase (decrease) in taxes resulting from:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Nondeductible expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> -0.026 0.033 0.236 -0.243 0.000 0.000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">As of December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Deferred tax asset:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Carrying values of ownership interests and other holdings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Tax loss and credit carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,492</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77,045</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Disallowed interest carryforwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,891</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">268</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">108,726</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116,578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(108,726</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(116,578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 33222000 31985000 68492000 77045000 6891000 7120000 47000 24000 180000 268000 -106000 136000 108726000 116578000 108726000 116578000 0 0 326000000 60000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,830</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,140</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,266</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">2027 and thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">145,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">266,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 45830000 50140000 17266000 7648000 145275000 266159000 0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">9.</em> Net Income (Loss) Per Share</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The calculations of net income (loss) per share were: </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands, except per share data)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Basic:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss) per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Diluted:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss) per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">If an equity method company has dilutive stock options, unvested restricted stock, DSUs, or warrants, diluted net income (loss) per share is computed by <em style="font: inherit;">first</em> deducting from net income (loss) the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Diluted income (loss) per share for the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em> do <em style="font: inherit;">not</em> reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">•</p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, options to purchase 18 thousand and 29 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 per share, and $10.37 to $17.11 per share per share, respectively, were excluded from the calculation.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">•</p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, unvested restricted stock, performance-based stock units and DSUs convertible into 0.2 million and 0.2 million shares of stock, respectively, were excluded from the calculations.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands, except per share data)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Basic:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss) per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Diluted:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,263</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,337</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss) per share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> -14263000 27004000 16337000 19827000 -0.87 1.36 -14263000 27004000 16337000 19827000 -0.87 1.36 18000 29 10.37 17.11 10.37 17.11 200000 200000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">10.</em> Related Party Transactions</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In the normal course of business, the Company’s officers and employees hold board positions with companies in which the Company has a direct or indirect ownership interest.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">11.</em> Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will <em style="font: inherit;">not</em> have a material adverse effect on the Company’s consolidated financial position or results of operations, however, <em style="font: inherit;">no</em> assurance can be given as to the outcome of these actions, and <em style="font: inherit;">one</em> or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its companies. The Company records costs associated with legal fees as such services are rendered.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company has provided a guarantee, which is fully funded by escrowed funds held by a <em style="font: inherit;">third</em> party, of $3.8 million at <em style="font: inherit;"> December 31, 2022</em> which related to <em style="font: inherit;">one</em> of the Company's private equity holdings.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under severance agreements for remaining employees is approximately $1.1 million at <em style="font: inherit;"> December 31, 2022</em> and 250,000 common shares.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In <em style="font: inherit;">2018,</em> the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in <em style="font: inherit;"> February 2019 </em>and <em style="font: inherit;"> June 2020, </em>known as the Amended and Restated Safeguard Scientifics Transaction Bonus Plan (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the business strategy that the Company adopted and announced in <em style="font: inherit;"> January 2018. </em>The <em style="font: inherit;"> June 2020 </em>amendment lowered the level of the <em style="font: inherit;">first</em> threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consistent with the business strategy.  Under the LTIP, participants, which includes certain current and former employees, have received awards that <em style="font: inherit;"> may </em>result in cash payments in connection with sales of the Company’s ownership interests (“Sale Transaction(s)”). The LTIP provides for a bonus pool corresponding to: (i) specified vesting thresholds or (ii) specified events. In the <em style="font: inherit;">first</em> case, the bonus pool will range from an amount equal to 0.2% (previously 1.0%) of received proceeds at the <em style="font: inherit;">first</em> threshold to 1.3% at higher thresholds. In the <em style="font: inherit;">second</em> case, a minimum pool will be created and paid under specified circumstances. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in cash within <em style="font: inherit;">60</em> days of the applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company recorded compensation expense of <span style="-sec-ix-hidden:c94272872">zero</span> and $0.7 million during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively.  The Company paid $2.5 million during the year ended <em style="font: inherit;"> December 31, 2021 </em>and has no amounts accrued under the LTIP as of  <em style="font: inherit;"> December 31, 2022</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In <em style="font: inherit;"> June 2011, </em>Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in <em style="font: inherit;"> March 2012, </em>Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in <em style="font: inherit;"> July 2015 </em>the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, <em style="font: inherit;">one</em> of which was filed in <em style="font: inherit;">2014</em> by an ex-employee of ABH that named the Company and <em style="font: inherit;">one</em> of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee. In addition, in connection with the above matters, the Company and other former equity holders in ABH entered into a settlement and release with Shire, which resulted in the release to Shire of all amounts held in escrow related to the sale of ABH.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> 3800000 1100000 250000 0.002 0.010 0.013 700000 2500000 0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">12.</em> Supplemental Cash Flow Information</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">During the years ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, the Company converted <span style="-sec-ix-hidden:c94272882">zero</span> and $1.0 million, respectively, of advances into ownership interests. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> 1000000.0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">13.</em> Segment Reporting</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company operates as <span style="-sec-ix-hidden:c94272886">one</span> operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">As of <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;">2021</em>, all of the Company’s assets were located in the United States.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">14.</em> Selected Quarterly Financial Information (Unaudited)</b>  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">March 31</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">June 30</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">September 30</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 43%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands, except per share data)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>2022:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,035</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,035</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Equity income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,454</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Net loss before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,873</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax benefit (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,873</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss per share (a)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>2021:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">706</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,733</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,588</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Equity income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,586</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Net income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(320</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax benefit (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(320</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss) per share (a)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</em></em></em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">March 31</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">June 30</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">September 30</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 43%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands, except per share data)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>2022:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,035</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,035</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Equity income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,454</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Net loss before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,873</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax benefit (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,873</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss per share (a)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>2021:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Operating loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Other income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">706</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,733</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,588</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Equity income (loss), net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,586</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Net income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(320</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax benefit (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(320</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net income (loss) per share (a)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 1234000 1146000 1360000 1035000 -1234000 -1146000 -1360000 -1035000 -1997000 30000 -1012000 -318000 101000 145000 230000 318000 -3579000 1454000 -1022000 -3838000 -6709000 483000 -3164000 -4873000 -6709000 483000 -3164000 -4873000 -0.40 0.03 -0.19 -0.30 -0.40 0.03 -0.19 -0.30 2463000 1991000 1564000 1135000 -2463000 -1991000 -1564000 -1135000 706000 6733000 20588000 -5992000 53000 74000 70000 79000 19329000 -5136000 -761000 -1586000 17625000 -320000 18333000 -8634000 17625000 -320000 18333000 -8634000 0.84 -0.02 0.88 -0.51 0.84 -0.02 0.88 -0.51 Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests. EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ˡ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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 163 282 1 true 60 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.safeguard.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity Consolidated Statements of Changes in Shareholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - General Sheet http://www.safeguard.com/20221231/role/statement-note-1-general Note 1 - General Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Ownership Interests and Advances Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances- Note 2 - Ownership Interests and Advances Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Acquisitions of Ownership Interests Sheet http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests Note 3 - Acquisitions of Ownership Interests Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Equity Sheet http://www.safeguard.com/20221231/role/statement-note-5-equity Note 5 - Equity Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Stock-Based Compensation Sheet http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation Note 6 - Stock-Based Compensation Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Employee Benefit Plan Sheet http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan Note 7 - Employee Benefit Plan Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Income Taxes Sheet http://www.safeguard.com/20221231/role/statement-note-8-income-taxes Note 8 - Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Net Income (Loss) Per Share Sheet http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share Note 9 - Net Income (Loss) Per Share Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Commitments and Contingencies Sheet http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies Note 11 - Commitments and Contingencies Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Supplemental Cash Flow Information Sheet http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information Note 12 - Supplemental Cash Flow Information Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Segment Reporting Sheet http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting Note 13 - Segment Reporting Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) Sheet http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited- Note 14 - Selected Quarterly Financial Information (Unaudited) Notes 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies 21 false false R22.htm 021 - Disclosure - Note 1 - General (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-1-general-tables Note 1 - General (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-1-general 22 false false R23.htm 022 - Disclosure - Note 2 - Ownership Interests and Advances (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables Note 2 - Ownership Interests and Advances (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances- 23 false false R24.htm 023 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements 24 false false R25.htm 024 - Disclosure - Note 6 - Stock-Based Compensation (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables Note 6 - Stock-Based Compensation (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation 25 false false R26.htm 025 - Disclosure - Note 8 - Income Taxes (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables Note 8 - Income Taxes (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-8-income-taxes 26 false false R27.htm 026 - Disclosure - Note 9 - Net Income (Loss) Per Share (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables Note 9 - Net Income (Loss) Per Share (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share 27 false false R28.htm 027 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables) Sheet http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables) Tables http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited- 28 false false R29.htm 028 - Disclosure - Note 1 - General (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual Note 1 - General (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-1-general-tables 29 false false R30.htm 029 - Disclosure - Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) Details 30 false false R31.htm 030 - Disclosure - Note 1 - General - Schedule of Leases (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details Note 1 - General - Schedule of Leases (Details) Details 31 false false R32.htm 031 - Disclosure - Note 2 - Ownership Interests and Advances (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual Note 2 - Ownership Interests and Advances (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables 32 false false R33.htm 032 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) Details 33 false false R34.htm 033 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) Details 34 false false R35.htm 034 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details) Details 35 false false R36.htm 035 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) Details 36 false false R37.htm 036 - Disclosure - Note 3 - Acquisitions of Ownership Interests (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual Note 3 - Acquisitions of Ownership Interests (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests 37 false false R38.htm 037 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual Note 4 - Fair Value Measurements (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables 38 false false R39.htm 038 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) Details 39 false false R40.htm 039 - Disclosure - Note 5 - Equity (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual Note 5 - Equity (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-5-equity 40 false false R41.htm 040 - Disclosure - Note 6 - Stock-Based Compensation (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual Note 6 - Stock-Based Compensation (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables 41 false false R42.htm 041 - Disclosure - Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Details 42 false false R43.htm 042 - Disclosure - Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) Details 43 false false R44.htm 043 - Disclosure - Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Employee Benefit Plan (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual Note 7 - Employee Benefit Plan (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan 45 false false R46.htm 045 - Disclosure - Note 8 - Income Taxes (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual Note 8 - Income Taxes (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables 46 false false R47.htm 046 - Disclosure - Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 47 false false R48.htm 047 - Disclosure - Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) Details 48 false false R49.htm 048 - Disclosure - Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details) Details 49 false false R50.htm 049 - Disclosure - Note 9 - Net Income (Loss) Per Share (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual Note 9 - Net Income (Loss) Per Share (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables 50 false false R51.htm 050 - Disclosure - Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) Details http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables 51 false false R52.htm 051 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual Note 11 - Commitments and Contingencies (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies 52 false false R53.htm 052 - Disclosure - Note 12 - Supplemental Cash Flow Information (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual Note 12 - Supplemental Cash Flow Information (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information 53 false false R54.htm 053 - Disclosure - Note 13 - Segment Reporting (Details Textual) Sheet http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual Note 13 - Segment Reporting (Details Textual) Details http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting 54 false false R55.htm 054 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) Sheet http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) Details http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables 55 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 40 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, sfe:CompensationCashAward, sfe:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent, sfe:EquityMethodInvestmentAllocationOfExcessFairValue, sfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationTerm, sfe:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAwardVestingTypes, us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockValue, us-gaap:DebtConversionConvertedInstrumentAmount1, us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations, us-gaap:NumberOfOperatingSegments, us-gaap:OperatingLeaseCost, us-gaap:OperatingLeasePayments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod, us-gaap:TreasuryStockShares, us-gaap:TreasuryStockSharesAcquired, us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease - sfe20221231_10k.htm 8, 10, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 sfe20221231_10k.htm ex_449898.htm ex_449899.htm ex_449901.htm ex_449902.htm ex_449903.htm ex_449904.htm ex_477546.htm sfe-20221231.xsd sfe-20221231_cal.xml sfe-20221231_def.xml sfe-20221231_lab.xml sfe-20221231_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sfe20221231_10k.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 574, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 163, "dts": { "calculationLink": { "local": [ "sfe-20221231_cal.xml" ] }, "definitionLink": { "local": [ "sfe-20221231_def.xml" ] }, "inline": { "local": [ "sfe20221231_10k.htm" ] }, "labelLink": { "local": [ "sfe-20221231_lab.xml" ] }, "presentationLink": { "local": [ "sfe-20221231_pre.xml" ] }, "schema": { "local": [ "sfe-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 431, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 33, "http://www.safeguard.com/20221231": 7, "http://xbrl.sec.gov/dei/2022": 6, "total": 46 }, "keyCustom": 46, "keyStandard": 236, "memberCustom": 33, "memberStandard": 25, "nsprefix": "sfe", "nsuri": "http://www.safeguard.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.safeguard.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Fair Value Measurements", "menuCat": "Notes", "order": "10", "role": "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "shortName": "Note 4 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Equity", "menuCat": "Notes", "order": "11", "role": "http://www.safeguard.com/20221231/role/statement-note-5-equity", "shortName": "Note 5 - Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Stock-Based Compensation", "menuCat": "Notes", "order": "12", "role": "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "shortName": "Note 6 - Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Employee Benefit Plan", "menuCat": "Notes", "order": "13", "role": "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan", "shortName": "Note 7 - Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Income Taxes", "menuCat": "Notes", "order": "14", "role": "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes", "shortName": "Note 8 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Net Income (Loss) Per Share", "menuCat": "Notes", "order": "15", "role": "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "shortName": "Note 9 - Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Related Party Transactions", "menuCat": "Notes", "order": "16", "role": "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions", "shortName": "Note 10 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Commitments and Contingencies", "menuCat": "Notes", "order": "17", "role": "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "shortName": "Note 11 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Supplemental Cash Flow Information", "menuCat": "Notes", "order": "18", "role": "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information", "shortName": "Note 12 - Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Segment Reporting", "menuCat": "Notes", "order": "19", "role": "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting", "shortName": "Note 13 - Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited)", "menuCat": "Notes", "order": "20", "role": "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-", "shortName": "Note 14 - Selected Quarterly Financial Information (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 1 - General (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.safeguard.com/20221231/role/statement-note-1-general-tables", "shortName": "Note 1 - General (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 2 - Ownership Interests and Advances (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables", "shortName": "Note 2 - Ownership Interests and Advances (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables", "shortName": "Note 4 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 6 - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables", "shortName": "Note 6 - Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 8 - Income Taxes (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables", "shortName": "Note 8 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 9 - Net Income (Loss) Per Share (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables", "shortName": "Note 9 - Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables", "shortName": "Note 14 - Selected Quarterly Financial Information (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 1 - General (Details Textual)", "menuCat": "Details", "order": "29", "role": "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "shortName": "Note 1 - General (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-6", "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "30", "role": "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details", "shortName": "Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "us-gaap:LesseeLeasesPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 1 - General - Schedule of Leases (Details)", "menuCat": "Details", "order": "31", "role": "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details", "shortName": "Note 1 - General - Schedule of Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "us-gaap:LesseeLeasesPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 2 - Ownership Interests and Advances (Details Textual)", "menuCat": "Details", "order": "32", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "shortName": "Note 2 - Ownership Interests and Advances (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "lang": null, "name": "sfe:ImpairmentOfOtherMethodSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details)", "menuCat": "Details", "order": "33", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AdvancesToAffiliate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AktanaIncMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)", "menuCat": "Details", "order": "34", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-InfoBionicIncMember", "decimals": "3", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details)", "menuCat": "Details", "order": "35", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "sfe:EquityMethodInvestmentPartnerCompanyResultsOfOperationTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_EquityMethodInvestmentNonconsolidatedInvesteeAxis-HighTractionStageMember", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_EquityMethodInvestmentNonconsolidatedInvesteeAxis-EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details)", "menuCat": "Details", "order": "36", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_EquityMethodInvestmentNonconsolidatedInvesteeAxis-EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 3 - Acquisitions of Ownership Interests (Details Textual)", "menuCat": "Details", "order": "37", "role": "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "shortName": "Note 3 - Acquisitions of Ownership Interests (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "sfe:EquityMethodAndOtherInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-SyapseIncMember", "decimals": "-5", "lang": null, "name": "sfe:ConvertibleBridgeLoan", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-BrightHealthMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedBalanceShares", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 4 - Fair Value Measurements (Details Textual)", "menuCat": "Details", "order": "38", "role": "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "shortName": "Note 4 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)", "menuCat": "Details", "order": "39", "role": "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "shortName": "Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 5 - Equity (Details Textual)", "menuCat": "Details", "order": "40", "role": "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual", "shortName": "Note 5 - Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2015-07-31_ShareRepurchaseProgramAxis-ShareRepurchaseProgramAuthorizedInJuly2015Member", "decimals": "-6", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 6 - Stock-Based Compensation (Details Textual)", "menuCat": "Details", "order": "41", "role": "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "shortName": "Note 6 - Stock-Based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31_TitleOfIndividualAxis-DirectorMember", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "42", "role": "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "shortName": "Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details)", "menuCat": "Details", "order": "43", "role": "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "shortName": "Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "sfe:ScheduleOfActivityForRestrictedStockUnitsDeferredStockUnitsAndPerformanceUnitsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details)", "menuCat": "Details", "order": "44", "role": "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "shortName": "Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "sfe:ScheduleOfActivityForRestrictedStockUnitsDeferredStockUnitsAndPerformanceUnitsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Employee Benefit Plan (Details Textual)", "menuCat": "Details", "order": "45", "role": "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual", "shortName": "Note 7 - Employee Benefit Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 8 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "46", "role": "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual", "shortName": "Note 8 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "menuCat": "Details", "order": "47", "role": "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "shortName": "Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "48", "role": "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "shortName": "Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "sfe:NetOperatingLossCarryforwardsExpiringInYearOne", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details)", "menuCat": "Details", "order": "49", "role": "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details", "shortName": "Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "sfe:NetOperatingLossCarryforwardsExpiringInYearOne", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 9 - Net Income (Loss) Per Share (Details Textual)", "menuCat": "Details", "order": "50", "role": "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual", "shortName": "Note 9 - Net Income (Loss) Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-10-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details)", "menuCat": "Details", "order": "51", "role": "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "shortName": "Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "sfe:EmployeeAndSeveranceAgreementMaximumAggregateExposure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "52", "role": "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "shortName": "Note 11 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "sfe:EmployeeAndSeveranceAgreementMaximumAggregateExposure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 12 - Supplemental Cash Flow Information (Details Textual)", "menuCat": "Details", "order": "53", "role": "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual", "shortName": "Note 12 - Supplemental Cash Flow Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 13 - Segment Reporting (Details Textual)", "menuCat": "Details", "order": "54", "role": "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual", "shortName": "Note 13 - Segment Reporting (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-10-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details)", "menuCat": "Details", "order": "55", "role": "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "shortName": "Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-10-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - General", "menuCat": "Notes", "order": "7", "role": "http://www.safeguard.com/20221231/role/statement-note-1-general", "shortName": "Note 1 - General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Ownership Interests and Advances", "menuCat": "Notes", "order": "8", "role": "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "shortName": "Note 2 - Ownership Interests and Advances", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "sfe:EquityMethodAndOtherInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Acquisitions of Ownership Interests", "menuCat": "Notes", "order": "9", "role": "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "shortName": "Note 3 - Acquisitions of Ownership Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "sfe:EquityMethodAndOtherInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-document-and-entity-information", "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-tables", "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables", "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-document-and-entity-information", "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-tables", "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables", "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "sfe_AdvantedgeHealthcareSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to AdvantEdge Healthcare Solutions, Inc.", "label": "AdvantEdge Healthcare Solutions, Inc. [Member]" } } }, "localname": "AdvantedgeHealthcareSolutionsIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_AktanaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Aktana, Inc.", "label": "Aktana, Inc. [Member]" } } }, "localname": "AktanaIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_AmendedAndRestatedSafeguardScientificsTransactionBonusPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents amended and restated safeguard scientifics transaction bonus plan.", "label": "Amended and Restated Safeguard Scientifics Transaction Bonus Plan [Member]" } } }, "localname": "AmendedAndRestatedSafeguardScientificsTransactionBonusPlanMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "sfe_BrightHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Bright Health.", "label": "Bright Health [Member]" } } }, "localname": "BrightHealthMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ClutchHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Clutch Holdings.", "label": "Clutch Holdings [Member]" } } }, "localname": "ClutchHoldingsMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_CommitmentToFundConvertibleBridgeLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents commitment to fund convertible bridge loan.", "label": "sfe_CommitmentToFundConvertibleBridgeLoan", "terseLabel": "Commitment To Fund Convertible Bridge Loan" } } }, "localname": "CommitmentToFundConvertibleBridgeLoan", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_CompensationCashAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the cash award for compensation.", "label": "sfe_CompensationCashAward", "terseLabel": "Compensation, Cash Award" } } }, "localname": "CompensationCashAward", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_ContingentProceedsFromOtherMethodInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of contingent proceeds from other method investment.", "label": "sfe_ContingentProceedsFromOtherMethodInvestment", "terseLabel": "Contingent Proceeds from Other Method Investment" } } }, "localname": "ContingentProceedsFromOtherMethodInvestment", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_ContingentProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of contingent proceeds received from the sale of equity method investments.", "label": "sfe_ContingentProceedsFromSaleOfEquityMethodInvestments", "terseLabel": "Contingent Proceeds from Sale of Equity Method Investments" } } }, "localname": "ContingentProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_ConvertibleBridgeLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of funding for convertible bridge loans in the period.", "label": "sfe_ConvertibleBridgeLoan", "terseLabel": "Convertible Bridge Loan" } } }, "localname": "ConvertibleBridgeLoan", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_CreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "represents credit facility.", "label": "Credit Facility [Member]" } } }, "localname": "CreditFacilityMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_DeferredTaxAssetDisallowedInterestCarryforwards": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the deferred tax assets, disallowed interest carryforwards.", "label": "Disallowed interest carryforwards" } } }, "localname": "DeferredTaxAssetDisallowedInterestCarryforwards", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "sfe_DutchAuctionSelftenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Dutch auction self-tender.", "label": "Dutch Auction Self-tender [Member]" } } }, "localname": "DutchAuctionSelftenderMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "sfe_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory tax expense (benefit)", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate (Negative Rate), Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "xbrltype": "percentItemType" }, "sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents maximum aggregate exposure for employee and severance agreement.", "label": "sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposure", "terseLabel": "Employee and Severance Agreement, Maximum Aggregate Exposure" } } }, "localname": "EmployeeAndSeveranceAgreementMaximumAggregateExposure", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposureShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents maximum aggregate shares exposure for employee and severance agreement.", "label": "sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposureShares", "terseLabel": "Employee and Severance Agreement, Maximum Aggregate Exposure, Shares (in shares)" } } }, "localname": "EmployeeAndSeveranceAgreementMaximumAggregateExposureShares", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "sharesItemType" }, "sfe_EquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2014 equity compensation plan.", "label": "2014 Equity Compensation Plan [Member]" } } }, "localname": "EquityCompensationPlanMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_EquityMethodAndOtherInvestmentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method and other investments.", "label": "Equity Method and Other Investments Disclosure [Text Block]" } } }, "localname": "EquityMethodAndOtherInvestmentsDisclosureTextBlock", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests" ], "xbrltype": "textBlockItemType" }, "sfe_EquityMethodInvestmentAllocationOfExcessFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the allocation of excess fair value under the equity method investment.", "label": "sfe_EquityMethodInvestmentAllocationOfExcessFairValue", "terseLabel": "Equity Method Investment Allocation of Excess Fair Value" } } }, "localname": "EquityMethodInvestmentAllocationOfExcessFairValue", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_EquityMethodInvestmentAssetsExceedCarryingValueOfInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the value by which the carrying value exceeded the company's assets under the equity method investment.", "label": "sfe_EquityMethodInvestmentAssetsExceedCarryingValueOfInvestment", "terseLabel": "Equity Method Investment Assets Exceed Carrying Value Of Investment" } } }, "localname": "EquityMethodInvestmentAssetsExceedCarryingValueOfInvestment", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_EquityMethodInvestmentDilutionGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain related to the equity issuance of equity method investee.", "label": "sfe_EquityMethodInvestmentDilutionGain", "terseLabel": "Equity Method Investment, Dilution Gain" } } }, "localname": "EquityMethodInvestmentDilutionGain", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_EquityMethodInvestmentPartnerCompanyResultsOfOperationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for results of operation for a partnering company under the equity method investment.", "label": "Equity Method Investment Partner Company Results Of Operation [Table Text Block]" } } }, "localname": "EquityMethodInvestmentPartnerCompanyResultsOfOperationTableTextBlock", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "sfe_EquityMethodInvestmentRealizedGainLossOnDisposalOtherReceivableRelatedToIndemnificationEscrow": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other receivable related to indemnification escrow for realized gain or loss on disposal under equity method investments.", "label": "sfe_EquityMethodInvestmentRealizedGainLossOnDisposalOtherReceivableRelatedToIndemnificationEscrow", "terseLabel": "\"Equity Method Investment, Realized Gain (Loss) on Disposal, Other Receivable Related to Indemnification Escrow" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposalOtherReceivableRelatedToIndemnificationEscrow", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_FlashtalkingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Flashtalking.", "label": "Flashtalking [Member]" } } }, "localname": "FlashtalkingMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_GainFromSaleOfOwnershipInterests": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain from the sale of ownership interest as of the end of the reporting period.", "label": "sfe_GainFromSaleOfOwnershipInterests", "negatedLabel": "Gain from sales of ownership interests" } } }, "localname": "GainFromSaleOfOwnershipInterests", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "sfe_GainLossFromObservablePriceChanges": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents gain (loss) from observable price changes.", "label": "sfe_GainLossFromObservablePriceChanges", "negatedLabel": "Gain from observable price changes" } } }, "localname": "GainLossFromObservablePriceChanges", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "sfe_HighTractionStageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to high traction stage.", "label": "High Traction Stage [Member]" } } }, "localname": "HighTractionStageMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "domainItemType" }, "sfe_ImpairmentOfOtherMethodSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment of other method securities.", "label": "sfe_ImpairmentOfOtherMethodSecurities", "terseLabel": "Impairment of Other Method Securities" } } }, "localname": "ImpairmentOfOtherMethodSecurities", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_IncludedPartnerCompanies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of equity method ownership interests.", "label": "Number of equity method ownership interests" } } }, "localname": "IncludedPartnerCompanies", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "integerItemType" }, "sfe_IncomeLossFromEquityMethodInvestmentsExcludingImpairments": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss), excluding impairments.", "label": "sfe_IncomeLossFromEquityMethodInvestmentsExcludingImpairments", "negatedLabel": "Equity (income) loss, net" } } }, "localname": "IncomeLossFromEquityMethodInvestmentsExcludingImpairments", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "sfe_IncreaseDecreaseInFairValueOfOwnershipInterests": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in the fair value of ownership interests as of the end of the reporting period.", "label": "sfe_IncreaseDecreaseInFairValueOfOwnershipInterests", "negatedLabel": "Change in fair value of ownership interests" } } }, "localname": "IncreaseDecreaseInFairValueOfOwnershipInterests", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "sfe_InfoBionicIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity InfoBionic, Inc.", "label": "InfoBionic, Inc. [Member]" } } }, "localname": "InfoBionicIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_IntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents intangible assets.", "label": "Intangible Assets [Member]" } } }, "localname": "IntangibleAssetsMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents Investments and Advances to Affiliates, Current and Noncurrent.", "label": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "totalLabel": "Investments and Advances to Affiliates, Current and Noncurrent" } } }, "localname": "InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.", "label": "2028, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeOperatingLeaseLiabilityToBePaidAfterYearSix": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of lessee's undiscounted obligation for lease payment for operating lease due after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "sfe_LesseeOperatingLeaseLiabilityToBePaidAfterYearSix", "terseLabel": "Thereafter, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearSix", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "sfe_LessorOperatingLeasePaymentToBeReceivedAfterYearSix": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 0.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents amount of lease payment to be received by lessor for operating lease after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)", "label": "sfe_LessorOperatingLeasePaymentToBeReceivedAfterYearSix", "terseLabel": "Thereafter, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearSix", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "sfe_LessorOperatingLeasePaymentsToBeReceivedSixYears": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor in sixth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "2028, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedSixYears", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "sfe_LongTermIncentivePlanPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount of payments under long-term incentive plan.", "label": "sfe_LongTermIncentivePlanPayments", "terseLabel": "Long-term Incentive Plan, Payments" } } }, "localname": "LongTermIncentivePlanPayments", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_LongtermIncentivePlanBonusPoolPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents bonus pool percent for long-term incentive plan.", "label": "sfe_LongtermIncentivePlanBonusPoolPercent", "terseLabel": "Long-term Incentive Plan, Bonus Pool Percent" } } }, "localname": "LongtermIncentivePlanBonusPoolPercent", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "sfe_LumesisIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Lumesis, Inc.", "label": "Lumesis, Inc. [Member]" } } }, "localname": "LumesisIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_MoxeHealthCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Moxe Health Corporation.", "label": "Moxe Health Corporation [Member]" } } }, "localname": "MoxeHealthCorporationMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_NetOperatingLossCarryforwardsExpiringInYearFiveAndThereafter": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent net operating loss carryforwards expiring in year five and thereafter.", "label": "sfe_NetOperatingLossCarryforwardsExpiringInYearFiveAndThereafter", "terseLabel": "2027 and thereafter" } } }, "localname": "NetOperatingLossCarryforwardsExpiringInYearFiveAndThereafter", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details" ], "xbrltype": "monetaryItemType" }, "sfe_NetOperatingLossCarryforwardsExpiringInYearFour": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents net operating loss carryforwards expiring in year four.", "label": "sfe_NetOperatingLossCarryforwardsExpiringInYearFour", "terseLabel": "2026" } } }, "localname": "NetOperatingLossCarryforwardsExpiringInYearFour", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details" ], "xbrltype": "monetaryItemType" }, "sfe_NetOperatingLossCarryforwardsExpiringInYearOne": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents net operating loss carryforwards expiring in year one.", "label": "sfe_NetOperatingLossCarryforwardsExpiringInYearOne", "terseLabel": "2023" } } }, "localname": "NetOperatingLossCarryforwardsExpiringInYearOne", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details" ], "xbrltype": "monetaryItemType" }, "sfe_NetOperatingLossCarryforwardsExpiringInYearThree": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents net operating loss carryforwards expiring in year three.", "label": "sfe_NetOperatingLossCarryforwardsExpiringInYearThree", "terseLabel": "2025" } } }, "localname": "NetOperatingLossCarryforwardsExpiringInYearThree", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details" ], "xbrltype": "monetaryItemType" }, "sfe_NetOperatingLossCarryforwardsExpiringInYearTwo": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents net operating loss carryforwards expiring in year two.", "label": "sfe_NetOperatingLossCarryforwardsExpiringInYearTwo", "terseLabel": "2024" } } }, "localname": "NetOperatingLossCarryforwardsExpiringInYearTwo", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details" ], "xbrltype": "monetaryItemType" }, "sfe_NonemployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents non-employee.", "label": "Non-Employee [Member]" } } }, "localname": "NonemployeeMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_OtherManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other management.", "label": "Other Management [Member]" } } }, "localname": "OtherManagementMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_OtherMethodInvestmentRealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale of other method investment.", "label": "sfe_OtherMethodInvestmentRealizedGainLoss", "terseLabel": "Other Method Investment, Realized Gain (Loss)" } } }, "localname": "OtherMethodInvestmentRealizedGainLoss", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_PerformanceBasedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents performance based options.", "label": "Performance Based Options [Member]" } } }, "localname": "PerformanceBasedOptionsMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_PerformanceStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents performance stock unit.", "label": "Performance Stock Unit [Member]" } } }, "localname": "PerformanceStockUnitMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_PreferredEquityInAcquirorInConnectionWithSaleOfZipnosisIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the preferred equity in acquiror in connection with the sale of Zipnosis, Inc.", "label": "Preferred Equity in Acquiror in Connection with Sale of Zipnosis, Inc [Member]" } } }, "localname": "PreferredEquityInAcquirorInConnectionWithSaleOfZipnosisIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ProceedsFromSaleOfOtherMethodInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from the sale of other method investment during the period.", "label": "sfe_ProceedsFromSaleOfOtherMethodInvestment", "terseLabel": "Proceeds From Sale of Other Method Investment" } } }, "localname": "ProceedsFromSaleOfOtherMethodInvestment", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_PrognosHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Prognos Health, Inc.", "label": "Prognos Health, Inc. [Member]" } } }, "localname": "PrognosHealthIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_RestrictedCashAndCashEquivalentsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "sfe_RestrictedCashAndCashEquivalentsFairValue", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsFairValue", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "sfe_RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents restricted stock, performance-based stock units, and deferred stock units.", "label": "Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]" } } }, "localname": "RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "sfe_RightofuseAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure for the accounting policy for right-of-use assets.", "label": "Right-of-use Assets [Policy Text Block]" } } }, "localname": "RightofuseAssetsPolicyTextBlock", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "sfe_ScheduleOfActivityForRestrictedStockUnitsDeferredStockUnitsAndPerformanceUnitsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for restricted stock unity. deferred stock units and performance units.", "label": "Schedule Of Activity For Restricted Stock Units Deferred Stock Units And Performance Units [Table Text Block]" } } }, "localname": "ScheduleOfActivityForRestrictedStockUnitsDeferredStockUnitsAndPerformanceUnitsTableTextBlock", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "sfe_ServiceBasedAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the service based award.", "label": "Service Based Award [Member]" } } }, "localname": "ServiceBasedAwardMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the share based compensation arrangement by share based payment award expiration term.", "label": "sfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationTerm", "terseLabel": "Share Based Compensation Arrangement, By Share Based Payment Award, Expiration Term (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationTerm", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "sfe_ShareRepurchaseProgramAuthorizedInJuly2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share repurchase program authorized in July 2015.", "label": "Share Repurchase Program Authorized in July 2015 [Member]" } } }, "localname": "ShareRepurchaseProgramAuthorizedInJuly2015Member", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ShareRepurchaseProgramAuthorizedInMarch2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the share repurchase programmed that was authorized in March 2022.", "label": "Share Repurchase Program Authorized in March 2022 [Member]" } } }, "localname": "ShareRepurchaseProgramAuthorizedInMarch2022Member", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ShareRepurchaseProgramAuthorizedInMay2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share repurchase program authorized in May 2021.", "label": "Share Repurchase Program Authorized in May 2021 [Member]" } } }, "localname": "ShareRepurchaseProgramAuthorizedInMay2021Member", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedAndVestedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that issued and vested during the reporting period.", "label": "sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedAndVestedInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued and Vested in Period (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedAndVestedInPeriod", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumTargetPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the maximum target percentage for equity instruments other then options under share based payment arrangement.", "label": "sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumTargetPercentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Target Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumTargetPercentage", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "percentItemType" }, "sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAwardVestingTypes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of award vesting types under share-based compensation arrangement by share-based payment award.", "label": "sfe_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAwardVestingTypes", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAwardVestingTypes", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "integerItemType" }, "sfe_StockIssuedDuringPeriodSharesRestrictedStockWithheldForTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued for restricted stock awards and withheld for taxes.", "label": "Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockWithheldForTaxes", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "sfe_StockIssuedDuringPeriodValueRestrictedStockAwardWithheldForTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of shares issued for restricted stock awards withheld for taxes.", "label": "Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net", "negatedLabel": "Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardWithheldForTaxes", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "sfe_SyapseIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Syapse, Inc.", "label": "Syapse, Inc. [Member]" } } }, "localname": "SyapseIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_The2020AwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2020 award.", "label": "The 2020 Award [Member]" } } }, "localname": "The2020AwardMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "sfe_TradingSecuritiesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of fair value for investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "sfe_TradingSecuritiesFairValueDisclosure", "terseLabel": "Ownership interests" } } }, "localname": "TradingSecuritiesFairValueDisclosure", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "sfe_TradingSecurityUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) from change in fair value for trading securities.", "label": "sfe_TradingSecurityUnrealizedGainLoss", "terseLabel": "Trading Security, Unrealized Gain (Loss)" } } }, "localname": "TradingSecurityUnrealizedGainLoss", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_TrexGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to T-Rex Group, Inc.", "label": "T-Rex Group, Inc [Member]" } } }, "localname": "TrexGroupIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_TriceMedicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Trice Medical, Inc.", "label": "Trice Medical, Inc. [Member]" } } }, "localname": "TriceMedicalIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_VelanoVascularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Velano Vascular.", "label": "Velano Vascular [Member]" } } }, "localname": "VelanoVascularMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_WebLincIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity WebLinc, Inc.", "label": "WebLinc, Inc. [Member]" } } }, "localname": "WebLincIncMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ZipnosisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Zipnosis.", "label": "Zipnosis [Member]" } } }, "localname": "ZipnosisMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "sfe_meQuilibriumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity meQuilibrium.", "label": "meQuilibrium [Member]" } } }, "localname": "meQuilibriumMember", "nsuri": "http://www.safeguard.com/20221231", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_statement-statement-note-1-general-schedule-of-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - General - Schedule of Leases (Details)" } } }, "localname": "statement-statement-note-1-general-schedule-of-leases-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details)" } } }, "localname": "statement-statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-1-general-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - General" } } }, "localname": "statement-statement-note-1-general-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details)" } } }, "localname": "statement-statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-14-selected-quarterly-financial-information-unaudited-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Selected Quarterly Financial Information (Unaudited)" } } }, "localname": "statement-statement-note-14-selected-quarterly-financial-information-unaudited-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-4-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "localname": "statement-statement-note-4-fair-value-measurements-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units and Performance Units (Details)" } } }, "localname": "statement-statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stock-Based Compensation - Schedule of Stock Options Activity (Details)" } } }, "localname": "statement-statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-6-stockbased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stock-Based Compensation" } } }, "localname": "statement-statement-note-6-stockbased-compensation-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" } } }, "localname": "statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details)" } } }, "localname": "statement-statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-8-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Income Taxes" } } }, "localname": "statement-statement-note-8-income-taxes-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details)" } } }, "localname": "statement-statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-9-net-income-loss-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Net Income (Loss) Per Share" } } }, "localname": "statement-statement-note-9-net-income-loss-per-share-tables", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "sfe_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.safeguard.com/20221231", "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r237", "r238", "r239", "r240", "r276", "r411", "r430", "r454", "r455", "r465", "r469", "r477", "r514", "r555", "r556", "r557", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r237", "r238", "r239", "r240", "r276", "r411", "r430", "r454", "r455", "r465", "r469", "r477", "r514", "r555", "r556", "r557", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "srt_PartnershipInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Partnership Interest [Member]" } } }, "localname": "PartnershipInterestMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r237", "r238", "r239", "r240", "r267", "r276", "r301", "r302", "r303", "r387", "r411", "r430", "r454", "r455", "r465", "r469", "r477", "r510", "r514", "r556", "r557", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r237", "r238", "r239", "r240", "r267", "r276", "r301", "r302", "r303", "r387", "r411", "r430", "r454", "r455", "r465", "r469", "r477", "r510", "r514", "r556", "r557", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r505", "r551" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r476" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r24", "r25", "r135", "r427", "r435", "r436" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r22", "r25", "r93", "r373", "r431", "r432", "r492", "r493", "r494", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r8" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r310", "r311", "r312", "r500", "r501", "r502", "r548" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r83", "r84", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvancesToAffiliate": { "auth_ref": [ "r123" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": 1.0, "parentTag": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.", "label": "Advances to companies" } } }, "localname": "AdvancesToAffiliate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "verboseLabel": "General and administrative expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "terseLabel": "Share-Based Payment Arrangement, Expense, after Tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r107", "r114", "r133", "r149", "r193", "r204", "r209", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r336", "r340", "r355", "r476", "r512", "r513", "r553" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r129", "r136", "r149", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r336", "r340", "r355", "r476", "r512", "r513", "r553" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r149", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r336", "r340", "r355", "r512", "r513", "r553" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r45", "r131", "r456" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r46", "r106" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r40", "r45", "r49" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r40", "r104" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r109", "r118" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r65", "r235", "r236", "r453", "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r500", "r501", "r548" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r476" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r73", "r74", "r75", "r85" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r47", "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionConvertedInstrumentAmount1", "terseLabel": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent", "terseLabel": "Deferred Compensation Liability, Current and Noncurrent, Total" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "auth_ref": [ "r90", "r545" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.", "label": "Carrying values of ownership interests and other holdings" } } }, "localname": "DeferredTaxAssetsEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r321" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Deferred Tax Assets, Gross, Total" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r544" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r90", "r545" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r90", "r545" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r88", "r90", "r545" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax loss and credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r90", "r545" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r90", "r545" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r322" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r278", "r306", "r307", "r309", "r313", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r144", "r158", "r159", "r160", "r161", "r162", "r166", "r168", "r170", "r171", "r172", "r176", "r345", "r346", "r425", "r428", "r459" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r144", "r158", "r159", "r160", "r161", "r162", "r168", "r170", "r171", "r172", "r176", "r345", "r346", "r425", "r428", "r459" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r51", "r52" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r317" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r542", "r546" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r542", "r546" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Nondeductible expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r67", "r126", "r140", "r141", "r142", "r153", "r154", "r155", "r157", "r163", "r165", "r180", "r224", "r266", "r310", "r311", "r312", "r326", "r327", "r344", "r356", "r357", "r358", "r359", "r360", "r361", "r373", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvesteeMember": { "auth_ref": [ "r59", "r414", "r416", "r418", "r420", "r422", "r424" ], "lang": { "en-us": { "role": { "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.", "label": "Equity Method Investee [Member]" } } }, "localname": "EquityMethodInvesteeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r128", "r149", "r223", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r128", "r149", "r223", "r355" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r487", "r499", "r509", "r549" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership Interest", "terseLabel": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r495", "r496", "r497" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal", "terseLabel": "Equity Method Investment, Realized Gain (Loss) on Disposal" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r60", "r194", "r489" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": 0.0, "parentTag": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Companies", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r220" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": 2.0, "parentTag": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Other Method, fair value measurement alternative", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r250", "r354", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r96", "r98" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r250", "r268", "r269", "r270", "r271", "r272", "r273", "r348", "r384", "r385", "r386", "r463", "r464", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r96", "r99", "r250", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r347", "r348", "r349", "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r250", "r268", "r273", "r348", "r384", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r250", "r268", "r273", "r348", "r385", "r463", "r464", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r250", "r268", "r269", "r270", "r271", "r272", "r273", "r348", "r386", "r463", "r464", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r250", "r268", "r269", "r270", "r271", "r272", "r273", "r384", "r385", "r386", "r463", "r464", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r150", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "terseLabel": "Federal Income Tax Expense (Benefit), Continuing Operations, Total" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r365", "r368", "r475" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of right of use asset" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r218", "r219", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r251", "r264", "r342", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r462", "r506", "r507", "r508", "r565", "r566", "r567", "r568", "r569", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expense", "verboseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r30", "r149", "r193", "r203", "r208", "r211", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r355", "r461", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.", "label": "us-gaap_GuaranteeObligationsCurrentCarryingValue", "terseLabel": "Guarantor Obligations, Current Carrying Value" } } }, "localname": "GuaranteeObligationsCurrentCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r63", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r26", "r105", "r112", "r121", "r193", "r203", "r208", "r211", "r426", "r461" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Net income (loss) before income taxes", "verboseLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r27", "r43", "r60", "r111", "r119", "r191" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Equity income (loss), net", "verboseLabel": "Equity income (loss), net" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r151", "r318", "r319", "r324", "r328", "r330", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r152", "r164", "r165", "r192", "r316", "r329", "r331", "r429" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax benefit (expense)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r139", "r314", "r315", "r319", "r320", "r323", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r42" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Accounts payable, accrued expenses, and other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r42" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r32", "r190" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r122", "r440" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "us-gaap_InvestmentOwnedBalanceShares", "terseLabel": "Investment Owned, Balance, Shares (in shares)" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r222", "r564" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "us-gaap_InvestmentsFairValueDisclosure", "terseLabel": "U.S. Government securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r490" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Ownership interests and advances" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.", "label": "Investments in and Advances to Affiliates, Schedule of Investments [Text Block]" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r371" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future minimum lease payments, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r371" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2023, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r371" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2027, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r371" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2026, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r371" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2025, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r371" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2024, operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r372" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "totalLabel": "Total future minimum lease payments, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r372" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears", "terseLabel": "2027, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r372" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears", "terseLabel": "2026, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r372" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "terseLabel": "2023, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r372" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears", "terseLabel": "2025, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r372" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears", "terseLabel": "2024, expected sublease receipts" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r149", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r337", "r340", "r341", "r355", "r460", "r512", "r553", "r554" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r108", "r117", "r476", "r499", "r509", "r549" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r130", "r149", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r337", "r340", "r341", "r355", "r476", "r512", "r553", "r554" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r149", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r337", "r340", "r341", "r355", "r512", "r553", "r554" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "us-gaap_MarketableSecurities", "terseLabel": "Marketable Securities, Total" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r40", "r41", "r44" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r44", "r113", "r120", "r128", "r137", "r138", "r142", "r149", "r156", "r158", "r159", "r160", "r161", "r164", "r165", "r169", "r193", "r203", "r208", "r211", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r346", "r355", "r461", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r193", "r203", "r208", "r211", "r461" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "verboseLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r369", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r364" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liability - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r364" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liability - non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r366", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r363" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r132" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingGainsLosses": { "auth_ref": [ "r33" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.", "label": "us-gaap_OtherNonoperatingGainsLosses", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (loss), net", "verboseLabel": "Other income (loss), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForAdvanceToAffiliate": { "auth_ref": [ "r37" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).", "label": "us-gaap_PaymentsForAdvanceToAffiliate", "negatedLabel": "Advances and loans to ownership interests" } } }, "localname": "PaymentsForAdvanceToAffiliate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r39" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r145" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Tax withholdings related to equity-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r58" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member] [Default]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r252" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6", "r476" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.10 par value; 1,000 shares authorized" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r491" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivateEquityFundsMember": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Investments held in private equity funds.", "label": "Private Equity Funds [Member]" } } }, "localname": "PrivateEquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r36" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from sales and distributions from ownership interests" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "terseLabel": "Proceeds from Issuance of Preferred Stock and Preference Stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": { "auth_ref": [ "r35", "r58" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.", "label": "Proceeds, from sales and maturities in marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments", "terseLabel": "Proceeds from Sale of Equity Method Investments" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r128", "r137", "r138", "r146", "r149", "r156", "r164", "r165", "r193", "r203", "r208", "r211", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r335", "r338", "r339", "r346", "r355", "r426", "r461", "r472", "r473", "r494", "r512" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r53", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r274", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r125", "r376", "r377", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r274", "r376", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r374", "r375", "r377", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r488", "r498", "r561", "r563" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "us-gaap_RestrictedCash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r488", "r498" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r68", "r116", "r434", "r436", "r476" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r126", "r153", "r154", "r155", "r157", "r163", "r165", "r224", "r310", "r311", "r312", "r326", "r327", "r344", "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r143", "r149", "r188", "r189", "r202", "r206", "r207", "r213", "r214", "r216", "r223", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r355", "r426", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A tabular presentation of the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates, as prescribed by the SEC. It reflects specified information about ownership, financial results from, and financial position in such entities. Includes the tabular presentations that disaggregate investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates.", "label": "Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]" } } }, "localname": "ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other units or shares or classes of ownership in a partnership.", "label": "Schedule of Other Ownership Interests [Table Text Block]" } } }, "localname": "ScheduleOfOtherOwnershipInterestsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r49", "r106", "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r77", "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r76", "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r185", "r186", "r187", "r193", "r195", "r205", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r42" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation, including liability classified awards" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Balance (in dollars per share)", "periodStartLabel": "Balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Shares available for future grant, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options exercisable, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Options exercisable , weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Options canceled/forfeited, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Balance, aggregative intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Balance, shares (in shares)", "periodStartLabel": "Balance, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Balance, weighted average exercise price (in dollars per share)", "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Options exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Options canceled/forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Options granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Options exercisable, aggregative intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options exercisable, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Balance, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r67", "r126", "r140", "r141", "r142", "r153", "r154", "r155", "r157", "r163", "r165", "r180", "r224", "r266", "r310", "r311", "r312", "r326", "r327", "r344", "r356", "r357", "r358", "r359", "r360", "r361", "r373", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-tables", "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables", "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r153", "r154", "r155", "r180", "r412" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-1-general", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-leases-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-schedule-of-restrictions-on-cash-and-cash-equivalents-details", "http://www.safeguard.com/20221231/role/statement-note-1-general-tables", "http://www.safeguard.com/20221231/role/statement-note-10-related-party-transactions", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information", "http://www.safeguard.com/20221231/role/statement-note-12-supplemental-cash-flow-information-details-textual", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting", "http://www.safeguard.com/20221231/role/statement-note-13-segment-reporting-details-textual", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-schedule-of-selected-quarterly-financial-information-unaudited-details", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-details-textual", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-restricted-stock-units-deferred-stock-units-and-performance-units-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan", "http://www.safeguard.com/20221231/role/statement-note-7-employee-benefit-plan-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-schedule-of-summary-of-operating-loss-carryforwards-details", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables", "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r6", "r7", "r67", "r68", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Options exercised, shares (in shares)", "negatedLabel": "Options exercised, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-schedule-of-stock-options-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r57", "r476", "r499", "r509", "r549" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-equity-method-investment-partner-company-results-of-operation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r91", "r92", "r94", "r126", "r127", "r141", "r153", "r154", "r155", "r157", "r163", "r224", "r266", "r310", "r311", "r312", "r326", "r327", "r344", "r356", "r357", "r361", "r373", "r432", "r433", "r499", "r509", "r549" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r72", "r148", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r362", "r380" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r362", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r362", "r380" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20221231/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20221231/role/statement-note-5-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Summary of Operating Loss Carryforwards [Table Text Block]" } } }, "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-1-general-tables", "http://www.safeguard.com/20221231/role/statement-note-14-selected-quarterly-financial-information-unaudited-tables", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20221231/role/statement-note-6-stockbased-compensation-tables", "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-tables", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r110", "r134", "r457" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Ownership interests", "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI, Total" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets", "http://www.safeguard.com/20221231/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20221231/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r218", "r219", "r251", "r264", "r342", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r506", "r507", "r508", "r565", "r566", "r567", "r568", "r569", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "us-gaap_TreasuryStockAcquiredAverageCostPerShare", "terseLabel": "Treasury Stock Acquired, Average Cost Per Share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r20", "r70" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r20", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r7", "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Repurchases of common stock (in shares)", "terseLabel": "Treasury Stock, Shares, Acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r20", "r70", "r71" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 5,478 and 5,068 shares at December 31, 2022 and 2021, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r67", "r68", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Repurchases of common stock", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.safeguard.com/20221231/role/statement-note-5-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies", "http://www.safeguard.com/20221231/role/statement-note-11-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r458", "r466", "r468", "r562" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r43" ], "calculation": { "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "us-gaap_UnrealizedGainLossOnInvestments", "negatedLabel": "Impairments of ownership interests and advances" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "terseLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-note-8-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r54", "r55", "r56", "r181", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r167", "r172" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares used in computing net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r166", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20221231/role/statement-consolidated-statements-of-operations", "http://www.safeguard.com/20221231/role/statement-note-9-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.2)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7,9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "https://asc.fasb.org/topic&trid=2126967", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 78 0001437749-23-006178-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-006178-xbrl.zip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

O&N@M_69,JZ1H&/PW_9$TJ MX;W6)'IJSL$@X/,)$:>"YE]D.SZ_A "[P'+R$>JV'>A6](H^-?3 H\09$),- M!M2EM@%D8K:X&'A"?Z( -J,10!"?LT>

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end